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Abstract 
 
Combination inhalers of long-acting β2 agonists (LABAs) with inhaled corticosteroids 
(ICSs) are now widely used for the treatment of asthma. However, corticosteroid (CS) 
insensitivity can be a major barrier for the treatment of chronic obstructive pulmonary 
disease (COPD). Existing ICSs are less beneficial on the decline of lung function in 
the long term. Even at the cellular level, CSs are less effective in primary cells, 
peripheral blood mononuclear cells (PBMCs) obtained from COPD patients compared 
to PBMCs from healthy volunteers. High levels of oxidative stress in COPD have 
been reported to be involved in CS insensitivity. In addition, oxidative stress has been 
reported to affect the β2 adrenergic receptor (β2AR) signalling itself.  
Here I hypothesise that oxidative stress affects the function of CSs and LABAs and/or 
their combination. Clarifying the molecular mechanism of this defect, will give new 
insights for the optimisation of the ideal CS/LABA combination therapy for the 
treatment of COPD. 
Primarily, pharmacological effects of fluticasone furoate (FF), a novel CS, were 
evaluated in various inflammation systems in respiratory cells and compared with 
those of currently available fluticasone propionate (FP) and budesonide (Bud). In the 
course of this study, FF was found to be a potent and long-acting CS. More 
importantly, the anti-inflammatory effects of FP were reduced under oxidative stress, 
whereas the effects of FF were not affected by oxidative stress. FF was also more 
effective on inhibiting cytokine release in PBMCs from COPD patients. Hence, this 
study demonstrated that FF is an oxidative stress insensitive CS.  
Furthermore, effects of oxidative stress on the function or signalling of LABAs were 
investigated. Salmeterol (SM)-induced cyclic AMP (cAMP) production was reduced 
under H2O2 treatment, while the effects of formoterol (FM) were not affected by H2O2. 
Under conditions of oxidative stress, SM also induced β2AR internalisation, whereas 
FM did not. Cell signalling analysis showed that FM partially inhibited H2O2-induced 
Akt phosphorylation, a footprint of phosphoinositide-3 kinase (PI3K) activation, 
whereas SM did not. Furthermore, add-on treatment with FM could improve 
sensitivity of either Bud or FP in U937 cells, under simulative conditions of oxidative 
stress or PBMCs from COPD patients, but SM did not improve it. Moreover, 
vilanterol trifenatate (VT), also known as GW642444, a novel ultra LABA showed 
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similar effects with FM, under oxidative stress. Thus, FM (and VT) is more robust 
than SM under oxidative stress conditions.       
Finally, the outcome of H2O2 on the anti-inflammatory effects of CS/LABA 
combination was evaluated. As concluded from the results above, FF and FM (or VT) 
were oxidative stress insensitive compounds. In fact, the combination of FF and VT, 
as well as a combination of mometasone furoate (MF) with FM showed the most 
potent anti-inflammatory effects under oxidative stress and in PBMCs from COPD 
patients.  
Consequently, the findings from this thesis might give new insights and support the 
development of new combination therapies for the treatment of chronic inflammatory 
airway diseases, where high levels of oxidative stress are seen.     
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GNB2L1 Guanine nucleotide binding protein, beta polypeptide 2-like 1 
GOLD Chronic Obstructive Lung Disease 
GPCR G protein coupled receptor 
GR Glucocorticoid receptor 
GRE GR responsive element 
GRK GPCR kinase 
H2O2 Hydrogen peroxide 
HBD Hormone-binding domain 
HDAC Histone deacetylase 
HRP Horseradish peroxidase 
HRQL Health-related quality of life 
HSP Heat shock protein 
ICS Inhaled corticosteroid 
IKK IκB kinase 
IL Interleukin 
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IL-1R IL-1 receptor 
iNOS Inducible NOS 
IκB Inhibitor of κB binding 
IRAK IL-1 receptor-associated kinase 
JNK c-Jun N-terminal kinase 
LABA Long-acting β2 agonist 
MAPK Mitogen-activated protein kinase 
MEK MAPK/ERK kinase 
MF Mometasone furoate 
MKP-1 MAPK phosphatase 1 
MR Mineralcorticoid receptor 
MSK Mitogen and stress-activated kinase 
NF-κB Nuclear factor kappa B 
NO Nitric oxide 
NO2 Nitrogen dioxide 
NOS Nitric oxide synthase 
nNOS Neuronal NOS 
O2
.-
 Superoxide anion 
O3 Ozone 
.
OH Hydroxyl radical 
ONOO
-
 Peroxynitrite 
PBMCs  Peripheral blood mononuclear cells 
PDK1 Phosphoinositide-dependent kinase 1 
PEF Peak expiratory flow 
PI3K Phosphoinositide-3 kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol 3,4,5-trisphosphate 
PKA Protein kinase A 
PKAi PKA inhibitor 
PR-LBD Progesterone ligand-binding domain 
PTX Pertussis toxin 
RNS Reactive nitrogen species 
RIP Receptor-interacting protein 
ROS Reactive oxygen species 
RTK Receptor tyrosine kinase 
SABA Short-acting β2 agonist 
SAPK Stress-activated protein kinase 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Ser Serine 
SM Salmeterol 
TGFβ1 Transforming growth factor beta 1 
Thr Threonine 
TIR Toll-IL-1 receptor 
TLR Toll-like receptor 
TNFα  Tumour necrosis factor α 
TNFR TNF receptor 
Tyr Tyrosine 
VT Vilanterol trifenatate 
β2AR β2 Adrenergic receptor 
βARK β Adrenergic receptor kinase 
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1.1 Inflammation 
 
Inflammation is a process triggered by tissue damage or an infectious agent that 
causes the release of cytokines and chemokines and other mediators at the site of 
inflammation. Traditionally, inflammation is defined by the four Latin words calor 
(heat), dolor (pain), rubor (redness) and tumor (swelling), all of which reflect the 
effects of cytokine and other mediators’ release on the local blood vessels. During this 
response three major events take place: increased blood supply, increased capillary 
permeability and leukocyte migration. The main cell types during inflammation are 
macrophages and neutrophils; however, the influx of neutrophils causes the 
recruitment of monocytes that differentiate into macrophages, amplifying the innate 
immune response (Murphy et al., 2008). 
An inflammatory response can be either acute or chronic. Acute inflammation is 
characterised by leukocyte recruitment in response to tissue injury or insult (Lawrence 
and Gilroy, 2007). In general, acute inflammatory response initiates within minutes 
and can be resolved within hours. Conversely, chronic inflammation carries on for 
weeks, months and can be persistent even for years (Lawrence and Gilroy, 2007). 
 
1.2 Signalling Pathways Implicated in the Regulation of 
Inflammatory Gene Expression 
 
The inflammatory response has evolved as a protective response to insult or injury 
and is characterised by the activation of various signalling pathways that regulate the 
expression of both pro-inflammatory (e.g. tumor necrosis alpha - TNFα, interleukin 
(IL)-8) and anti-inflammatory (transforming growth factor beta 1 – TGFβ1, IL-10) 
mediators (Lawrence and Gilroy, 2007). Evidence on inflammation and innate 
immunity comes mainly from studies on the IL-1 receptor (IL-1R)/Toll-like receptor 
(TLR) (Akira et al., 2006) and the TNF receptor (TNFR) (Locksley et al., 2001) 
families. Once the receptors are activated, several adaptor proteins are recruited that 
acquire Toll-IL-1 receptor (TIR) domains for TLRs and IL-1R or death domains (DD) 
in the case of TNFRs (Karin et al., 2006). Once recruited these adaptors, a variety of 
signalling proteins and various protein kinases are employed. Such kinases 
 21 
incorporate the IL-1 receptor-associated kinase (IRAK)-1 and -4, in the case of TIR 
signalling (Suzuki et al., 2002), while receptor-interacting protein (RIP) kinases are 
recruited when TNFR signalling is activated (Kelliher et al., 1998).  Oxidative stress 
has also been implicated as a driving force of inflammatory response and is a typical 
activator of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases 
(MAPKs). Consistently, upon stimulus recruitment to the receptor, several pathways 
are activated that include kinases such as MAPKs, inhibitor of κB binding (IκB) 
kinases and phosphoinositide-3 kinase (PI3K).       
 
1.2.1 The MAPK Signalling Pathways 
 
MAPK pathways can be activated by a wide variety of stimuli, allowing the cell to 
respond leading to regulation of gene transcription and protein synthesis. This 
subsequently triggers cellular processes, such as, cell survival and proliferation, as 
well as cell death and apoptosis (Kyriakis and Avruch, 2001). There are three major 
MAPK pathways that have been identified in mammalian cells: JNK, extracellular 
signal-regulated protein kinase (ERK) and p38 MAPK signalling pathways. MAPK 
pathways are highly conserved and a common feature they share is that they are 
activated by the simultaneous phosphorylation of both tyrosine (Tyr) and threonine 
(Thr) residues. This phosphorylation is catalysed by a family of dual specificity 
kinases, MAPK kinase (MAPKK), such as MAPK/ERK kinases (MEKs), which, in 
turn, are catalysed by a protein kinase family referred to as MAPK-kinase kinases 
(MAPKKKs) (Fig. 1.1).       
 
1.2.1.1 The ERK Signalling Pathway 
 
The mammalian ERK pathway was the first MAPK pathway identified and has been 
characterised as the classical mitogen kinase cascade. It consists of the Raf family of 
MAPKKKs: Raf-1, A-Raf, B-Raf and c-Mos; the MEK1 and MEK2 MAPKKs; and 
the MAPKs ERK1 and ERK2. ERK1 and ERK2 have 83 % amino acid identity and 
are ubiquitously expressed in a wide range of tissues (Roux and Blenis, 2004). This 
cascade is strongly activated by growth factors and lipoglycans, such as  
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Figure 1.1 Summary of the MAPK signalling pathways.  The three signalling 
pathways (ERK, JNK, and p38 MAPK) are activated by diverse stimuli (LPS, growth 
factors, pro-inflammatory stimuli and cell stresses, such as reactive oxygen species 
(ROS), UV light and heat). The pathways pursue a general cascade, in which a 
MAPKKK is activated and in turn phosphorylates a MAPKK, which activates a 
MAPK. The MAPKs can phosphorylate numerous downstream substrates; 
transcription factors such as AP-1 (c-Jun and c-Fos), NF-κB (p50 and p65), ATF-2 
and protein kinases (MNK-1/2, MSK1/2) that entail transcriptional regulation, 
cytokine production and several inflammatory and immune responses. 
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lipopolysaccharide (LPS). ERK1/2 pathways were originally thought to be implicated 
in cell proliferation, whereas later studies have shown that they are also involved in 
inflammatory responses (Dumitru et al., 2000). Moreover, LPS-induced TNFα release 
was shown to be regulated through a tumour specific locus-2 (Tpl-2)/MEK1/ERK1/2 
cascade. 
Activation of ERK1/2 results in a signalling cascade that links cell surface receptor 
signal with nuclear events, therefore upon stimulation, phosphorylated ERK1/2 
translocates and resides into the nucleus (Khokhlatchev et al., 1998; Lenormand et al., 
1998). Activated ERK1/2 can in turn phosphorylate a number of transcription factors, 
including the activator protein 1 (AP-1) family (c-Fos and c-Jun), activating 
transcription factor 2 (ATF-2) and several protein kinases, such as mitogen- and 
stress-activated protein kinase (MSK)-1 and MSK2 (Roux and Blenis, 2004) (Fig. 
1.1).   
 
1.2.1.2 The JNK Signalling Pathway 
 
JNK1 and JNK 2 were biochemically characterised using in-gel kinase assays. The 
two isoforms (46 and 56 kDa in size) were initially predicted to be distinct from 
ERKs. This prediction was confirmed later by molecular cloning studies (Karin and 
Gallagher, 2005). JNKs are also known as stress-activated protein kinases (SAPKs). 
They are now encoded by three genes: JNK1 (SAPKγ), JNK2 (SAPKα) and JNK3 
(SAPKβ) (Kyriakis and Avruch, 2001).  
Like all MAPKs, JNKs require dual phosphorylation on both Tyr and Thr residues 
within the Thr-Pro-Tyr motif, a reaction catalysed by MAPKK4 and MAPKK7. These 
are activated by several MAPKKKs, incorporating the MAPKKK4, 5, 7 and MEKK1-
4 (Roux and Blenis, 2004) (Fig. 1.1).  
Similarly to ERK1/2, JNKs phosphorylate the AP-1 family of transcription factors, 
ATF-2 (Karin and Gallagher, 2005), as well as the heat-shock transcription factor-1 
(HSF-1) and the signal transducer and activator of transcription 3 (STAT3) 
transcription factor (Roux and Blenis, 2004).  
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1.2.1.3 The p38 MAPK Signalling Pathway 
 
The p38 MAPK signalling pathway is the third MAPK pathway. The p38α MAPK 
shares a ~ 60-70 % identity with ERK and JNK, however it differs from the others in 
its activation in response to different stimuli (Kumar et al., 2003).  The human p38α 
MAPK was originally identified as the molecular target of pyridinyl imidazole 
compounds, known to inhibit inflammatory cytokines, such as IL-1 and TNFα in 
response to LPS. Database searches revealed further isoforms of p38 MAPKs and 
currently four isoforms are known: p38α, p38β, p38γ and p38δ. 
p38 MAPK is activated by dual phosphorylation on both Thr180 and Tyr182 by an 
upstream MAPKK, MKK6. Other studies have also shown that MKK3 is involved as 
well. These MKKs are consecutively activated by a wide range of MAPKKKs, a 
process that depends on the different stimuli and the cell type (Kumar et al., 2003).  
There are several substrates downstream of p38 MAPKs, including transcription 
factors AP-1, nuclear factor kappa B (NF-κB), ATF-2 and several kinases, such as 
MNK1/2 and MSK1/2, which are all involved in pro-inflammatory cytokine 
production. Hence, the importance of p38 MAPKs in transcriptional regulation and 
cytokine production (Kumar et al., 2003; Saklatvala, 2004). The p38 MAPK pathway 
has also been associated with bone homeostasis, glutamine catabolism in liver, in 
cardiac and platelet function as well as haemopoiesis and bone resorption (Saklatvala, 
2004).  
 
1.2.2 The IκB Kinase (IKK) Signalling Pathway (NF-κB Signalling) 
 
The NF-κB signalling pathway regulates numerous immune responses and is 
associated with the pathogenesis of inflammatory diseases. It is comprised of several 
components that regulate its activity either positively or negatively (Pasparakis, 2009).  
NF-κB was first identified in the 1980s as a transcription factor that binds to the 
intronic enhancer of the kappa light chain gene of B cells (κB site) (Vallabhapurapu 
and Karin, 2009). The NF-κB family of transcription factors is comprised of NF-κB1 
(p50 and its precursor p105), NF-κB2 (p52 and its precursor p100), RelA (p65), RelB 
and c-Rel.  
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There are two known pathways of NF-κB activation; the classical pathway, also 
known as the canonical NF-κB pathway, and the alternative pathway of NF-κB 
(Bonizzi and Karin, 2004) (Fig. 1.2).  
In the canonical pathway, ΝF-κB is activated by a variety of inflammatory stimuli, 
such as viruses and pro-inflammatory cytokines (IL-1β, TNFα). NF-κB activation is 
controlled by NF-κB-interacting proteins, its inhibitors,  the inhibitor of κB binding 
(IκB); IκBα, IκBβ, ΙκBγ, IκBε and the novel IκBδ and IκBδ (Vallabhapurapu and 
Karin, 2009). IκBs bind to NF-κB dimers, a process that retains the dimer in the 
cytoplasm. Pro-inflammatory stimuli in turn, activate the IKK trimeric complex, 
which is comprised of the catalytic IKKα and IKKβ subunits and the regulatory IKKγ 
subunit (Vallabhapurapu and Karin, 2009). Activated IKKα phosphorylates IκBα, 
leading to subsequent polyubiquitination of IκB, resulting in degradation by the 26S 
proteasome (Beck et al., 2009). Consequently, NF-κB is released and translocates into 
the nucleus, where it binds to specific genomic sequences and the production of 
several inflammatory proteins, such as cytokines (IL-6, TNFα, IL-1β), chemokines 
(IL-8, RANTES), enzymes (iNOS, COX-2) and adhesion molecules (VCAM-1, e-
selectin) (Bonizzi and Karin, 2004). 
The alternative pathway is strictly IKKα-dependent, and independent on either IKKβ 
or IKKγ (Bonizzi and Karin, 2004). It is initiated by the B cell-activating factor 
(BAFF), lymphotoxin β and other inducers.  IKKα homodimers target the p100 
subunit in the p100/RelB complex, which is phosphorylated at Ser865, Ser869 and 
Ser871 residues (Beck et al., 2009). Then p100 undergoes constitutive cleavage to 
produce p52, which forms the p52/RelB complex. The complex is able to translocate 
into the nucleus to induce expression of Irf3, BLC and GlyCAM-1.  
       
1.2.3 The PI3K Signalling Pathway  
 
PI3Ks are intracellular signalling proteins that are involved in co-ordinating a number 
of cellular functions. They act as heterodimers formed by a catalytic and a regulatory 
subunit and are primarily entailed in the initiation of cell surface receptor-mediated 
signalling cascades (Marwick et al., 2010). PI3Ks are divided into three classes, class 
I, II and III. Class I PI3Ks are subdivided into class IA (p110α, p110β and p110δ) and 
class IB (p110γ), whereas class II consist of a single subunit with three isoforms (C2α,  
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Figure 1.2 Summary of the NF-κB pathways.  (A) The canonical NF-κB pathway is 
activated by several pro-inflammatory cytokines, through the IKK complex. 
Phosphorylation of the IKK complex results in IκBα degradation and subsequent 
translocation of NF-κB into the nucleus, where it binds to specific genome sequences 
and several inflammatory proteins are expressed. (B) The alternative NF-κB pathway 
is activated by stimuli, such as BAFF and lymphotoxin β, that phosporylate IKKα 
homodimers. This process causes constitutive cleavage of p100 to produce p52 and in 
turn progresses into the formation of p52/RelB complex and its subsequent 
translocation into the nucleus that targets specific promoters of inflammatory genes 
for their activation. (Figure is adapted by Bonizzi and Karin, 2004 (Bonizzi and Karin, 
2004)) 
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C2β and C2γ), while class III consists of a single family member, vacuolar protein 
sorting mutant 34 protein (Vps34p) (Liu et al., 2009).  
Growth factors, cytokines and G-protein coupled receptors (GPCRs) can activate 
class I PI3Ks via activation of receptor tyrosine kinases (RTKs) (Ito et al., 2007). 
Once activated class I PI3Ks convert phosphatidylinositol 4,5-bisphosphate 
[PI(4,5)P2/PIP2] to phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3/PIP3] (Fig. 
1.3). PIP3 then activates downstream signalling molecules, such as phosphoinositide-
dependent kinase 1 (PDK1) and PKB (also known as Akt) (Ito et al., 2007). These 
molecules activate various downstream molecules, such as tuberous sclerosis (TCS) 1 
and 2 proteins, IKKα, serum- and glucocorticoid-induced kinase (SGK), protein 
phosphatase 2A (PP2A), and ribosomal protein, S6 kinase 70 kD (p70S6 kinase) 
(Cully et al., 2006). These signalling molecules orchestrate a plethora of cell functions, 
including cell growth and proliferation, apoptosis, DNA repair and production of 
inflammatory mediators.  
 
1.3 Chronic Inflammatory Airway Disease 
 
The most common inflammatory diseases of the airways are asthma, chronic 
obstructive pulmonary disease (COPD) and cystic fibrosis (Barnes, 2009a). Cytokines 
play an important role in orchestrating chronic inflammation by recruiting and 
activating a plethora of inflammatory cells in the respiratory tract (Barnes, 2008b).   
Asthma and COPD share some common features, as both are chronic diseases that 
involve airflow limitation and are characterised by mucus hypersecretion and 
bronchoconstriction (Buist, 2003). However, they have different anatomical sites. 
COPD affects both the airways and the parenchyma, whereas asthma affects mainly 
the airways. In asthma, the most important inflammatory cells involved are 
eosinophils, mast cells and CD4
+
 T lymphocytes. In COPD, neutrophils, macrophages 
and CD8
+
 T cells are implicated (Buist, 2003; Guerra, 2005). 
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Figure 1.3 The PI3K Pathway. Schematic representation of the signalling mediators 
involved in the PI3K pathway. Class I PI3Ks are activated by receptor tyrosine 
kinases (RTKs) and convert phosphatidylinositol 4,5-bisphosphate (PIP2) into 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 triggers a downstream 
signalling cascade involving phosphoinositide-dependent kinase 1 (PDK1) and PKB 
(also known as Akt). Downstream substrates of PKB include PP2A, TSC1/TSC2, 
IKKα, SGK and p70S6 kinase. All these signalling cascades are engaged in a plethora 
of functions, such as cell growth, proliferation, apoptosis, production of inflammatory 
mediators and DNA repair. 
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1.3.1 Asthma 
 
1.3.1.1 Definition 
 
In the Global Initiative for Asthma (GINA) guidelines (Global Initiative for Asthma 
(GINA), 2009) asthma has been defined as: 
“…a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness and coughing, particularly at night or in the early morning. These 
episodes are usually associated with widespread but variable obstruction within the 
lung that is often reversible either spontaneously or with treatment.” 
 
1.3.1.2 Morbidity, Mortality and Socio-economic Burden in Asthma 
 
Asthma is a worldwide problem, with an estimated population of 300 million 
individuals of all ages and ethnic backgrounds.  Asthma has become more common in 
both adults and children around the world owing to the increased atopic sensitisation 
and the parallel increase of other allergic disorders (Masoli et al., 2004).  
The total number of disability-adjusted life years (DALYs) is estimated to be around 
15 million per year, reflecting high prevalence and severity of asthma. The economic 
cost is considerably high, as it accounts for both medical (hospital admissions, 
pharmaceuticals) and non-medical (premature death, loss of work hours) costs 
(Masoli et al., 2004). Thus, there is need of cost-effective management of asthma to 
reduce morbidity and mortality rates worldwide.      
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1.3.2 Chronic Obstructive Pulmonary Disease (COPD) 
1.3.2.1 Definition 
 
In the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 
(Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2009) Chronic 
Obstructive Pulmonary Disease (COPD) has been defined as: 
“…a preventable and treatable disease with some significant extrapulmonary effects 
that may contribute to the severity in individual patients. Its pulmonary component is 
characterised by airflow limitation that is not fully reversible. The airflow limitation 
is usually progressive and associated with an abnormal inflammatory response of the 
lung to noxious particles or gases.” 
The characteristics of chronic airflow limitation in COPD are caused by a mixture of 
small airway disease (i.e. obstructive bronchiolitis) and parenchymal destruction (i.e. 
emphysema) (Rabe et al., 2007). Cigarette smoking is the most commonly 
encountered risk factor for COPD, as well as environmental pollution in developing 
countries. Noxious gases, i.e. oxidative stress may play an important role in the 
pathogenesis of COPD (Cazzola et al., 2007a; Cazzola et al., 2007b).  
 
1.3.2.2 Morbidity, Mortality and Socio-economic Burden in COPD 
 
According to the World Health Organisation (WHO), COPD is the 5
th
 leading cause 
of death in high-income countries (Mannino and Buist, 2007). WHO has also 
proposed that COPD will be the 3
rd
 leading cause of death in the western world by 
2020 (Buist et al., 2007). In the UK, it has been estimated that total costs to NHS for 
COPD have been £486 - £848 million. These figures exclude the socio-economic 
losses by inability to work and absence from work (Starkie et al., 2008). Many people 
suffer from COPD for years and die prematurely, due to lack of sufficient research, 
ageing of the population and the continuous use of tobacco (Buist et al., 2007; Rabe et 
al., 2007). 
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1.4 Oxidative Stress 
1.4.1 Oxidant/Antioxidant Imbalance  
 
Airways are exposed to high levels of environmental oxidants, but simultaneously 
encompass high concentrations of antioxidants that are sufficient to maintain oxidants 
at physiological levels, preventing the disruption of normal physiologic conditions 
(Bowler et al., 2004). Increased oxidants, or decreased antioxidant protection will lead 
to an imbalance between oxidants and antioxidants, a phenomenon termed as 
oxidative stress.  
 High levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
are observed in COPD (Bowler et al., 2004). ROS include superoxide anion (O2
.-
), 
hydrogen peroxide (H2O2) and hydroxyl radical (
.
OH) and RNS include nitric oxide 
(NO), peroxynitrite (ONOO
-
) and nitrogen dioxide (NO2). Other molecules that 
contribute to oxidative stress are protein radicals and lipid peroxide radicals that can 
cause non specific damage to cells and the extracellular matrix (Bowler et al., 2004).  
 
1.4.2 Sources of Oxidants 
 
ROS and RNS can be generated by both exogenous and endogenous sources.  
Cigarette smoke and air pollution are predominant exogenous sources. Cigarette 
smoke contains > 4700 chemicals, with more than 10
15
 free radicals per puff in the 
gas phase and 10
17 
free radicals per gr in the particulate (tar) phase (Bowler et al., 
2004). Cigarette smoke oxidants can injure the lungs via numerous mechanisms: 
direct damage to lipids; proteins and nucleic acids; depletion of antioxidants, such as 
glutathione; initiation of redox-cycling reactions and enhancement of the respiratory 
tract with macrophages and neutrophils (Bowler et al., 2004).  Likewise, air pollution 
contains a wide variety of chemicals and reactive species, such as, NO2 and ozone 
(O3). Other components that contribute to oxidative stress by air pollution are 
polycyclic aromatic hydrocarbons and endotoxin.  
Endogenous sources of oxidants in the lungs are by-products of normal metabolism. 
Mitochondria are the largest source of free radicals, such as, superoxide, as a result of 
the electron leak from the electron transport chain onto oxygen and xanthine oxidase, 
 32 
another important source of oxygen-free radicals. Membrane oxidases, such as 
cytochrome P450 and NADPH oxidases can also produce endogenously substantial 
amounts of free radicals (Bowler et al., 2004; Valko et al., 2006). Moreover, 
peroxisomes include H2O2-producing enzymes such as D-amino acid oxidase, urate 
oxidase and fatty acyl-CoA oxidase that contribute to the endogenous oxidant source. 
RNS are mainly derived by NO, whose sources in the lung are three NO synthases 
(NOS); neuronal NOS (nNOS) originating from the nerve plexus of the trachea, 
inducible NOS (iNOS) found in respiratory epithelium and activated macrophages 
and endothelial NOS (eNOS) found in respiratory epithelium and vascular 
endothelium (Bowler et al., 2004).      
 
1.4.3 Oxidative Stress in COPD 
 
The major risk factor in COPD is cigarette smoking, one of the most potent oxidants, 
as well as air pollutants, infections and occupational dusts. The oxidant load in the 
lungs of smokers is enhanced by cigarette smoke and the release of ROS from 
recruited macrophages and neutrophils (MacNee, 2001). As the half-life of these ROS 
and RNS is normally short, indirect determination of stable product after reactions 
with ROS/RNS, a technique based on spin trapping and footprinting has been used.  
There is now extended evidence that links oxidative stress with COPD (Bowler et al., 
2004).  
Spin trapping technique revealed increased ROS in the bronchoalveolar lavage (BAL) 
fluid of patients with COPD (Pinamonti et al., 1998). Footprint involves measuring 
products of protein and lipid oxidation, such as carbonyls, isoprostane, ethanol and 
ONOO
-
. Aldehydes, like malondialdehyde, hexanal and heptanal were increased in 
exhaled breath condensate (EBC) of COPD patients compared to non-smoking control 
subjects (Corradi et al., 2003). Furthermore, elevation of ONOO
-
 was observed in 
EBC from COPD patients, whose production was confirmed in sputum macrophages 
(Osoata et al., 2009a).  Brindicci et al discovered that nNOS expression and activity 
was increased in peripheral lung tissue from patients with COPD that correlated with 
the severity of the disease, as well as NO and ONOO
-
 production in peripheral lung 
(Brindicci et al., 2010).  This is a novel source of ROS/RNS in COPD.   
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1.5 Current Therapies/Clinical Implications 
 
1.5.1 Current Therapies in Asthma 
 
According to GINA guidelines, most symptoms of intermittent and mild asthma are 
well controlled by short-acting β2 agonists (SABAs) (Global Initiative for Asthma 
(GINA), 2009). Inhaled long-acting β2-agonists (LABAs) are widely used for patient 
relief from asthma symptoms (Pauwels et al., 1997). Low dose inhaled corticosteroids 
(ICSs) or in combination with LABAs are used as an additional treatment step. Higher 
doses of ICSs or even low doses of oral corticosteroids (CSs) are required to control 
symptoms in more severe stages of the disease (Global Initiative for Asthma (GINA), 
2009).  
Studies have shown that combining LABAs with ICSs led to a greater improvement 
in the control of asthma symptoms and lung function comparing to patients on double 
dosing of ICS alone (Pauwels et al., 1997). The first reports showing beneficial effects 
on clinical efficacy of LABAs with ICS combination therapy was from a 6-month 
trial. In this trial, the efficacy of salmeterol (SM) was evaluated, when it was co-
administered with a standard dose of beclomethasone dipropionate (BD) compared to 
higher doses of the ICS alone (Greening et al., 1994). Patients in the combination 
therapy showed improvement in airway function with fewer asthma symptoms and 
reduced need for a reliever. Other studies have also shown the benefit of adding SM 
to ICS therapy was superior to doubling the dose of fluticasone propionate (FP) alone 
(Ind et al., 2003). 
In the FACET study, the effects of the addition of formoterol (FM) to lower or higher 
doses of budesonide (Bud), on symptom control and lung function were evaluated. 
Addition of FM showed decreased severe and mild exacerbations, with a lower rate 
compared to patients on treatment with higher doses of Bud. Patients on combination 
therapy also showed improved asthma-symptom scores, lung function and reduced 
need of rescue medications (Pauwels et al., 1997). 
However, a small number of asthmatic patients are CS-resistant, consequently they 
show no clinical improvement even after high doses of oral CSs (Barnes and Adcock, 
2009). These severe asthma patients, jointly with smoking asthmatics, are less 
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sensitive to the short-term beneficial effects of ICSs on asthma symptoms and lung 
function (Thomson and Chaudhuri, 2009). An early and more accurate diagnosis will 
aid improved pharmacologic interventions in order to overcome the CS insensitive 
asthma.  
 
1.5.2 Current Therapies in COPD 
 
In COPD, LABAs and inhaled anticholinergic drugs are used as bronchodilators as 
the mainstay of the current management of COPD and other airway disorders 
(Cazzola and Matera, 2009). Several studies have reported their usefulness and the 
daily symptom relief to patients with COPD. It has been acknowledged that either FM 
or SM significantly improve health-related quality of life in patients suffering from 
COPD (Miller-Larsson and Selroos, 2006). Still, current bronchodilators for COPD 
have limited efficacy and shorter duration of action. Therefore, the logical approach 
would be to improve the existing bronchodilators that can achieve longer duration of 
action and higher potency (Barnes, 2008a). 
In a multi-centre study, the treatment of patients with mild COPD with inhaled Bud 
was associated with a one-time improvement in FEV1 after bronchodilator use, 
however, it failed to affect the long-term decline of FEV1 and improve lung function 
(Pauwels et al., 1999). In the TORCH study, a randomised, double-blind trial, FP did 
not have any benefit on mortality or decline of lung function over three years. In 
addition, the risk of pneumonia was slightly increased (Calverley et al., 2007). 
Furthermore, other studies shown that high doses of ICSs significantly reduced the 
rate of decline of FEV1 in patients with COPD. A meta-analysis study demonstrated 
that the use of ICSs reduced the progression of airflow limitation, however they were 
not capable to portray any dose response effect as there was only one study on lower 
ICS dose for comparison (Sutherland et al., 2003). Thus, studies that demonstrate the 
benefit of ICS for the treatment of COPD are limited. 
As described above, the LABA/ICS combination is currently used in asthma and the 
beneficial effects of adding a LABA to an ICS treatment have been reported both 
clinically and in vitro. However, clinical trials comparing the effects of LABA/ICS 
combination therapy for the treatment of COPD are limited in comparison to asthma 
and the efficacy of the combination is not, as yet, very clear. So far, SM/FP 
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(Calverley et al., 2003a; Hanania et al., 2003; Mahler et al., 2002) and FM/Bud 
(Calverley et al., 2003b; Szafranski et al., 2003) combinations have been tested in 
patients with COPD.  
SM/FP (SM, 50 μg, FP, 250 μg) combination improved morning lung function 
compared to each drug administered alone (Hanania et al., 2003). Peak expiratory 
flow (PEF) was also improved within 24 h of the trial and it was greater for the 
combination other than SM alone indicating the beneficial effect of ICS/LABA 
combination (Hanania et al., 2003). Mahler et al, investigators in the TORCH study 
and the TRISTAN study group have also pointed out the effectiveness of the 
combination of SM/FP. All studies showed that each drug alone, either SM or FP 
significantly improved to some extent the lung function but the combination was more 
efficacious than either placebo or each drug alone (Calverley et al., 2003a; Calverley 
et al., 2007; Mahler et al., 2002). 
Two studies investigating the effect of the FM/Bud combination showed that lung 
function was significantly improved. Health-related quality of life (HRQL) was also 
improved compared to placebo; the rate of exacerbations was reduced, as well as the 
use of reliever medication and COPD symptoms (Calverley et al., 2003b; Szafranski 
et al., 2003). 
Such clinical studies demonstrate that LABA/ICS combination therapy have superior 
control of either asthma or COPD than each drug administered alone. The 
additive/synergistic effect has also been investigated and no safety issues emerged 
(Miller-Larsson and Selroos, 2006). However, the molecular mechanisms underlying 
this effect are not clear yet and especially in COPD. 
 
1.6 Corticosteroid (CS) 
 
CSs are hormones that can modulate the activity of a plethora of cells in the body. 
Endogenously, the principal CSs are cortisone and cortisol and are produced by most 
mammalian species. CSs regulate the expression of 10 % of genes that are essential to 
life, and exert a surplus of biological actions, including the maintenance of 
homeostasis, coping with physical and emotional stress, and regulating immune and 
inflammatory processes (Buckingham, 2006). However, CSs when administered 
therapeutically, generate unnecessary effects (side effects) (Buckingham, 2006).   
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1.6.1 CS Receptor 
 
CSs exert all their actions through intracellular receptors, which belong to the nuclear 
family of receptors and regulate the transcription of several genes. By the late 1970s 
there was evidence of two receptors, initially known as type 1 and 2 CS receptors, but 
later were termed as mineralcorticoid receptor (MR) and glucocorticoid receptor (GR), 
respectively (Buckingham and Hodges, 1974; Buckingham, 2006).  
 
1.6.1.1 The Mineralcorticoid Receptor (MR) 
 
The MR has a high and equal affinity for cortisol, corticosterone and aldosterone, a 
mineralocorticoid. It is localised mainly to the distal renal tubule and other cells or 
tissues concerned with Na
+
/K
+
 balance, however is also found in specific brain 
regions, such as the entorhinal cortex, neurones within the limbic system and the 
hypothalamus (Buckingham, 2006).  
 
1.6.1.2 The Glucocorticoid Receptor (GR) 
 
The GR is a member of the steroid-hormone family of proteins.  It binds with high 
affinity to cortisol and is widely distributed in the body.  The bound cortical endorses 
the dissociation of molecular chaperones, i.e. heat shock proteins (hsp) from the 
receptor. The human GR gene is found on chromosome 5, locus q31-32. Its genomic 
structure includes three transcritpion-initation sites, producing an alternative first exon 
that is spliced to a common exon 2. Human GR has alternative splice variants, with 
exons 2 to 8 being constant components, whereas there are two exon 9 isoforms; 9α 
produces GRα mRNA and 9β produces GRβ mRNA (Rhen and Cidlowski, 2005). 
Once GRα and GRβ mRNAs translated from the first methionine codon, a 777 amino 
acid (aa) protein (GRα-A) and a 742 aa protein (GRβ-A) are produced. Translation 
from a second methionine codon results in a 751 aa (GRα-B) and 716 aa (GRβ-B). 
The two isoforms (GRα-A and GRα-B) have important functional differences 
between themselves as it has been demonstrated by gene expression in vitro studies 
(Yudt and Cidlowski, 2001). Recently, more isoforms or splicing variants have been 
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identified but the function of each GR isoform has yet to be clarified (Lu and 
Cidlowski, 2005). 
 
1.6.1.3 Post-translational Modifications of GR 
 
The human GR has five serine (Ser) residues that are phosphorylated by either cyclin-
dependent kinases or MAPKs. Ligand binding, like cortisol binding to the GR causes 
phosphorylation of several Ser residues; however other Ser’ phosphorylation is 
independent from ligand binding (Rhen and Cidlowski, 2005). Cortisol binding 
induces another important modification of GR, the covalent attachment of ubiquitin 
molecules, with subsequent proteasomal degradation, a process known as 
ubiquitination (Rhen and Cidlowski, 2005).  Sumoylation involves the attachment of 
small, ubiquitin-related modifiers that potentiates GR’s transcriptional activity (Rhen 
and Cidlowski, 2005). Recent evidence suggests that NO induces nitrosylation of GR 
at the binding site of hsp90 and prevents GR dissociation from hsp90 complex and 
induces reduction in ligand binding (Galigniana et al., 1999; Ito et al., 2006a). Finally 
it has been also shown that GR can be acetylated on ligand binding and its 
deacetylation is critical for p65 interaction (Ito et al., 2006a; Ito et al., 2006b). 
 
1.6.2 The GR Signalling Pathway 
 
CSs can diffuse freely across the cell membrane and exert their effects by binding to 
the GR that is localised to the cytoplasm. Cytoplasmic GR is bound to molecular 
chaperones, such as hsp90 and FK-binding protein. These proteins protect the 
receptor and prevent its nuclear localisation by occupying the sites responsible for 
translocation across the nuclear membrane into the nucleus (Barnes, 2006). Once CSs 
are bound to GR, the chaperone molecules dissociate from the receptor resulting in its 
rapid translocation into the nucleus. The CS/GR complex binds to specific regions in 
the promoter region called glucocorticoid responsive elements (GREs), resulting in 
increased gene transcription (Barnes, 2006). GR molecules can dimerise to form a 
homodimer that binds to GRE and promote changes in gene transcription. In the 
classical way, GR/GRE binding leads to transactivation; alternately through negative 
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GRE sites, GR can bind and lead to gene suppression, a process known as cis-
repression (Fig. 1.4). GRs may also increase transcription by binding to coactivator 
molecules, such as cAMP responsive element binding (CREB) binding protein (CBP) 
and pCAF, consequently inducing histone acetylation and gene transcription (Barnes, 
2006).   
 
1.6.3 Current Available CSs 
 
Currently there is considerable debate regarding the role of ICSs in COPD. 
Nonetheless, these anti-inflammatory agents are recommended as add-on therapy for 
the treatment of patients staged III and IV, according to GOLD guidelines (Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), 2009; Hanania, 2008).  
Aerolised CSs are available in formulations via oral, inhalation and intranasal delivery.  
Currently, several aerolised CSs are used as pharmacotherapy of respiratory diseases. 
Beclomethasone dipropionate (QVAR) is administered at a dose of 40 – 80 μg, twice 
daily. Triamcinolone acetonide is topically active and high initial doses of 12 – 16 
inhalations/day maybe required. Flunisolide is another topically active aerolised CS 
with a longer duration of action prescribed twice daily at 80 μg/puff or 250 μg/puff. 
Fluticasone propionate is a synthetic CS with high topical anti-inflammatory potency 
and is administered in three different doses: 50, 100, and 250 μg, twice daily. 
Budesonide is available in two forms: 200 μg/metered dose delivered by the inhaler 
and 0.25, 0.5 and 1 mg as an inhaled solution. Mometasone furoate is available as an 
inhaler administered once daily, at a dose of 220 μg/actuation dosing. Fluticasone 
furoate, a newer intranasal CS has been recently developed, is active beyond 24 hrs 
and has higher affinity for the GR. Ciclesonide is the newest CS on the market, and is 
available as a once-daily inhaler in 80 and 160 μg/puff (Gardenhire D, 2008).   
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Figure 1.4 The GR signalling pathway. CSs diffuse freely across the cell membrane 
and bind to the GR. Once CSs are bound to the receptor, the homodimer rapidly 
translocates into the nucleus. The CS/GR complex binds to specific regions in the 
promoter region of glucocorticoid responsive elements (GREs), resulting in increased 
gene transcription.  In the classical way, GR/GRE binding leads to transactivation, 
while it has been shown that negative GRE sites exist, where GR can bind and lead to 
gene suppression, a process known as cis-repression. GRs may also increase 
transcription by binding to coactivator molecules, such as cAMP responsive element 
binding protein (CBP) activated by transcription factors (TF) such as NF-κB, c-fos 
and STAT, resulting in histone acetylation and gene transcription. (Adopted by 
Barnes, 2006 (Barnes, 2006))   
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1.6.4 Molecular Mechanism of CS Insensitivity 
 
Although ICSs are highly effective for asthma treatment, patients with COPD, 
smoking and severe asthmatics are insensitive to CSs. There are several mechanisms 
that contribute to CS resistance in these patients.  
Studies showed that rare CS resistant (CR) asthma was common within families, 
suggesting that genetic factors might be implicated, known as familial CS resistance 
(Carmichael et al., 1981; Barnes, 2010).   
Several studies have shown increased expression of GRβ in CR patients with asthma 
(Sousa et al., 2000; Hamid et al., 1999), rheumatoid arthritis (Kozaci et al., 2007) and 
inflammatory bowel disease (Orii et al., 2002). GRβ is induced by pro-inflammatory 
cytokines and acts as a dominant negative inhibitor, as it competes with GRα for 
binding to the GRE. In most cell types GRβ is much lower than GRα, apart from 
neutrophils, suggesting that this may not contribute to CS insensitivity. However, it is 
believed that it interferes with GRα nuclear translocation instead, as knockdown of 
GRβ in alveolar macrophages, resulted in elevated GRα nuclear translocation and 
increased CS responsiveness (Goleva et al., 2006). 
Additionally, GR post-translational modifications cause defective GR binding and GR 
nuclear translocation. Patients with CR asthma were found to have increased IL-2 and 
IL-4, and these cytokines were also found to decrease GR nuclear translocation and its 
affinity to bind to the nucleus (Irusen et al., 2002). Phosphorylation of GR by several 
kinases might also reduce its ability to translocate into the nucleus and bind to the 
GRE in order to trigger anti-inflammatory gene transcription. JNK, at serine 226,  
(Barnes, 2010; Ismaili and Garabedian, 2004; Itoh et al., 2002) and ERK (Barnes, 
2010; Li et al., 2004) have also been shown to be involved in GR phosphorylation and 
consequently resistance to CSs. Furthermore, GR may be nitrosylated in vitro by NO 
causing reduced binding affinity of CSs (Barnes, 2010; Galigniana et al., 1999).  
Overexpression of pro-inflammatory transcription factors has also been reported to 
contribute to CS insensitivity. Excess AP-1 produced in asthma binds to GR, 
preventing activated GR to interact with GREs and other transcription factors 
(Adcock et al., 1995; Barnes, 2010).   
Histone deacetylase (HDAC) 2 is known to be a key co-repressor of GR action. 
HDAC2 binds to and deacetylates activated GR, enabling its binding to NF-κB and 
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subsequently the inhibition of pro-inflammatory cytokine production. As HDAC2 
expression and activity is decreased in severe asthma (Ito and Mercado, 2009) and 
COPD (Ito et al., 2005), these defects might account for the CS insensitivity seen in 
these diseases (Barnes, 2009b).  
 
1.7 Adrenergic Receptor Agonist 
 
1.7.1 Adrenergic Receptors (ARs) 
 
In the early 1980’s the primary structure of rhodopsin, the first identified GPCR was 
published (Nathans and Hogness, 1983). GPCRs are the largest family of membrane 
proteins in the human genome (Lagerstrom and Schioth, 2008) and are responsible for 
transmembrane signal transduction in response to several stimuli, such as 
neurotransmitters and hormones (Rasmussen et al., 2007). Once the first draft of the 
human genome was available in 2001 (Lander et al., 2001; Venter et al., 2001), 
Fredriksson and colleagues were able to divide the 802 different human GPCRs into 
five families; glutamate, adhesion, frizzled/taste2, secretin and rhodopsin families 
(Fredriksson et al., 2003). Twenty three sequences could not be included in any of the 
above families, so they have been classified as “other 7TM receptors” (Fredriksson et 
al., 2003).  
The rhodopsin receptor family is the largest subfamily, representing the 90 % of the 
GPCRs (Palczewski et al., 2000). There are ~ 670 full-length human receptor proteins 
included that can be further subdivided into four main groups: α, β, γ and δ 
(Lagerstrom and Schioth, 2008). The α-Group of rhodopsin receptors consist of five 
main groups: the opsin, the prostaglandin, the melatonin, the amine and the MECA 
receptor clusters. The β-Group includes thirty six receptors; the γ-Group has three 
main branches: the SOG, the MCH and the chemokine receptor clusters and finally 
the δ-Group has four main branches: the MAS-related, the purin, the glycoprotein and 
the olfactory receptor clusters. For the purposes of this project, of interest is the amine 
receptor cluster of the α-Group of rhodopsin receptors, which include the serotonin 
(HTR), muscarinic (CHRM), histamine (HRH), dopamine (DRD), trace amine (TAR), 
adrenergic (ADR) and several orphan receptors (Fredriksson et al., 2003). 
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Adrenergic receptors (ARs) mediate the central and peripheral actions of the primary 
sympathetic neurotransmitter, nor-adrenaline and the central neurotransmitter, 
adrenaline (Bylund et al., 1994). ARs are found in many peripheral tissues and 
neuronal populations within the central nervous system. They have been of major 
interest as drug targets by pharmaceutical industries as they are involved in various 
functions, such as airway reactivity, control of blood pressure and myocardial 
contractile rate and force (Bylund et al., 1994). Ahlquist’s quantitative approach 
suggested the existence of two adrenergic receptor subtypes: subtype α and subtype β 
(AHLQUIST, 1948). Currently, ARs have been classified into three main categories: 
the α1-AR, the α2-AR and the β-AR. Each subfamily is further subdivided into 3 
subtypes (Xiao et al., 2006). 
 
1.7.2 Classification of ARs 
 
1.7.2.1 Classification of the α1 and α2 ARs 
 
The α1-AR belongs to a class of receptors that are multifunctional in nature. They are 
implicated in a general signal transduction mechanism for the release of calcium and 
activation of protein kinase C (Berridge, 1984; Johnson and Minneman, 1987), a 
mechanism based on the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PtdIns4,5P2) (Johnson and Minneman, 1987).  The α1-ARs have initially been 
divided into the α1A- and α1B-AR subtypes, but later homology screening and 
molecular cloning studies revealed a novel receptor, the α1C-AR (Perez, 2007). 
The α2-ARs can be activated by nor adrenaline and adrenaline with no significant 
selectivity between all identified α2-AR subtypes. They have been linked with the 
mechanism of the inhibition of adenylyl cyclase (Bylund et al., 1994).  The α2-ARs 
have been subdivided based on functional and radioligand-binding studies, into highly 
homologous subtypes: α2A-AR, α2B-AR and α2C-AR (Bylund et al., 1994). 
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1.7.2.2 Classification of the β-Adrenergic Receptor (β-AR) 
 
The β-AR family has been divided into three groups: the β1, β2 and β3ARs and are 
found in cardiac, airway smooth muscle (ASM) and adipose tissue, respectively 
(Johnson, 1998). They share a 65 – 70 % homology between β1 - β3 and β2 receptors 
(Johnson, 2006). However, studies have shown that a putative β4-receptor, which is 
distinct from the other three, exists in the human heart involved in the modulation of 
human cardiac function (Kaumann, 1997).  
 
1.7.3 The β2 Adrenergic Receptor (β2AR) 
 
1.7.3.1 β2AR Structure and Density 
 
β2ARs are comprised of 413 amino acids, are about 43600 Da in size and share a 
common feature with other GPCRs. They consist of 7 transmembrane-spanning α-
helices, with three extracellular loops, with an amino (NH2)-terminus and 3 
intracellular loops, with carboxy (COOH)-terminus (Fig. 1.5) (Johnson, 2006; Liggett, 
2002). At positions 6, 15 and 187 there are N-glycosylation sites. These sites aid to 
the β2 agonist trafficking through the cell membrane into the cytoplasm. At position 
341 the COOH-terminus of the receptor is anchored to the cell membrane (Johnson, 
2006). 
Autoradiographic studies in the human lung demonstrated that β2ARs are widely 
distributed at cellular level. They were found to be more abundant in ASM cells, but 
were also discovered in other cells such as epithelial, endothelial, type II and mast 
cells (Johnson, 2006).  Even though β2ARs are widely scattered within cells, their 
density is much higher in ASM cells compared to others. Other measurements showed 
that airway β2ARs are of higher abundance compared to cardiac tissue (Johnson, 
2006). 
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Figure 1.5 The human β2 adrenergic receptor. The diagram shows the structure of 
the human β2 adrenergic receptor. There are 7 transmembrane-spanning α helices with 
three extracellular loops at the amino (NH2)-terminus and three intracellular loops at 
the carboxy (COOH)-terminus. Specific regions are colour-indicated; coupling with 
the G protein (red), downregulation (yellow), desensitisation (pink). Specific sites are 
also specified; amino acid residues where β2 agonists bind (brown) and polymorphic 
mutations sites (green) (Adapted from Johnson, 2006) (Johnson, 2006). 
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1.7.3.2 Activation of β2AR 
 
Evidence suggests that β2ARs oscillate between two forms. Under resting conditions, 
β2ARs are found in equilibrium between the active and inactive form, with the latter 
being predominant. In the activated form, β2AR is coupled with the α-subunit of the 
trimeric Gs protein and a molecule of guanosine triphosphate (GTP) (Johnson, 2006). 
The α-subunit dissociates from the receptor upon GTP replacement from guanosine 
diphosphate (GDP), causing the return of the receptor to its low energy state, the 
inactive form. Probably β2 agonists bind to the β2AR, causing a temporary 
stabilisation of the receptor to its activated state, rather than inducing a 
conformational change (Johnson, 2006). Full agonists act differently to partial 
agonists and β-antagonists, upon binding to the receptor, as it will be explained below. 
 
1.7.3.3 β2AR Signalling 
 
Since the 1960s, it is accepted that β2AR activation is mediated by elevated 
intracellular cyclic adenosine 3’,5’-monophosphate (cAMP) levels (Robison et al., 
1967). Binding of β2 agonists to the β2AR stabilises the receptor to its activated state, 
thus shifting the equilibrium. Consecutively, the α-subunit of the Gs protein 
dissociates and adenylyl cyclase is activated, leading to the conversion of adenosine 
triphosphate (ATP) is converted into cAMP (Johnson, 2001). In the classical pathway, 
elevated levels of cAMP trigger the activation of protein kinase A (PKA) (Fig. 1.6). 
Activation of PKA in the lung results in ASM cell relaxation through effects on K
+ 
channels and Na
+
 / K
+
 ATPases (Shore and Moore, 2003). Cell relaxation can also be 
achieved through the inhibition of intracellular calcium (Ca
2+
) ions release and Ca
2+
 
sequestration (Johnson, 1998). 
Xiao et al have demonstrated that β2AR stimulation in cardiac myocytes, can lead to 
the activation of a pertussis toxin (PTX)-sensitive G protein, in parallel to Gs protein 
(Xiao et al., 1995). The PTX-sensitive G proteins include three Gi subtypes: Gi1, Gi2 
and Gi3, but unfortunately they did not manage to determine of the particular Gi 
subtype involved (Xiao et al., 1995). Coupling of the β2AR to Gi protein is a process 
regulated by PKA phosphorylation prior to PTX-sensitive MAPK activation. Gβγ 
release by PTX-sensitive Gi coupled receptor can activate MAPK in a pathway that  
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Figure 1.6 The β2 Adrenergic Receptor Signalling. Binding of the β2 agonist 
stabilises the β2 receptor to its activated state. The α-subunit dissociates of the Gs 
protein and adenylyl cyclase is activated. Adenosine triphosphate (ATP) is converted 
into cAMP. In the classical pathway, elevated levels of cAMP trigger the activation of 
protein kinase A (PKA) and downstream pathways involve the activation of either 
CREB or Rap1. Alternatively to the classical pathway cAMP activates exchange 
protein directly activated by cAMP (Epac), triggering pathways involving 
Rap1/MEK/ERK kinases.  
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involves the non receptor tyrosine kinase cSrc and the RaS protein (Daaka et al., 
1997). 
Alternative to the classical pathway, cAMP regulates its biological effects through a 
PKA-independent pathway. cAMP ion channels and exchange protein directly 
activated by cAMP (Epac) are targets that are involved in cAMP responses (Bos, 
2006). Epac variants, Epac1 and Epac2 are guanine-nucleotide-exchange factors 
(GEF) for Rap1 and Rap2. Their catalytic functions might mediate cAMP-induced 
control of cell adhesion and cell-junction formation (Bos, 2006). Epac1 contains a 
cAMP binding site and a domain homologous of known GEFs for Ras and Rap1 (de 
Rooij et al., 1998). 
 
1.7.3.4 β2 Agonist Interaction with the β2AR 
 
Site-directed mutagenesis has revealed β2 agonist binding sites on the β2AR, known as 
the active site of the receptor. This region is responsible for the β2 agonists to exert 
their biological effects. They are positioned one third of the way into the receptor core, 
approximately 15 Å (Johnson, 2006). The regions on the receptor responsible for β2 
agonist binding to the active site of the receptor are: an aspartate residue at position 
113 in the third domain, two serine residues at 204 and 207 in the fifth domain and an 
asparagine 293 in the sixth domain (Johnson, 2006). 
The way that agonists interact with the β2AR has been shown by computational 
molecular modelling. SABAs, such as albuterol, are hydrophilic and enter the receptor 
directly from the extracellular aqueous compartment and interact with the active site 
of the receptor (Johnson, 2006). Although the onset of  action is very rapid, SABAs 
have a short residency time at the active site of the receptor, which results in a short 
duration of action, approximately 4 – 6 hours (Johnson, 2006). 
LABAs have different mechanism of action. FM is a cationic and a somewhat 
lipophilic β2 agonist. It is taken up to the receptor in a form of a depot and then it 
dissolves till it reaches the active site where it interacts (Johnson, 2006). SM is highly 
lipophilic, and diffuses laterally through the membrane to the receptor and approaches 
the active site. This is a slow process, which explains the shorter onset of action of 
SM (i.e. ~ 30 min), compared to FM and salbutamol (Johnson, 2006).  
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1.7.3.5 β2AR Desensitisation 
 
β2AR desensitisation is an autoregulatory process associated with β2AR activation. 
Overstimulation of receptors by prolonged β2 agonist exposure is prevented by 
desensitisation (Johnson M, 2000).  The molecular mechanism of desensitisation 
consists of three distinct processes: i) uncoupling of the receptor from adenylyl 
cyclase followed by ii) internalisation and iii) phosphorylation of uncoupled receptors. 
Upon β2 agonist binding phosphorylation of the receptor occurs by the cAMP-
independent kinase (βARK) or other GPCR kinases (GRK). Phosphorylation prompts 
β arrestin binding that results in partial uncoupling of the receptor from the Gs protein, 
limiting its function. Prolonged exposure to agonists triggers internalisation of the 
receptor causing loss of cell surface receptors (Johnson M, 2000; Krasel et al., 2005). 
Once the receptor is sequestered into the cytoplasm, dephosphorylation occurs. This 
triggers the resensitisation, i.e. the recycling of the receptor back to the cell membrane 
(Johnson M, 2000; Tran et al., 2007). 
 
1.7.4 Development of β2AR Agonists 
 
1.7.4.1 Characteristics of SABAs 
 
SABAs have been used as bronchodilators for the treatment of asthma since the 
discovery of α- and β-ARs, replacing epinephrine and avoiding some side effects 
(Johnson M, 2000). Initially isoproterenol, a highly selective β-AR agonist proved to 
be of greater significance than epinephrine in reducing airway constriction (Johnson 
M, 2000). Further research aided to the development of other compounds. 
Metaproterenol emerged as a more stable compound than isoproterenol; however it 
was linked with several cardiac side effects. Once β-receptors were classified β1 and 
β2ARs by Lands et al, more selective agonists were developed that produced marked 
bronchodilation with less adverse side effects (Johnson M, 2000; Lands et al., 1967). 
The first SABA was albuterol, which is still in clinical use compared to other SABAs, 
i.e. fenoterol, proceterol and clenbuterol.  Their short duration of action (4 – 6 hrs) 
and the need to further reduce side effects, such as vasodepression and skeletal muscle 
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tremor, drove pharmacologists to more research in order to advance β2 agonist 
pharmacology (Johnson M, 2000). 
The first LABAs, bitolterol and bambuterol have achieved longer duration of action; 
however they are orally administered to the patient and they are liable to side effects, 
such as tachycardia and physiological tremor (Johnson M, 2000). Salbutamol was also 
developed as a relatively longer-acting inhaled β2 agonist, but is currently recognised 
as a SABA compared to novel LABAs, FM and SM. 
 
1.7.4.2 Characteristics of LABAs 
 
LABAs are used as bronchodilators in the treatment of asthma and COPD as well as 
anticholinergics and methylxanthines (Celli and MacNee, 2004). They appear to be 
important in ASM relaxation and improving lung emptying during tidal breathing 
(Celli and MacNee, 2004). They have a prolonged duration of action compared to that 
of SABAs’. They have been developed in order to be administered only twice daily 
(Johnson M, 2000).  
Two compounds that have been shown to have significantly longer therapeutic 
duration of action are FM and SM. These LABAs are administered through the 
inhaled route of administration (Johnson M, 2000). Although FM had been originally 
developed to be administered orally, it was confirmed that FM has a bronchodilation 
activity for up to 12 hours, following inhalation (Johnson M, 2000). SM has been 
developed recently, and was designed to have a longer duration of action through both 
oral and inhaled route of administration (Johnson M, 2000). Lately, several 
pharmaceutical companies have developed various new candidates for LABAs. 
Particularly, ultra LABAs, such as, GW642444, arformoterol, carmoterol and 
indacaterol, that require once-daily administration are under development for the 
treatment of COPD and asthma (Cazzola et al., 2005). 
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1.8 Interaction between the GR and the β2AR 
 
1.8.1 LABA Effect on CS Activity 
 
LABAs are known to activate GR directly or increase CS-induced GR activation.  
Eickelberg et al have demonstrated activation of GR by two β2 agonists, SM and 
salbutamol (Eickelberg et al., 1999). Upon stimulation with these β2 agonists, GR was 
rapidly depleted from the cytoplasm of primary human lung fibroblasts and vascular 
smooth muscle cells and translocated into the nucleus. GR was active and functional 
as it bound to its specific recognition sequence, GRE. The effect of β2 agonists was 
β2AR specific, suggesting that the β2 agonist/β2AR interaction was responsible for 
downstream signalling of GR activation (Eickelberg et al., 1999).  GR nuclear 
translocation activated by the β2 agonists was PKA-dependent, however was less 
effective than a CS, dexamethasone (Dex) (Adcock et al., 2002; Eickelberg et al., 
1999). Roth et al also showed that LABAs promote GR nuclear translocation in ASM 
cells (Roth et al., 2002). 
Other than direct  GR activation by a LABA, LABAs also enhance CS-dependent GR 
activation by priming the GR for successive CS binding (Johnson, 2005). The priming 
of the GR by a LABA is achieved by phosphorylation through MAPK activation 
(Johnson, 2005). The dissociation of the Gas subunit upon LABA binding, the residual 
Gβγ subunit triggers a cascade that involves the non-receptor tyrosine kinase C-Src 
and the G-protein Ras concluding to MAPK activation (Daaka et al., 1997; Johnson, 
2005). β2AR is phosphorylated, probably by PKA and activated MAPK in turn 
phosphorylates the GR at several proline-directed serine residues at its N-terminal. A 
potential increase in negative charge at the N-terminal causes a conformational 
change in the GR protein that leads to the “priming” of the receptor, making it more 
prone to CS-dependent activation (Johnson, 2005).  
In vivo, Usmani and colleagues showed that addition of SM to low doses of FP 
significantly enhanced GR nuclear translocation in sputum epithelial cells and 
macrophages from asthma patients. Consistent with the in vivo data, SM addition to 
low dose FP significantly improved GR nuclear translocation in macrophage airway 
cell lines in vitro (Usmani et al., 2005). In addition, although CS had no effect on 
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LABA-induced cAMP responsive element (CRE)-dependent transcription in human 
airway epithelial cells, LABA synergistically enhanced GRE-dependent transcription 
induced by CSs (Black et al., 2009; Kaur et al., 2008).   
 
1.8.2 CS Effect on β2AR Function  
 
As shown above, β2 agonists enhance CS-dependent effects. In addition, several 
studies have shown that CS influence β2AR function (Johnson, 2004; Black et al., 
2009).  CSs support the transcription of β2ARs by means of binding to GREs in the 5’ 
non coding promoter region of the β2AR gene (Johnson, 2004). Dex increased β2AR 
mRNA expression and β2AR number in a concentration- and time-dependent manner 
in human peripheral lung tissues (Mak et al., 1995a). CSs are also reported to 
stimulate an increase in β2ARs of DDT1 MF-2 hamster vas deferens cells after 48 hrs 
of exposure to the CS and sustained for up to 72 hrs (Hadcock and Malbon, 1988). In 
agreement with this, Collins et al demonstrated that β2ARs in DDT1 MF-2 cells are 
regulated by CSs. Addition of steroid resulted in a rapid rise in steady state levels of 
β2AR mRNA, followed by the accumulation of new membrane receptors (Collins et 
al., 1988). 
Moreover, treatment with CSs rescued, in a limited extent, the β2 agonist-induced 
downregulation of the receptors (Hadcock et al., 1989). This study is in agreement 
with the in vivo study by Mak et al in rats. Chronic stimulation with β2 agonist 
propagated the downregulation of β2ARs, which was reversed by the addition of Dex. 
Additionally, the reduction in β2AR mRNA after chronic exposure was also reversed 
by Dex treatment (Mak et al., 1995b) and CSs increased β2 agonist-dependent cAMP 
induction. CSs can augment the coupling between β2AR and the Gs subunit of the 
receptor, consequently increasing adenylyl cyclase activity in response to stimulation 
of the receptor (Shore et al., 1997; Black et al., 2009). 
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1.9 Effect of Oxidative Stress on the GR and the β2AR 
 
1.9.1 Effect of Oxidative Stress on the GR 
 
Steroid binding sites are located on the COOH-terminal of the steroid receptor, in a 
region known as the hormone-binding domain (HBD). The HBD must be folded to 
form a high affinity steroid-binding pocket and is associated with Hsp90, in the case 
of the GR, in order to encourage CS binding. Oxidative stress and several oxidising 
agents compromise the steroid-binding activity by disulfide bond formation between 
the thiols in the GR HBD (Simons, Jr. and Pratt, 1995).  
HDAC2 has been proposed to be a prerequisite molecule for GR action  (Ito et al., 
2005). However, a reduction in HDAC2 has been shown in surgically resected lung 
tissue, airway biopsies and alveolar macrophages from COPD patients (Cosio et al., 
2004; Ito et al., 2005). In vitro studies demonstrated that oxidative stress reduced 
HDAC2 activity and expression (Cosio et al., 2004; Ito et al., 2005; Moodie et al., 
2004; Osoata et al., 2009b) causing CS insensitivity.  
 
1.9.2 Effect of Oxidative Stress on the β2AR 
 
Oxidative stress has been shown to affect the affinities for both α- and β-ARs in 
cardiac membranes. This effect was more rapid for β-ARs as it was evident within 10 
min of incubation with xanthine oxidase, a well known O2
-.
-generating system 
(Kaneko et al., 1991). H2O2-induced depression of isoproterenol-stimulated adenylyl 
cyclase activity in a concentration-dependent manner was identified in cardiac 
membranes of rat hearts (Persad et al., 1998).  
β-ARs, as well as adenylyl cyclase are known to possess sulphydryl (SH) groups in 
their active site. Their modification by oxidative stress might alter the characteristic of 
the protein (Skurat et al., 1985; Persad et al., 1997).  It has been suggested that both 
SH groups and lipid peroxidation products (Heikkila, 1983) might be involved in the 
alteration of β-AR/adenylyl cyclase pathway (Persad et al., 1997; Schimke et al., 
1992). Furthermore, reports suggest that oxidative stress-induced SH modifications 
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disrupt cellular mechanisms for calcium homeostasis (Scherer and Deamer, 1986; 
Trimm et al., 1986).  
There are many reports that illustrate the effects of oxidative stress in cardiac β-ARs, 
however, this effect has not been extensively studied in lung disease and especially 
how β2AR signalling is affected by the presence of ROS.  
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1.10 Hypothesis and Aims 
 
It is now recognised that combination therapy of ICSs with LABAs is effective in 
controlling airflow limitation and inflammation in both asthma and COPD better than 
each component alone or any other drugs. However, the efficacies of current available 
combination therapies are limited because of relatively shorter duration of action and 
less efficacy of current CSs under oxidative stress, especially in patients with COPD 
or smoking asthma, where high levels of oxidative stress are observed. 
Hence, combination therapy (either LABA or CS) that is oxidative stress insensitive 
and has longer duration of action would be ideal for the treatment of COPD, smoking 
and severe asthma.  
Based on the above, I hypothesise that oxidative stress affects the pharmacological 
efficacies of CSs, LABAs and/or their combination. 
There is a great need for understanding and dissecting the mechanism involved in CS 
insensitivity and β2AR signalling, under oxidative stress. This study will propose an 
optimal combination (ICS/LABA) therapy for the treatment of COPD. 
 
To test the hypothesis of this project specific aims were set and are listed below: 
  
 Investigate the potency and duration of action of CSs, in either the presence 
or absence of oxidative stress. The effects of novel CS, FF on pro-inflammatory 
cytokine production and GR-dependent gene expression were evaluated. These 
effects were compared to that of FP and Bud, in different human airway cell lines 
(A549, Beas-2B and U937 cell lines) and under simulated conditions of oxidative 
stress. The duration of action for these CSs were also evaluated by comparison of 
efficacies at 4 hrs and 16 hrs (or longer) pre-treatment. The data were confirmed 
in primary cells, i.e. in PBMCs from patients with COPD, mild asthma and 
healthy volunteers.  
  
 Investigate the effect of oxidative stress on β2AR-dependent signalling. The 
potency of FM or SM to produce cAMP, in either the presence or absence of 
oxidative stress was investigated. Extensive screening of stress kinase activation 
was performed in the presence or absence of LABAs and the effects of LABAs on 
PI3K signalling and β2AR internalisation, under oxidative stress, were further 
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evaluated. Finally, the effect of either FM or SM on restoring CS sensitivity was 
investigated in PBMCs from COPD patients and healthy volunteers, or in U937 
cells, under H2O2 treatment. 
 
 Investigate the effect of combinations of CS with LABAs in PBMCs from 
COPD patients, or in cell lines, under oxidative stress. This was studied by 
investigating the effect of add-on treatment of LABA to CS-dependent anti-
inflammatory action in U937 cells, i.e. transrepression (inhibition of IL-8 release) 
or transactivation (induction of MKP-1 mRNA expression). The same effects 
were studied in PBMCs from healthy volunteers and COPD patients.  
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2.1 Materials 
 
2.1.1 General Reagents 
 
Hydrogen peroxide solution 30 % (w/w) in H2O is from Sigma-Aldrich Company Ltd 
(Poole, Dorset, UK). RNeasy® Mini, QIAEX® II Gel Extraction, QIAprep® Spin 
Miniprep and HiSpeed® Plasmid Maxi kits were obtained from Qiagen Ltd. (Crawley, 
West Sussex, UK). Amersham ECL
TM
 and ECL Plus
TM
 Western blotting reagent pack 
and rainbow
TM
 molecular weight marker were purchased from GE Healthcare 
(Chalfont St Giles, Buckinghamshire, UK). LB agar powder, terrific broth, One 
Shot® TOP10 Chemically Competent E. coli, Nu-PAGE® Novex 10% Bis-Tris pre-
cast gels, 20X NuPAGE® MOPS SDS Running buffer for Bis-Tris gels, 4X 
NuPAGE® LDS sample buffer and nitrocellulose iBlot
TM 
Transfer stack were from 
Invitrogen (Paisley, Renfrewshire, UK). ProteoExtract® Transmembrane protein 
extraction kit was purchased from Novagen (Madison, WI, USA). ReBlot mild 
antibody stripping solution (10X) was from Chemicon (Chandlers Ford, Southampton, 
UK). BCA protein assay reagent was obtained from Perbio Science UK Ltd 
(Cramlington, Northumberland, UK).  Nuclear extract kit was from Active motif 
(Rixensart, Belgium). Recombinant human TNFα, human CXCL8/IL-8, IL-6 and 
GM-CSF Duoset ELISA kits, ELISA substrate reagent pack and Proteome Profiler 
Human Phospho-MAPK Array kits were purchased from R&D Systems Europe Ltd 
(Abingdon, Oxfordshire, UK). Cyclic AMP EIA kit was obtained from Cayman 
Chemical (Ann Arbor, MI, USA). High capacity cDNA reverse transcription kit and 
Taqman® Universal PCR Master Mix were acquired from Applied Biosystems 
(Warrington, Cheshire, UK). Bio-Rad protein assay dye reagent was from Bio-Rad 
laboratories Ltd (Hemel Hempsted, Hertfordshire, UK). Fuji medical x-Ray films 
were purchased from Genetic Research Instrumentation Ltd (Braintree, Essex, UK). 
Other general laboratory reagents were purchased from Sigma-Aldrich Company Ltd 
(Poole, Dorset, UK), VWR International (Lutterworth, Leicestershire, UK) and Fisher 
Scientific (Loughborough, Leicestershire, UK). 
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2.1.2 Antibodies 
 
Table 2.1. List of antibodies used (primary and secondary antibodies used for western 
blotting) 
 
Name 
(Catalogue #) 
Antibody species 
/ Type 
Source 
 
Beta actin 
(ab8226) 
 
Mouse monoclonal 
 
Abcam 
(Cambridge, UK) 
 
Beta 2 adrenergic receptor 
(ab40834) 
 
Goat polyclonal 
 
Abcam 
(Cambridge, UK) 
 
Beta 2 adrenergic receptor 
(ab69598) 
 
Rabbit polyclonal 
 
Abcam 
(Cambridge, UK) 
 
GR (E-20) 
sc-1003 
 
Rabbit polyclonal 
 
Santa Cruz 
(Heidelberg, Germany) 
Phospho Akt1/PKBα 
(Ser473) 
(05-669) 
 
Mouse monoclonal 
Upstate 
(Chandlers Ford, 
Southampton ,UK) 
 
Total Akt 
(07-416) 
 
Rabbit polyclonal 
 
Upstate 
(Chandlers Ford, 
Southampton ,UK) 
Phospho p38 MAPK 
(Thr180/Tyr182) 
(9211S) 
 
Rabbit polyclonal 
 
Cell Signaling 
(Danvers, MA, USA) 
 
p38 MAPK 
(9212) 
 
Rabbit polyclonal 
 
Cell Signaling 
(Danvers, MA, USA) 
 
Anti-mouse IgG/HRP 
(P0447) 
 
Goat polyclonal 
 
Dako 
(Ely, Cambridgeshire, UK) 
 
Anti-rabbit IgG/HRP 
(P0448) 
 
Goat polyclonal 
 
Dako 
(Ely, Cambridgeshire, UK) 
 
Anti-goat IgG/HRP 
(P0449) 
 
Rabbit polyclonal 
 
Dako 
(Ely, Cambridgeshire, UK) 
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2.1.3 Compounds 
 
Table 2.2. List of compounds used 
 
 
Compound 
 
Source 
 
 
Solvent 
 
Molecular 
weight 
Stock 
concentration 
(M) 
Storage 
temperature 
(
o
C) 
 
Inhaled corticosteroids 
 
 
Budesonide 
 
Astra 
Zeneca 
 
DMSO 
 
430.5 
 
10
-2
 
 
- 20 
 
 
Fluticasone  
Furoate
*
 
 
GSK 
 
DMSO 
 
538.5 
 
10
-2
 
 
-20 
 
 
Fluticasone  
Propionate 
 
Sigma-
Aldrich 
 
DMSO 
 
500.5 
 
10
-2
 
 
- 20 
 
 
Mometasone  
Furoate 
 
GSK 
 
DMSO 
 
521.4 
 
10
-2
 
 
- 20 
 
 
Long-acting β2 agonists 
 
 
Formoterol  
Fumarate 
 
Astra 
Zeneca 
 
DMSO 
 
840.9 
 
10
-2
 
 
- 20 
 
GW642444
$ 
Vilanterol
 
Trifenatate 
 
GSK 
 
DMSO 
 
774.8 
 
10
-2
 
 
- 20 
 
Salmeterol  
Xinofoate 
 
GSK 
 
DMSO 
 
415.5 
 
10
-2
 
 
-20 
 
 
Short-acting β2 agonist 
 
 
Salbutamol 
Sulphate 
 
Sigma-
Aldrich 
 
DMSO 
 
239.3 
 
10
-2
 
 
-20 
 
 
*
 Ultra long-acting corticosteroid; 
 
$
 Ultra long –acting β2 agonist 
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2.1.4 Enzymes used for Molecular Biology 
 
All restriction enzymes and buffers were purchased from Promega, otherwise stated in 
table 2.3. 
 
Table 2.3. List of enzymes used 
Name Description Source 
 
MultiScribe
TM
 Reverse 
Transcriptase 
 
Synthesises single-stranded cDNA from 
total RNA 
 
Applied 
Biosystems 
 
T4 DNA ligase 
Catalyzes the joining of two DNA strands 
between the 5´-phosphate and the 3´-
hydroxyl groups of adjacent nucleotides 
 
Promega 
 
2.1.5 Plasmids 
 
An YFP-conjugated GR (YFP-GR) plasmid was provided by GlaxoSmithKline. 
 
 
 
Figure 2.1 YFP-GRα plasmid map. Schematic representation of the YFP-GRα 
plasmid used in this study. Briefly, hGRα was inserted in the 4.7 kb pEYFP-C1 vector 
by ligation. 
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2.1.6 Buffers 
 
2.1.6.1 General Buffers 
 
20X Phosphate Buffered Saline (PBS)                                                          160 g NaCl 
23.2 g Na2HPO4 
4 g KCl 
4g KH2PO4 
Make up to 1 litre with deionised H2O 
 
10X Tris/Borate/EDTA (TBE)                                                                108 g Tris base 
55 g Boric acid 
40 ml 0.5M EDTA 
Make up to 1 litre with deionised H2O 
 
5 M NaCl                                                                                                       292 g NaCl 
Make up to 1 litre with deionised H2O 
 
Tris Buffered Saline - Tween (TBS - Tween)                                        30 ml 5 M NaCl 
10 ml TrisHCl, pH 8.0 
Make up to 1 litre with deionised H2O 
Prior to use add 500 μl Tween-20 
 
TrisHCl, pH 7.4 or pH 8.0                                                                       121 g Tris base 
Adjust to desired pH with HCl 
Make up to 1 litre with deionised H2O 
 
Terrific Broth (TB) Medium                                                                               47 g TB 
4 mllit
-1 
glycerol 
Make up to 1 litre with deionised H2O 
 
Luria Bertani (LB) agar                                                                                       32 g LB 
Make up to 1 litre with deionised H2O 
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2.1.7 Tissue Culture Reagents 
 
RPMI-1640 medium with sodium bicarbonate, without L-glutamine was obtained 
from Sigma-Aldrich Company Ltd (Poole, Dorset, UK). RPMI-1640 medium, phenol 
red free, without L-glutamine and Opti-MEM® I reduced-serum medium, without L-
glutamine were from Invitrogen (Paisley, Renfrewshire, UK). Foetal bovine serum 
(FBS) was purchased from PAA Laboratories Ltd (Yeovil, Somerset, UK) and was 
stored as 50 ml aliquots at -20 
o
C until needed. L-glutamine was from Sigma-Aldrich 
Company Ltd (Gillingham, Medway, UK) and was stored as 5 ml aliquots at – 20 oC 
until needed. Culture medium was prepared using freshly thawed FBS and L-
glutamine and was stored at 4 
o
C. 
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2.2 Methods 
 
2.2.1 Cell Culture 
 
All cell culture was carried out in a Scanlaf Class II Microbiological Safety cabinet. 
 
2.2.1.1 U937 Cells 
 
U937 cells (human leukemic monocytic lymphoma cell line) were purchased from 
ATCC (Manassas, VA, USA) and were grown to confluence in 150 cm
2
 flasks 
containing 30 ml RPMI-1640 medium supplemented with 10 % (v/v) FBS and 2 mM 
L-glutamine (complete medium) and were maintained in a humidified atmosphere of 
5 % CO2 at 37 
o
C. For passaging, cells were collected in a 50 ml falcon tube and were 
centrifuged at 1200 x g for 3 min at room temperature. Cells were then resuspended in 
the appropriate amount of complete medium and were seeded. For general 
maintenance seeding ratios were 1:15 or 1:30 depending on the number of days 
between passaging. 
 
2.2.1.2 A549 Cells 
 
A549 cells (human carcinomic alveolar basal epithelial cell line) were grown to 
confluence in 150 cm
2
 flasks containing 30 ml D-MEM supplemented with 10 % 
(v/v) FBS and 2 mM L-glutamine (complete medium) and were maintained in a 
humidified atmosphere of 5 % CO2 at 37 
o
C. For passaging, cells were collected in a 
50 ml falcon tube after 5 min exposure to 0.05 % Trypsin/EDTA at 37 
o
C, and were 
centrifuged at 1200 x g for 3 min at room temperature. Cells were then resuspended in 
the appropriate amount of complete medium and were seeded. For general 
maintenance seeding ratios were 1:15 or 1:30 depending on the number of days 
between passaging. 
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2.2.1.3 Beas-2B Cells 
 
Beas-2B cells (human bronchial epithelial cell line transformed by SV40 T-antigen) 
were grown to confluence in 150 cm
2
 flasks containing 30 ml Keratinocyte-SFM 
medium supplemented with 10 % (v/v) FBS (complete medium) and were maintained 
in a humidified atmosphere of 5 % CO2 at 37 
o
C. For passaging, cells were collected 
in a 50 ml falcon tube after 5 min exposure to 0.05 % Trypsin/EDTA at 37 
o
C, and 
were centrifuged at 1200 x g for 3 min at room temperature. Cells were then 
resuspended in the appropriate amount of complete medium and were seeded. For 
general maintenance seeding ratios were 1:15 or 1:30 depending on the number of 
days between passaging. 
 
2.2.1.4 Peripheral Mononuclear Blood Cells (PBMCs) 
 
The study was approved by the Ethics Committee of the Royal Brompton & Harefield 
Hospitals National Health Service Trust and all patients and healthy volunteers had 
given informed consent. Venous blood (60 ml) was collected into three 20 ml syringes 
containing 1 ml of acid citrate dextrose (ACD) solution. Peripheral blood 
mononuclear blood cells (PBMCs) were isolated using the ACCUSPIN
TM
 System-
Histopaque
®
-1077 that utilises specially designed tubes with two chambers separated 
by a porous high density polyethylene barrier (Sigma-Aldrich, UK). Desired number 
of tubes was brought to room temperature. Freely, 20 ml of anticoagulated blood was 
poured in each tube and then centrifuged at 1000 x g for 10 min at room temperature. 
After centrifugation the plasma layer “upper layer” was carefully removed and the 
opaque interface, containing mononuclear cells (PBMCs) was transferred into a clean 
tube. PBMCs were washed into 10 ml Hank’s buffered saline solution (HBSS) and 
centrifuged at 250 x g for 10 min at room temperature. This procedure was carried out 
twice. PBMCs were then resuspended in the appropriate volume of RPMI-1640 
medium supplemented with 10 % (v/v) FBS and 2 mM L-glutamine (complete 
medium). PBMCs were counted using a cell counting chamber and seeded onto 96-
well plates for further experiments to be carried out. 
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2.2.2 Molecular Biology 
 
2.2.2.1 Transformation of Competent Cells 
 
Transformation was carried out using One Shot® TOP10 Chemically Competent E. 
coli competent cells (Invitrogen). 2 μl of DNA (20 ng) were added to one vial, thawed 
on ice, competent E. coli cells. The mixture was incubated on ice for 15 min and then 
heat-shocked at 42 
o
C for 1 min, followed by an immediate 2 min incubation on ice. 
250 μl of SOC medium (maximises the transformation efficiency of competent cells) 
were added to the mixture, which was then incubated in a shaker at 37 
o
C for 1 hr. 
The mixture was plated (either 50 or 150 μl) on pre-warmed LB agar plates 
containing the appropriate antibiotic for selection of transformants. Plates were 
incubated at 37 
o
C overnight and single colonies were picked the following day for 
further experiments. 
 
2.2.2.2 Miniprep Preparation of Plasmid DNA 
 
Small scale DNA plasmid preparations were performed using the QIAprep® Spin 
Miniprep kit (Qiagen) using a silica membrane technology, according to the 
manufacturer’s instructions. Single colonies were selected from LB agar plates and 
were cultured in a shaker overnight at 37 
o
C in 3 ml TB medium containing the 
appropriate antibiotic. Bacterial cultures were centrifuged at 2500 x g at 4 
o
C for 25 
min. The bacterial pellets were lysed under alkaline conditions using the appropriate 
buffers provided within the kit. The lysates were subsequently neutralised and 
adsorpted onto the silica membrane, in a high salt buffer solution. Endonucleases 
were efficiently removed by a brief wash step followed by several wash steps to 
remove remaining salts. Plasmid DNA was eluted in 50 μl elution buffer (10 mM 
Tris
.
Cl, pH 8.5). The concentration of DNA was determined by measuring the 
absorbance of the plasmid DNA at 260 nm (A260). The purity was assessed by 
measuring the absorbance at 280 nm (A280) and calculating A260/A280 ratio. 
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2.2.2.3 Maxiprep Preparation of Plasmid DNA 
 
Large scale DNA plasmid preparations were performed using the HiSpeed® Plasmid 
Maxi kit (Qiagen), according to the manufacturer’s instructions. Single colony was 
selected from LB agar plates and was cultured in a shaker overnight at 37 
o
C in 100 
ml TB medium containing the appropriate antibiotic. Bacterial cultures were 
centrifuged at 2500 x g at 4 
o
C for 25 min. Bacterial pellets were lysed in alkaline 
conditions using the appropriate buffers provided within the kit. The lysate was then 
neutralised, filtered and was allowed to freely enter the QIAGEN Anion-Exchange 
resin by gravity flow under the appropriate low salt and pH conditions. The column 
was then washed by a medium-salt buffer in order to remove RNA, proteins and other 
low-molecular weight impurities. The purified plasmid was then eluted in 15 ml 
elution buffer and DNA was precipitated by the addition of 10.5 ml isopropanol. The 
eluate/isopropanol mixture was filtered and washed with 70 % ethanol, before the 
DNA being eluted with 1 ml elution buffer (10 mM Tris.Cl, pH 8.0; 1 mM EDTA). 
DNA concentration was determined as explained in section 2.2.2.2. 
 
2.2.2.4 Preparation of Glycerol Stocks 
 
Single colony was selected from LB agar plates and was cultured in a shaker 
overnight at 37 
o
C in 3 ml TB medium containing the appropriate antibiotic. 500 μl of 
bacterial culture were added to equal volume of 50 % glycerol (v/v) into a Nalgene® 
Cryovial (Fisher Scientific) and stored at -80 
o
C. 
 
2.2.2.5 Transient Transfection of Beas-2B Cells with Plasmid DNA 
 
Beas-2B cells were seeded into 8-well Lab-Tek
TM
 chamber slides at a density 1 X 10
4
 
cells per well, containing 400 μl of growth medium (Keratinocyte-SFM medium 
supplemented with 10 % (v/v) FBS) and were allowed overnight to adhere. Once 
confluent, cells were washed with 1X HBSS. Cells were transfected with 2.5 ng YFP-
GR plasmid. An empty YFP vector was added as a negative control. A total of 2.5 ng 
of DNA were mixed with 30 μl of Opti-MEM® I reduced-serum medium 
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(transfection medium). 2 μl of LipofectamineTM 2000 were mixed with 30 μl of 
transfection medium. Mixtures were incubated for 30 min at room temperature. 
Mixtures were then combined and were further incubated together for 10 – 15 min at 
room temperature. The 70 - 100 μl (total volume) complex was then added to the cells. 
Cells were incubated for 4 – 6 hrs, when the medium was replaced with growth 
medium and cells were incubated for 24 or 48 hrs at 37 
o
C, 5 % CO2 in a humidified 
atmosphere, prior to testing for transgene expression. 
 
2.2.3 RNA Extraction 
 
Total RNA was isolated using the RNeasy® Mini kit (Qiagen), according to 
manufacturer’s instructions. Cells were harvested, lysed and homogenised using a 
highly denaturing guanidine-thiocyanate-containing buffer. Addition of ethanol 
provided appropriate binding conditions of RNA onto the silica-based membrane. 
RNA bound to the membrane and contaminants were washed away. RNA was then 
eluted in 50 μl RNase-free water. RNA concentration was determined similarly as 
explained for DNA concentration in section 2.2.2.2. 
 
2.2.4 Reverse Transcription (RT) 
 
Reverse transcription (RT) was performed using the High Capacity Reverse 
Transcription kit from Applied Biosystems (Warrington, Cheshire, UK), according to 
manufacturer’s instructions. 0.5 – 1 μg of total RNA were reversely transcribed in 
single stranded cDNA in a single 20 μl reaction. The 2X reverse transcription master 
mix was prepared prior to total RNA addition; containing 10X RT buffer, 25X dNTP 
mix, 10X RT random primers and MultiScribe
TM
 reverse transcriptase. The reaction 
was incubated in Thermo Hybaid MBS 0.2S thermal cycler (Waltham, MA, USA) at 
25 
o
C for 10 min followed by 2 hr incubation at 37 
o
C and a final step at 85 
o
C for 5 
sec to inactivate the enzyme. cDNAs where then stored either at 4 
o
C or – 20 oC for 
further experiments. 
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2.2.5 Taqman Quantitative Real-time Polymerase Chain Reaction (PCR) 
 
Gene expression was measured by quantitative real-time PCR using 2X TaqMan 
universal PCR master mix and a set of pre-designed and validated Taqman® gene 
expression assays (6-FAM dye-labelled) (Table 2.4), all purchased from Applied 
Biosystems  (Warrington, Cheshire, UK). 
 
Table 2.4. TaqMan® gene expression assays used 
 
 
Gene Name 
 
Gene Code 
TaqMan® Gene 
Expression Assay 
 
MAPK phosphatase 1 
 
MKP-1/DUSP1 
 
Hs00610256_g1 
 
 
Glyceraldehyde-3-phosphate 
dehydrogenase
*
 
 
GAPDH 
 
402869 
 
Guanine nucleotide binding protein (G 
protein), beta polypeptide 2-like 1
* 
 
GNB2L1 
 
Hs00272002_m1 
 
* 
Housekeeping gene 
 
Quantitative PCR was performed using 10 μl of cDNA and 20 μl of PCR reaction 
mixture containing 2X Taqman® PCR master mix and gene specific TaqMan 
expression assay. The reaction was carried out in a Corbett Rotor-Gene 6000 thermal 
cycler (Sydney, Australia) using the following thermal cycling conditions; Hold 1: 50 
o
C for 2 min (for optimal AmpErase UNG activity), Hold 2: 95 
o
C for 10 min (for 
enzyme activation) followed by 40 – 50 cycles consisting of a denaturing step at 95 
o
C for 15 sec and an annealing/extension step at 60 
o
 C for 60 sec. Data analysis was 
performed using ΔΔCt relative quantification and the rotor-gene 6000 series software, 
v 6.0.  mRNA expression levels were normalised either to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene or to guanine nucleotide 
binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1), an oxidative stress 
insensitive housekeeping gene.  
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2.2.6 Protein Extraction 
 
2.2.6.1 Whole Cell Protein Extraction 
 
Cells were seeded in 150 cm
2
 flasks or 6-well plates, at a density of 3 x 10
6
 cells/flask 
or 1 X 10
6
 cells/well. Whole cell extraction was performed using the Active motif 
nuclear extraction kit (Rixensart, Belgium) from a single confluent flask or three 
confluent wells, according to manufacturer’s instructions.  Briefly, at the end of all 
appropriate treatments and stimulations, cells in suspension were harvested and 
collected by centrifugation at 850 x g for 5 min at 4 
o
C in 15 ml falcon tubes. They 
were then washed twice in ice-cold PBS and collected by centrifugation at 3,200 x g 
for 5 min at 4 
o
C. Adherent cells were washed twice in ice-cold PBS prior to scraping 
with a cell scraper and collected by centrifugation at 3200 x g for 5 min at 4 
o
C. When 
phosphorylated proteins were in question, phosphatase inhibitors were added directly 
to the medium or they were present in the ice-cold PBS for suspension and adherent 
cells, respectively. Cell lysis was performed by the addition of a complete lysis buffer 
(lysis buffer, 10 mM DTT, and protease inhibitor cocktail) and 30 min incubation on 
ice.  Cell lysates were then centrifuged at 9600 x g for 30 min at 4 
o
C to separate cell 
debris and the supernatants were transferred in pre-chilled eppendorf tubes and were 
either, used for further experiments, or stored at -80 
o
C. Protein concentrations were 
determined by Bradford assay or BCA assay, using BSA protein standards as control. 
Absorbance was measured at 600 nm or 562 nm, for Bradford and BCA assays, 
respectively, on a Synergy
TM
 HT multi-detection microplate reader from BioTek 
Instruments, Inc (Winooski, VT, USA).  Protein concentrations were determined by 
comparison to the BSA standard curve. 
 
2.2.6.2 Membrane Protein Extraction 
 
Cells were seeded in 150 cm
2
 flasks at a density of 1 x 10
7
 cells/treatment. Membrane 
protein extraction was performed using the ProteoExtract® Transmembrane protein 
extraction kit from Novagen (Madison, WI, USA), using a two-step protocol for the 
enrichment of transmembrane proteins, according to manufacturer’s instructions. In 
brief, at the end of all appropriate treatments and stimulations suspension cells were 
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harvested and collected by centrifugation at 850 x g for 5 min at 4 
o
C in 15 ml falcon 
tubes. They were then washed twice in ice-cold PBS and collected by centrifugation 
at 3,200 x g for 5 min at 4 
o
C. In the first step, cells were permeabilised using 
extraction buffer I and 10 min incubation at 4 
o
C. Permeabilised cells were then 
centrifuged at 1,000 x g for 5 min at 4 
o
C and the cytosolic (soluble) fragment was 
separated from the membrane (insoluble) fragment. In the next step, membrane 
fragments were extracted from the lipid bilayer, using extraction buffer IIA, on a 
rocking platform for 1 hr at room temperature.  Membrane fragments were then 
centrifuged at 16,000 x g for 25 min at 4 
o
C and supernatants, enriched in integral 
membrane proteins, were transferred into fresh tubes. Protein concentrations were 
determined by BCA assay at 562 nm, using BSA protein standards as control, as 
explained in section 2.2.6.1. 
 
2.2.6.3 Nuclear and Cytoplamic Fraction Separation 
 
Cells were seeded in 150 cm
2
 flasks or 6-well plates, at a density of 3 x 10
6
 cells/flask 
or 1 X 10
6
 cells/well. Nuclear and cytoplasmic separation was performed using the 
Active motif nuclear extraction kit (Rixensart, Belgium) from a single confluent flask 
or three confluent wells, according to manufacturer’s instructions. Briefly, at the end 
of all appropriate treatments and stimulations, cells in suspension were harvested and 
collected by centrifugation at 850 x g for 5 min at 4 
o
C in 15 ml falcon tubes. They 
were then washed twice in ice-cold PBS and collected by centrifugation at 3200 x g 
for 5 min at 4 
o
C. Adherent cells were washed twice in ice-cold PBS prior to scraping 
with a cell scraper and collected by centrifugation at 3200 x g for 5 min at 4 
o
C. 
Cytoplasmic fraction collection was performed by the addition of 1X hypotonic buffer 
and 15 min incubation on ice, followed by the addition of a detergent and a 
centrifugation step at 14,000 x g for 30 sec at 4 
o
C. Supernatants (cytoplasmic 
fractions) were transferred in fresh tubes, and pellets were used for nuclear fraction 
collection. Pellets were resuspended in complete lysis buffer (lysis buffer, 10 mM 
DTT, and protease inhibitor cocktail) and were incubated for 30 min on ice followed 
by centrifugation at 10,000 x g for 30 min at 4 
o
C. Supernatants were transferred in 
pre-chilled eppendorf tubes and were either used for further experiments or stored at -
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80 
o
C. Protein concentrations were determined by Bradford assay at 600 nm, using 
BSA protein standards as control as explained in section 2.2.6.1. 
  
2.2.7 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blotting 
 
Protein extracts (30 μg) were size fractionated by SDS-PAGE on a 10 % NuPAGE® 
Novex Bis-Tris pre-cast gel from Invitrogen (Paisley, Renfrewshire, UK). Protein 
extracts were incubated together with NuPAGE® 4X LDS sample buffer (Paisley, 
Renfrewshire, UK) at 100 
o
C for 5 min, or overnight at room temperature. 
Electrophoresis was performed at 120 mA in 1X NuPAGE® MOPS SDS Running 
buffer in an XCell SureLock
TM
 Mini-Cell (Paisley, Renfrewshire, UK). Once 
electrophoresis was complete, proteins were transferred from the gel on a 
nitrocellulose membrane by the iBlot
TM
 Dry Blotting system (Paisley, Renfrewshire, 
UK) using programme 3, at 20 V for 7 min. Membranes were blocked for 20 min with 
blocking buffer and then probed with primary antibodies for either 90 min at room 
temperature or overnight at 4 
o
C. Membranes were washed in 1 X TBS Tween for 5 
min. The process was repeated two times for a total of three washes. Then membranes 
were incubated with the appropriate horseradish peroxidase (HRP-)-conjugated 
secondary antibody for a further 45 min prior to a final wash step of 10 min intervals. 
Immunoreactive bands were detected by chemiluminescence using ECL
TM
 or ECL 
Plus
TM 
Western Blotting detection reagents from GE Healthcare (Chalfont St Giles, 
Buckinghamshire, UK) for various film exposures. Relevant band intensities were 
quantified by densitometric analysis using the UVP GelDoc-It system and the 
LabWorks
TM
 Image Acquisition and analysis software v. 4.6 Ultra-Violet Products 
(Upland, CA, USA). 
 
2.2.8 Enzyme-linked Immunosorbent Assay (ELISA) 
 
Concentrations of human IL-8, IL-6 and granulocyte macrophage colony-stimulating 
factor (GM-CSF) in culture medium were assayed by ELISA. Anti-human 
CXCL8/IL-8, IL-6 and GM-CSF DuoSet
®
 ELISA kits were from R&D Systems 
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(Abingdon, Oxfordshire, UK). Concentrations of antibodies and standard curves are 
summarised in table 2.5. The Chemokine Nomenclature Subcomittee of the 
Nomenclature Committee of the International Union of Immunological Societies have 
re-classified and renamed existing cytokines and chemokines (Bacon et al., 2002). 
However, the original generic names are more commonly used and for simplicity, 
CXCL8/IL-8 will be denoted as IL-8 in this thesis.   
Microplate Immuno MaxiSorp 96 well plates were coated with the desired capture 
antibody diluted in 1X PBS overnight at room temperature. Plates were washed three 
times with wash buffer (Table 2.6) and then blocked with 100 μl of block buffer 
(Table 2.6) for a minimum of 1 hr at room temperature. Plates were washed (as 
above) and 100 μl of samples (either neat or diluted 1:2 in the appropriate diluent) 
were pipetted onto the plates in triplicates. Dilutions for a standard curve were 
prepared (as shown in table 2.5) and pipetted onto the plate in duplicate. Samples 
were incubated for 2 hrs at room temperature. The plates were washed (as above) and 
100 μl of biotinylated detection antibody diluted in the appropriate diluent were 
pipetted onto the plates and were incubated for a further 2 hrs at room temperature. 
The plates were then washed as above and detection was performed by the addition of 
100 μl streptavidin HRP diluted 1:200 in the appropriate diluent. The plates were 
further incubated for 20 min at room temperature, avoiding direct sunlight. After a 
final wash step 100 μl of substrate solution (1:1 mixture of H2O2 and 
tetramethylbenzidine) were then added to allow for colorimetric detection of HRP 
activity. The reaction was stopped by the addition of 50 μl 2 N H2SO4. Absorbance 
was measured at 450 and 550 nm on a Synergy
TM
 HT multi-detection microplate 
reader from BioTek Instruments, Inc (Winooski, VT, USA). IL-8, IL-6 and GM-CSF 
concentrations were quantified by using a standard curve generated to known 
concentrations of hrIL-8, hrIL-6 and hrGM-CSF by Gen5
TM
 Microplate Data 
Collection & Analysis software, version 1.00.14 (Winooski, VT, USA). 
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Table 2.5. Antibodies used for ELISA and standard curve concentrations 
 
 Type Concentrations 
 
CXCL8/IL-8 
  
 
Capture antibody 
 
Mouse anti-human IL-8 
 
4 μgml-1 
 
Detection antibody 
Goat anti-human IL-8  
(biotinylated) 
 
20 ngml
-1
 
 
Standard curve 
Human recombinant 
(hr) IL-8 
 
2000 – 31.25 pgml-1 
 
IL-6 
  
 
Capture antibody 
 
Mouse anti-human IL-6 
 
2 μgml-1 
 
Detection antibody 
Goat anti-human IL-6  
(biotinylated) 
 
200 ngml
-1
 
 
Standard curve 
Human recombinant 
(hr) IL-6 
 
600 – 9.375 pgml-1 
 
GM-CSF 
  
 
Capture antibody 
 
Mouse anti-human GM-CSF 
 
2 μgml-1 
 
Detection antibody 
Mouse anti-human GM-CSF 
(biotinylated) 
 
0.5 μgml-1 
 
Standard curve 
Human recombinant 
(hr) GM-CSF 
 
1000 – 15.625 pgml-1 
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Table 2.6. Buffers used for ELISA 
 
CXCL8/IL-8  
 
Wash buffer 
 
1X PBS / 0.05 % Tween
®
 20 
 
 
Block buffer 
 
1 % BSA in 1X PBS with 0.05 % NaN3 
 
 
IL-8 Reagent 
diluent 
 
0.1 % BSA, 0.05 % Tween
® 
20 in Tris-buffered saline 
(20 mM Tris
.
HCl pH 7.4, 150 mM NaCl)
 
  
IL-6  
 
Wash buffer 
 
1X PBS / 0.05 % Tween
®
 20 
 
 
Block buffer 
 
IL-6 Reagent diluent 
 
 
IL-6  
Reagent diluent 
 
1 % BSA in 1X PBS pH 7.2 – 7.4 
 
  
GM-CSF  
 
Wash buffer 
 
1X PBS / 0.05 % Tween
®
 20 
 
 
Block buffer 
 
GM-CSF Reagent diluent 
 
 
GM-CSF  
Reagent diluent 
 
1 % BSA in 1X PBS pH 7.2 – 7.4 
 
 
 
 
 
 75 
2.2.9 Cyclic Adenosine Monophosphate (cAMP) Assay 
 
cAMP assay was performed using the Cayman cAMP EIA kit (Boldon Colliery 
Tyne & Wear, UK), according to manufacturer’s instructions. In brief, cells were 
seeded in a 6-well plate at a density of 50,000 cells/treatment. After all appropriate 
treatments, cells were lysed in 0.1 M HCl at room temperature for 20 min, followed 
by 10 min centrifugation at 1,000 x g. Supernatants were transferred into fresh tubes 
and were either assayed immediately or stored at -80 
o
C.  The cAMP assay itself is a 
competitive assay and is based on a competition between free cAMP and a cAMP-
acetylcholinesterase (AChE) conjugate (cAMP tracer) for a limited number of cAMP-
specific rabbit antibody binding sites. Plates are pre-coated with mouse monoclonal 
anti-rabbit IgG and blocked with a selective formulation of proteins. Samples were 
then incubated with the standards, the cAMP tracer and a specific cAMP antiserum 
for 18 hr at 4 
o
C. Plates were then washed to remove any unbound reagents and then 
developed with Ellman’s reagent. Absorbance was measured at 420 nm and 
concentrations were determined using the Cayman EIA analysis tool based on a 
standard curve generated by a cAMP standard. 
 
2.2.10 Human Phospho-MAPK Array 
 
Human phospho MAPK array was performed using Proteome Profiler
TM 
antibody 
arrays from R&D Systems Europe Ltd (Abingdon, Oxfordshire, UK), according to 
manufacturer’s instructions. Concisely, U937 cells were seeded in  150 cm2 flasks at a 
density 1 x 10
7
 cells/flask before being treated with several LABAs prior to H2O2 
stimulation, or left untreated. Cells were then harvested and solubilised in lysis buffer. 
Lysates were transferred onto the individual arrays and were incubated overnight at 4 
o
C. Immunoreactive dots (coordinates shown at Table 2.7) were detected by 
chemiluminescence using ECL or ECL Plus
TM 
Western Blotting detection reagents. 
Phosphorylation of kinases (Table 2.8) was determined by quantifying relevant dot 
intensities by densitometry using the UVP GelDoc-It system and LabWorks
TM
 Image 
Acquisition and analysis software v. 4.6 (Upland, CA, USA). 
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Table 2.7. Panel & coordinates of pre-spotted capture and control antibodies on 
nitrocellulose membranes (human phospho-MAPK array) 
 
→ 
↓ Well 
 
1/2 
 
3/4 
 
5/6 
 
7/8 
 
9/10 
 
11/12 
 
13/14 
 
15/16 
 
17/18 
 
19/20 
 
21/22 
 
A 
 
+ve 
          
+ve 
 
B 
  
ERK1 
 
JNK1 
 
JNK 
pan 
 
p38γ 
 
p38δ 
 
RSK1 
 
GSK-
3α/β 
 
Akt1 
 
Akt2 
 
 
C 
  
ERK2 
 
JNK2 
  
p38α 
 
p38β 
 
RSK2 
 
GSK-
3β 
 
Akt 3 
 
Akt 
pan 
 
 
D 
   
JNK3 
 
MSK2 
    
HSP27 
 
p70 S6 
Kinase 
  
 
E 
  
Rabbit 
IgG 
 
Mouse 
IgG1 
 
Mouse 
IgG2A 
 
Mouse 
IgG2B 
 
Goat 
IgG 
 
PBS 
    
 
F 
 
+ve 
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Table 2.8. List of control and target kinases and phosphorylation sites detected 
 
Target/Control Phosphorylation Site 
Detected 
Positive Control (+ve) n/a 
Negative Control (–ve) n/a 
Goat IgG (–ve) n/a 
Mouse IgG1 (–ve) n/a 
Mouse IgG2A (–ve) n/a 
Mouse IgG2B (–ve) n/a 
PBS (–ve) n/a 
Rabbit IgG (–ve) n/a 
Akt pan S473, S474, S472 
Akt1 S473 
Akt2 S474 
Akt3 S472 
ERK1 T202/Y204 
ERK2 T185/Y187 
GSK-3α/β S21/S9 
GSK-3β S9 
HSP27 S78/S82 
JNK pan T183/Y185, T221/Y223 
JNK1 T183/Y185 
JNK2 T183/Y185 
JNK3 T221/Y223 
MSK2 S360 
p38α T180/Y182 
p38β T180/Y182 
p38γ T183/Y185 
p38δ T180/Y182 
p70 S6 Kinase T421/S424 
RSK1 S380 
RSK2 S386 
n/a: not applicable 
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2.2.11 FITC-Dexamethasone Incorporation 
 
PBMCs were isolated from whole blood from COPD patients and were treated with 
either FM (10
-9
 and 10
-8
 M) or SM (10
-7
 M) followed by 30 min incubation with 
FITC-conjugated dexamethasone (FITC-Dex, 10
-6
M). As a negative control, to allow 
for non-specific translocation of FITC-Dex, non-conjugated Dex at 10
-5 
M was added 
to the cells. Cells were harvested for nuclear extraction using the Active motif kit, as 
explained previously in section 2.2.6.3. FITC fluorescent levels were determined in 
the nuclear protein fractions at 488 nm in a Synergy
TM
 HT multi-detection microplate 
reader.  
 
2.2.12 Statistical Analysis 
 
Results are expressed as mean ± SEM. The IC50 values were calculated from 
concentration response curves. IC50 was considered the concentration of a compound 
inducing 50 % of its inhibitory effect. The EC50 was defined as the concentration of a 
compound to produce 50 % of its maximal effect. The EC300 was defined as the 
concentration of the drug to produce a 300 % enhancement. Statistical significance 
was calculated by analysis of variance for repeated measures. If significant, Dunnett 
post test was performed. Paired comparisons were compared using paired t-test. 
Differences were considered significant when p < 0.05. Statistical analysis was 
performed using Prism 4 for Windows, v. 4.0.3 by GraphPad Software, Inc (La Jolla, 
CA, USA).  
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Chapter 3, 
Pharmacological Evaluation of a Novel Long-acting 
Corticosteroid, Fluticasone Furoate in Human Respiratory 
Cells 
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3.1 Introduction 
 
CSs are the mainstay of asthma therapy, as they reverse chronic airway inflammation 
(Chung et al., 2009; Ito et al., 2006a). They mediate their function by binding to the 
GR residing in the cytoplasm (Ito et al., 2006a). Upon CS binding, GR translocates 
into the nucleus, where it binds to GRE and in turn triggers, anti-inflammatory gene 
transcription (Ito et al., 2006a). Activated GR induces downstream non-genomic 
transrepression pathways through inhibition of transcription factors, such as AP-1 and 
NF-κB, or by recruitment of co-repressors such as HDAC2 (Barnes et al., 2005). 
Patients with mild to moderate asthma have been reported to respond well to ICSs 
with the addition of a LABA reliever. However, patients with severe asthma are 
steroid insensitive (Bhavsar et al., 2008; Ito and Mercado, 2009). Further to that CSs 
are of less clinical benefit to COPD patients, as they fail to slow disease progression. 
The CS insensitivity maybe due to elevated oxidative stress levels arising from 
infiltrating neutrophils and macrophages (Barnes et al., 2004). 
FF is a novel enhanced affinity CS with a unique combination of pharmacodynamic 
and physiochemical properties (Salter et al., 2007). FF is structurally related to FP, 
but a distinct chemical and pharmacological entity, with a greater lung tissue retention 
(Valotis and Hogger, 2007). FF (Avamys
TM
 nasal spray) is administered via a unique 
side-actuated device for the treatment of allergic rhinitis (Kaiser et al., 2007; NeLM 
NHS UK, 2009). FF in combination with a novel LABA is now in clinical trials for 
the treatment of COPD (Clinicaltrials.gov, 2010).  
The aim of the work in this chapter was to evaluate the potency and duration of action 
of FF compared to other currently available CSs, such as FP and Bud in a range of 
cultured human respiratory cell lines, especially under simulated conditions of 
oxidative stress, and PBMCs from COPD and asthma patients. 
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3.2 Methods 
 
3.2.1 TNFα-induced IL-8 Release in U937 Cells  
 
U937 cells were seeded at a density of 200,000 cells/ well in a 96-well plate. Cells 
were treated with increasing concentrations (10
-14
 – 10-6 M, 1/100 dilution) of three 
different CSs; FF, FP and MF for 4 hrs, or left untreated. After 4 hrs cells were 
stimulated overnight with TNFα (10 ngml-1). Supernatants were collected for IL-8 
analysis by ELISA. 
 
3.2.2 IL-1β-induced GM-CSF Release in A549 Cells  
 
A549 cells were seeded at a density 25,000 cells/ well in a 96-well plate, until 90 % 
confluence. Once confluent, cells were treated with increasing concentrations (10
-14
 – 
10
-6 
M, 1/100 dilution) of FF, FP, Bud and/or MF for 1 or 4 hrs, or left untreated, 
followed by overnight stimulation with IL-1β (1 ngml-1). Supernatants were collected 
for GM-CSF analysis by ELISA. 
 
3.2.3 TNFα-induced IL-8 Release in PBMCs 
 
Whole blood was taken after subjects had given written informed consent. PBMCs 
were isolated from whole blood and were seeded at a density of 100,000 cells/well in 
a 96-well plate. PBMCs were treated with increasing concentrations (10
-14
 – 10-6 M, 
1/100 dilution) of either FF or FP for 20 min, or left untreated, prior to overnight 
stimulation with TNFα (10 ngml-1). Supernatants were collected for IL-8 analysis by 
ELISA. 
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3.2.4 GR Nuclear Translocation 
 
3.2.4.1 YFP-GR Overexpression 
 
Beas-2B cells were seeded at a density of 10,000 cells/well in an 8-well LabTek® II 
chamber slide, prior to transfection. Once 70 % confluent, YFP-conjugated GR 
plasmid was transfected into Beas-2B using lipofectamine
TM
 2000 for 24 hrs. After 24 
hrs cells were treated with either FF or FP (both at 10
-10
 M) for 4, 12 and 30 hrs, or 
left untreated. Slides were fixed and YFP-GR was detected by fluorescent microscopy. 
More than 300 cells were examined and the cells with a positive signal (i.e. YFP-GR 
present in the nucleus) were counted. 
 
3.2.4.2 Western Blot Analysis 
 
A549 cells were seeded at a density of 3 x 10
6
 cells /flask and once confluent were 
treated with either FF (10
-9
 M) or FP (10
-9
 M), or left untreated. After 4 and 16 hrs 
treatment cells were harvested for nuclear extraction and nuclear GR protein levels 
were detected by western blot analysis.  
 
3.2.5 Determination of Transcription Factor Activity 
 
A549 cells were seeded at a density of 3 x 10
6
 cells/flask and once confluent, were 
treated with 10
-9
 M and 10
-10
 M of either FF or FP, or left untreated, prior to IL-1β (1 
ngml
-1
) stimulation. Cells were harvested for nuclear extraction. Nuclear extracts were 
used to determine NF-κB and AP-1 activity by evaluating p65 and c-fos activation, 
respectively, using the Active Motif Trans-AM kits.  
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3.2.6 Effect of H2O2 on p38 Phosphorylation and MKP-1 mRNA 
Expression 
 
U937 cells were seeded at a density of 5 x 10
5
 cells/well in a 6-well plate and were 
treated with either FF (10
-8
 M) or FP (10
-8
 M) for different time points (4, 24 and 48 
hrs), prior to 1 hr stimulation with H2O2 (200 μM). Cells were harvested for RNA 
extraction (1 well) or whole cell extraction (3 wells). MKP-1 mRNA expression 
levels were quantified by real-time PCR and were normalised to GNB2L1 
(housekeeping gene). Phosphorylation levels of p38 were quantified by western blot 
analysis and were normalised to β actin. 
 
3.2.7 IL-1β-induced GM-CSF Release under Oxidative Stress 
 
A549 cells were seeded at a density of 200,000 cells/well in a 96-well plate and were 
pre-treated with 200 μM H2O2 for 4 hrs. This was followed by treatment with 
increasing concentrations (10
-14
 – 10-7 M) of either FF or FP or left untreated for 1 hr, 
prior to overnight stimulation with IL-1β (1 ngml-1). Supernatants were collected for 
GM-CSF analysis by ELISA. The concentration-inhibitory response curves for FF 
and FP in response to IL-1β stimulation were generated and the IC50 values were 
calculated.   
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3.3 Results 
 
3.3.1 The Effect of CSs on Pro-inflammatory Cytokine Release 
 
The potency of CSs was evaluated in A549, Beas-2B and U937 cells. A549, Beas-2B 
and U937 cells were seeded in 96-well plates and were treated with increasing 
concentrations (10
-14
 – 10-6 M) of FF, FP, Bud (and/or MF) for 4 hrs,  or left untreated 
prior to overnight stimulation with different stimuli (i.e. IL-1β, TNFα). Supernatants 
were collected for IL-8, IL-6 and GM-CSF analysis by ELISA. 
 
3.3.1.1 IL-1β-induced GM-CSF and IL-8 Release in A549 cells 
 
At the beginning, I tried to optimise the assay, determining IL-1β-induced GM-CSF 
release in A549 cells. Therefore, A549 cells were treated with CSs (10
-14
 – 10-6 M) for 
1 hr and then stimulated with IL-1β (1 ngml-1) overnight. IL-1β induced GM-CSF 
release 110-fold (187.5 ± 6.0 pgml
-1
) compared to basal GM-CSF release (1.7 ± 1.5 
pgml
-1
). As shown in Fig. 3.1, FF, FP and MF inhibited GM-CSF release 
concentration-dependently and maximum effects on GM-CSF were similar between 
CSs; 97.50 % for FF (6.3 ± 0.4 pgml
-1
), 97.20 % for FP (6.9 ± 2.1 pgml
-1
) and 
95.00 % for MF (12.1 ± 3.9 pgml
-1
). In contrast, the IC50 values (the concentration of 
a compound needed to have a 50 % inhibition) of both FF and MF indicated that they 
were more potent than FP (IC50 values (nM): FF 0.092; MF 0.081; FP 0.32). However, 
GM-CSF concentrations were low and in order to identify differences on the potency 
of the CSs, a later time-point of CS incubation was subsequently used.   
A549 cells were treated for 4 hrs with different CSs (i.e. FF, FP and Bud) prior to IL-
1β stimulation (1 ngml-1). GM-CSF release was measured in the supernatants. IL-1β 
significantly stimulated GM-CSF release (GM-CSF (ngml
-1
): non treated cells: 39.6 ± 
5.7; IL-1β-stimulated cells: 1274.5 ± 93.7). FF inhibited GM-CSF release in a 
concentration-dependent manner with an IC50 of 0.009 nM. FF was 16.7-fold more 
potent than Bud in inhibiting GM-CSF release compared to FP (IC50 (nM): 0.016), 
which was 9.4-fold more potent (Table 3.1). 
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Figure 3.1 Effect of CSs on IL-1β-induced GM-CSF release. Α549 cells were 
treated with increasing concentrations of fluticasone furoate (FF), fluticasone 
propionate (FP) and mometasone furoate (MF) (10
-14
 – 10-6 M) for 1 hr, or left 
untreated, prior to overnight stimulation with IL-1β (1 ngml-1). Supernatants were 
collected for analysis of GM-CSF by ELISA. Plot shows the % inhibition of GM-CSF 
release compared to IL-1β induction. Values represent mean of triplicate readings, at 
each concentration, of an individual experiment. 
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Table 3.1. IC50 values calculated from concentration response curves from different 
experiments (Stimulus-induced cytokine release) 
 
Cell type n Stimulus Cytokine 
release 
Time 
(hrs) 
IC50 (nM) 
FF 
IC50 (nM) 
FP 
IC50 (nM) 
Bud 
 
A549 
 
4 
 
 
IL-1β 
 
GM-CSF 
 
4 
 
0.009 
 
0.016 
 
0.15 
 
  
4 
 
IL-1β 
 
IL-8 
 
4 
 
0.063 
 
0.11 
 
nd 
 
 
U937 
 
3 
 
 
TNFα 
 
IL-8 
 
4 
 
0.20 
 
0.55 
 
nd 
 
 
Beas-2B 
 
3 
 
IL-1β 
 
GM-CSF 
 
4 
 
0.002 
 
0.005 
 
nd 
 
  
3 
 
IL-1β 
 
IL-8 
 
4 
 
0.014 
 
0.024 
 
nd 
 
  
3 
 
IL-1β 
 
IL-6 
 
4 
 
0.086 
 
0.14 
 
nd 
 
 
nd: not determined 
 
 
 
 
 
 
 
 87 
IL-1β also significantly stimulated IL-8 (IL-8 (ngml-1): non-treated cells 85.6 ±13.2; 
IL-1β stimulated cells 1994.7 ± 219.4). FF inhibited IL-8 release in a concentration-
dependent manner with an IC50 of 0.063 nM. Compared to FP (IC50 (nM): 0.11), FF 
was 1.8-fold more potent when evaluating inhibitory effects on IL-8 release (Table 
3.1)  
 
3.3.1.2 TNFα-induced IL-8 Release in U937 Cells 
 
Cells from a human monocytic cell line, U937, were stimulated with TNFα and IL-8 
production in supernatants was evaluated. Basal level of IL-8 was 71.0 ± 9.9 pgml
-1 
and TNFα stimulation resulted in an 8.5-fold increase (603.6 ± 33.9 pgml-1). FF, FP 
and MF inhibited TNFα-induced IL-8 release in a concentration-dependent manner 
(Fig. 3.2). At the highest concentration 10
-6
 M, FF significantly inhibited TNFα-
induced IL-8 release by 78.5 ± 1.6 % (184.3 ± 9.3 pgml
-1
), whereas FP had a 
maximum inhibitory effect of 69.2 ± 6.0 % (214.6 ± 4.4 pgml
-1
). The inhibitory effect 
of MF was 83 % ± 4.4 % (157.6 ± 25.7 pgml
-1
), which is similar to the effects of FF 
(Fig 3.2). 
The potency of the CSs was evaluated by comparing their IC50 values. As shown in 
Table 3.1, FF inhibited TNFα-induced IL-8 production with 2.8-fold greater potency 
than FP in U937 cells (IC50 (nM): FF: 0.20; FP: 0.55). 
 
3.3.1.3 IL-1β-induced GM-CSF, IL-8 and IL-6 Release in Beas-2B Cells 
 
IL-1β-induced GM-CSF, IL-8 and IL-6 release were also measured in supernatants 
from Beas-2B cells. Similarly, Beas-2B cells were treated with CSs for 4 hrs prior to 
overnight IL-1β stimulation. Cytokine production was determined by ELISA. FF was 
2.5-, 1.7- and 1.6-fold more potent than FP in inhibiting GM-CSF, IL-8 and IL-6 
production, respectively ((IC50 (nM): GM-CSF: 0.002; IL-8: 0.014; IL-6: 0.086) after 
4 hrs pre-treatment in Beas-2B cells (Table 3.1.) 
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Figure 3.2 Effect of CSs on TNFα-induced IL-8 release. U937 cells were treated 
with increasing concentrations (10
-14
 – 10-6 M) of fluticasone furoate (FF), fluticasone 
propionate (FP) and mometasone furoate (MF) for 4 hrs, or left untreated (NT), prior 
to overnight stimulation with TNFα (10 ngml-1). Supernatants were collected for 
analysis of IL-8 by ELISA. Graphs show TNFα-induced IL-8 release and the effect of 
(A) FF, (B) FP, (C) MF. Values represent mean ± SEM of three individual 
experiments. 
# Significant difference from NT, p < 0.01 
* Significant difference from NT+, p < 0.05 
** Significant difference from NT+, p < 0.01 
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3.3.1.4 Potency of FF in PBMCs from Asthma and COPD Patients 
 
The potency of FF in cell lines shown above was confirmed in PBMCs obtained from 
healthy volunteers and patients with mild asthma or COPD. Subject demographics are 
summarised in table 3.2.  
Both FF and FP inhibited TNFα-induced IL-8 production in a concentration-
dependent manner, to similar extent, in PBMCs from healthy volunteers. The IC50 
values were 14.2 ± 8.0 nM and 6.0 ± 1.3 nM for FF and FP, respectively (Fig. 3.3). FF 
inhibited TNFα-induced IL-8 release in PBMCs from patients with mild asthma with 
an IC50 of 1.9 ± 0.64 nM, which was 2.1-fold more potent than FP (IC50 = 4.0 ± 1.6 
nM). In contrast, in PBMCs from COPD patients FF (IC50 = 10.2 ± 4.1 nM) was 18-
fold more potent than FP (IC50 = 184.2 ± 129.8 nM). Thus, FP showed much weaker 
effects in COPD compared to healthy volunteers, suggesting that PBMCs from COPD 
patients are insensitive to FP. However, FF showed similar efficacies in PBMCs from 
healthy volunteers, mild asthmatics and COPD patients.   
 
3.3.2 Effects of CSs on GR Genomic Effects 
 
The ability of CSs to induce transactivation (genomic effects) was evaluated in A549 
cells. In order to evaluate the transactivation of CSs, GR binding to GRE and CS-
dependent MKP-1 mRNA expression were used. 
 
3.3.2.1 Impact of CSs on GR-GRE Binding 
 
Treatment of A549 cells with FF for 4 hrs resulted in an increase in GR-GRE binding 
in a concentration-dependent manner. The EC300 for FF, i.e. the concentration to 
enhance GR-GRE binding activity from baseline by 300 %, was 0.16 nM, similar to 
that of FP (0.21 nM) (Table 3.3). FF was also 7-fold more potent than Bud (EC300 = 
1.1 nM). FF has a greater potency to recruit GR and enhance binding with the GRE, 
resulting in increased anti-inflammatory gene transcription.  
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Table 3.2. Subject demographics 
 
 Healthy 
Volunteers 
Asthma  
Patients 
COPD 
Patients 
 
N 
 
 
5 
 
 
4 
 
 
4 
 
 
Gender 
(M / F) 
 
4 / 1 
 
1 / 3 
 
4 / 0 
 
Age 
(yrs) 
 
34.2 ± 5.1 
 
35.8 ± 8.5 
 
56.3 ± 6.8 
 
Atopy 
 
No 
 
 
Yes (4) 
 
No 
 
FEV1 
(% pred.) 
 
101.0 ± 7.3 
 
92.1 ± 10.1 
 
63.1 ± 12.0 
 
FEV1/FVC 
(% pred.) 
 
81.6 ± 5.5 
 
82.6 ± 7.2 
 
65.9 ± 13.1 
 
Medication 
 
 
n/a 
 
Albuterol on demand (4) 
 
ICS (4) 
 
Values represent mean ± SEM 
FEV1: Forced expiratory volume in the 1
st
 sec of exhalation 
FVC:  Forced vital capacity 
n/a: not applicable 
ICS: inhaled corticosteroid 
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Figure 3.3 Effect of FF or FP in PBMCs from healthy volunteers, mild asthma 
and COPD patients. PBMCs were isolated from whole blood from healthy 
volunteers (n = 5), mild asthma (n = 4) and COPD (n = 4) patients. PBMCs were 
treated for 20 min with either FF or FP at different concentrations, prior to overnight 
stimulation with TNFα (10 ngml-1). Supernatants were collected for IL-8 analysis by 
ELISA and IC50 values were calculated from the concentration response curves. (A) 
IC50 values for healthy volunteers (red circles), mild asthmatics (red triangles) and 
COPD patients (red squares) in response to FF treatment. (B) IC50 values for healthy 
volunteers (green circles), mild asthmatics (green triangles) and COPD patients (green 
squares) in response to FP treatment. Values represent median ± interquartile range of 
each subject group. 
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Table 3.3. EC300 values calculated from different experiments 
 
 
Cell type 
 
 
N 
 
Stimulus 
 
Readout 
 
Time 
(hrs) 
 
EC300 (nM) 
FF 
 
EC300 (nM)  
FP 
 
EC300 (nM) 
Bud 
 
 
A549 
 
 
3 
 
CSs 
 
MKP-1 
 
4 
 
0.29 
 
 
0.44 
 
1.5 
  
3 
 
CSs 
 
GRE 
 
4 
 
0.16 
 
0.21 
 
 
1.1 
 
Beas-2B 
 
3 
 
CSs 
 
GRE 
 
4 
 
0.85 
 
0.47 
 
1.2 
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3.3.2.2 Impact of CSs on MKP-1 mRNA Expression 
 
FF also increased MKP-1 mRNA expression in a concentration-dependent manner 
(Fig. 3.4)   with an EC300 of 0.29 nM, which was 1.5- and 5.2-fold more potent than 
FP (EC300 = 0.44 nM) and Bud (EC300 = 1.5 nM) (Table 3.3). Hence, FF has a 
superior impact on genomic effects compared to FP and Bud.  
 
3.3.3 Assessment of the Duration of Action of CSs 
 
3.3.3.1 Effects of CSs on Transrepression 
 
After establishing the potency of the different CSs, the next step was to assess the 
duration of action of each CS. As FF has been developed as a long-acting CS, to be 
administered once-daily, the longer duration of action of FF needed to be confirmed 
in an in vitro system.  
A549 cells were treated with either FF or FP for 4 and 16 hrs, or left untreated, prior 
to overnight stimulation with IL-1β (1 ngml-1). As shown in Fig. 3.5 both CSs 
inhibited IL-1β-induced GM-CSF release in a concentration-dependent manner with 
maximum inhibitory effect (Emax) at 94.1 ± 7.33 % and 88.3 ± 20.1 % for FF and FP, 
respectively. After 16 hrs treatment with the CSs, Emax was slightly reduced for both 
(FF: 73.0 ± 15.1 %; FP: 64.2 ± 9.7 %). As shown in Fig. 3.5, Panel B, the 
concentration response curve for FP at 16 hrs has a greater rightward shift compared 
to that for FF (Fig. 3.5, Panel A). Comparing the IC50 values FP was 587.5-fold 
weaker (4 hrs: IC50 = 0.016 nM; 16 hrs: IC50 = 9.4 nM), whereas FF was still effective 
at 16 hrs, being only 5.4-fold weaker than at 4 hrs (4 hrs: IC50 = 0.009 nM; 16 hrs: 
IC50 = 0.049 nM).   
Longer duration of action was also confirmed in A549 and U937 cells with respect to 
suppression of TNFα-induced IL-8 release, and IL-1β-induced GM-CSF, IL-8 and IL-
6 release in Beas-2B cells. The IC50 values are listed in table 3.4.  In all cell systems, 
with respect to different cytokine release, FF was 5.4- to 15-fold weaker after 16 hrs, 
whereas after 16 hrs FP was 71.1- to > 4166-fold weaker than at 4 hrs pre-treatment. 
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Figure 3.4 The impact of CSs on MKP-1 mRNA expression. A549 cells were 
treated with increasing concentration (10
-10
 - 10
-8 
M) of either FF or FP or Bud (10
-9
 
M or 10
-8
 M) for 4 hrs, or left untreated. Cells were harvested for RNA extraction and 
reverse transcription was carried out. Relative levels of MKP-1 mRNA were 
measured by real-time PCR and were normalised to GAPDH. Graphs show % 
increase of MKP-1 mRNA expression in the presence of (A) FF, (B) FP, (C) Bud.   
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Figure 3.5 Duration of action of CSs and their effect on IL-1β-induced GM-CSF 
release. A549 cells were treated with increasing concentrations of either fluticasone 
furoate (FF) or fluticasone propionate (FP), or left untreated for 4 or 16 hrs, prior to 
overnight IL-1β stimulation (1 ngml-1). Supernatants were collected for GM-CSF 
analysis by ELISA. Graphs show % inhibition of IL-1β-induced GM-CSF release in 
the presence of (A) FF, (B) FP. Values represent mean ± SEM of four individual 
experiments.  
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Table 3.4. IC50 values calculated from various experiments  
 
 
Cell type 
 
n 
 
Stimulus 
 
Cytokine 
release 
 
Time 
(hrs) 
 
IC50 (nM) 
FF 
 
IC50 (nM) 
FP 
 
IC50 (nM) 
Bud 
 
A549 
 
4 
 
IL-1β 
 
GM-CSF 
 
 
4 
 
 
0.009 
 
0.016 
 
0.15 
 
  
4 
   
16 
 
0.049 
 
9.4 
 
4.1 
 
  
4 
 
IL-1β 
 
IL-8 
 
4 
 
0.063 
 
 
0.11 
 
nd 
 
  
4 
   
16 
 
0.36 
 
> 100 
 
nd 
 
 
U937 
 
3 
 
TNFα 
 
IL-8 
 
4 
 
0.20 
 
0.55 
 
nd 
 
  
3 
   
16 
 
1.4 
 
39.1 
 
nd 
 
 
Beas-2B 
 
3 
 
IL-1β 
 
GM-CSF 
 
4 
 
0.002 
 
0.005 
 
nd 
 
  
3 
   
16 
 
0.025 
 
0.8 
 
nd 
 
  
3 
 
IL-1β 
 
IL-8 
 
4 
 
0.014 
 
0.024 
 
nd 
 
  
3 
   
16 
 
0.21 
 
> 100 
 
nd 
 
  
3 
 
IL-1β 
 
IL-6 
 
4 
 
0.086 
 
0.14 
 
nd 
 
  
3 
   
16 
 
0.68 
 
> 100 
 
nd 
 
 
nd: not determined 
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3.3.3.2 Effects of CSs on Transactivation 
 
The efficacy of GR binding to GRE, as well as the CS-dependent MKP-1 mRNA 
expression was evaluated. 
Treatment of A549 cells with FF for 4 hrs resulted in an increase in GR-GRE binding 
by 385 ± 59 %. Similarly FP increased GR-GRE binding by 341 ± 66 %, but more 
potently than Bud, which increased GR-GRE binding by 173 ± 37 %. As shown in 
Fig. 3.6, Panel A, FF was still able to enhance GR-GRE binding by 276 ± 54 %, after 
16 hrs pre-treatment. This effect at 16 hrs was very weak for FP and Bud as there was 
only 43 ± 20 % and 18 ± 2 % increase, respectively. As shown in table 3.5, the EC300 
value for GR-GRE binding after 16 hrs FF treatment was 0.37 nM. This was only 
reduced 2.3-fold as the EC300 at 4 hrs was 0.16 nM. FP and Bud were 309- and 28-
fold weaker, respectively, compared to the effects at 4 hrs. Comparing the three CSs 
at 16 hrs, FF was 175- and 82-fold more potent, increasing the efficacy of GR to bind 
to GRE than FP and Bud, respectively. 
Similarly, as shown in Fig. 3.6, Panel B, CS-dependent MKP-1 mRNA expression 
was still enhanced after 16 hrs of FF treatment by 477 ± 70 %, whereas the 
enhancement for FP and Bud was weaker at 153 ± 13 % and 142 ± 25 %, respectively. 
The EC300 values of MKP-1 induction by FF was 0.85 nM after 16 hrs incubation, 
which was 81-and >118-fold more potent than FP and Bud, respectively.   
As shown in Fig. 3.7, Panel A, MKP-1 mRNA expression peaked at 4 hrs after FP 
treatment (MKP-1/GAPDH mRNA: 0.19 ± 0.013) compared to baseline (MKP-
1/GAPDH mRNA: 0.019 ± 0.002). After 16 hrs FP treatment MKP-1 mRNA 
expression returned to baseline (MKP-1/GAPDH: 0.015 ± 0.003) and remained to 
these levels even after 24 hrs of incubation. Addition of a second dose of FP after 12 
hrs resulted in a new peak of MKP-1 gene expression at 16 hrs, however, MKP-1 
mRNA levels returned to baseline after 24 hrs incubation (Fig. 3.7, Panel B). On the 
other hand, incubation with a single dose of FF resulted in elevated MKP-1 mRNA 
expression, compared to baseline levels, even after 16 hrs and lasted up to 24 hrs (Fig. 
3.7, Panel C). This effect was significantly greater than either a single dose or even 
two doses of FP.   
 
 
 
 
 98 
 
 
A
B
FF FP Bud
0
250
500
750
1000
4 hrs
16 hrs
*
*
*
*
M
K
P
-1
/G
A
P
D
H
 m
R
N
A
(%
 i
n
d
u
ct
io
n
)
FF FP Bud
0
200
400
4 hrs
16 hrs
*
*
*
*
G
R
-G
R
E
 b
in
d
in
g
(%
 I
n
d
u
ct
io
n
)
 
 
 
Figure 3.6 The longer duration of action of FF on genomic effects. A549 cells 
were treated with FF (10
-9
 M), FP (10
-9
 M) and Bud (10
-8
 M), or left untreated. Cells 
were treated for either 4 hrs (closed bars) or 16 hrs (open bars). Cells were harvested 
for either GR-GRE binding activity or for RNA extraction and real-time PCR. (A) % 
Induction of GR-GRE binding activity compared to baseline. (B) % Induction of 
MKP-1 mRNA expression levels compared to baseline, normalised to GAPDH 
housekeeping gene. Values represent mean ± SEM of three individual experiments. 
* Significant difference from non-treated cells, p < 0.05 
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Table 3.5. EC300 values calculated from various experiments  
 
 
Cell type 
 
n 
 
Stimulus 
 
Readout 
 
Time 
(hrs) 
 
 
EC300 (nM) 
FF 
 
EC300 (nM)  
FP 
 
EC300 (nM) 
Bud 
 
A549 
 
 
3 
 
CSs 
 
MKP-1 
 
4 
 
0.29 
 
 
0.44 
 
1.50 
  
3 
 
CSs 
 
MKP-1 
 
16 
 
0.85 
 
 
69.0 
 
 
> 100.00 
  
3 
 
 
CSs 
 
GRE 
 
4 
 
0.16 
 
0.21 
 
 
1.10 
  
3 
 
CSs 
 
GRE 
 
16 
 
0.37 
 
 
64.80 
 
30.20 
 
 
Beas-2B 
 
 
3 
 
CSs 
 
GRE 
 
4 
 
0.85 
 
0.47 
 
1.20 
 
  
3 
 
 
CSs 
 
GRE 
 
16 
 
nd 
 
nd 
 
nd 
 
nd: not determined 
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Figure 3.7 FF has longer duration of action than FP. A549 cells were treated with 
either FP or FF or left untreated, at different time points. Cells were harvested for 
RNA extraction and reverse transcription. Relative levels of MKP-1 mRNA were 
verified by real-time PCR and were normalised to housekeeping gene GAPDH. Graph 
represents MKP-1 mRNA expression levels after (A) a single dose of FP, i.e. at t1 = 0. 
(B) Two doses of FP, i.e. at t1 = 0 and t2 = 12 hrs. (C) A single dose of FF, i.e. at t1 = 
0. Arrows indicate time of CS addition. Values represent mean ± SEM of three 
individual experiments.    
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3.3.4 GR Nuclear Translocation Induced by CS treatment 
 
FF was confirmed to have longer duration of action functionally (i.e. cytokine 
inhibition and anti-inflammatory gene transcription). In this study, the mechanism of 
longer duration of action was evaluated at the molecular level. YFP-conjugated GR 
was overexpressed by plasmid transfection in Beas-2B cells and the distribution of 
labelled GR was detected by fluorescent microscopy to evaluate GR nuclear 
translocation. 
Both FF and FP increased nuclear translocation at 4 hrs of treatment, as YFP-GR was 
detected in the nuclei for both treatments as shown in Fig. 3.8, Panel A. Significantly, 
even after 30 hrs treatment with FF, YFP-GR was still detected in the nuclei, as there 
were 18.1 ± 4.5 % GR positive cells, compared to 6.6 ± 1.6 % and 6.3 ± 2.2 % in non-
treated and FP-treated cells, respectively (Fig. 3.8, Panel B, Table 3.6). 
Nuclear translocation was also confirmed by western blot analysis. A549 cells were 
treated with either FF or FP for 4 or 16 hrs and GR protein levels were detected in 
nuclear fragments. As shown in Fig. 3.8, Panel C, considerable levels of nuclear GR 
was detected after both FF and FP treatment. After 16 hrs of FF treatment, GR protein 
levels in nuclear fragments were still high compared to nuclear GR levels after FP 
treatment.  
All the above findings indicate once more that FF has a longer duration of action than 
FP, in terms of GR nuclear translocation.  
 
3.3.5 FF has Superior Effects on Inhibition of Transcription Factor 
Activity 
 
The anti-inflammatory effects of FF and FP have been investigated above. As the 
molecular mechanism of the anti-inflammatory action, the effects of CSs on pro-
inflammatory transcription factors, such as NF-κB and AP-1, were evaluated. 
A549 cells were treated with either FF or FP, prior to IL-1β stimulation. p65 (NF-κB 
activity) and c-fos (AP-1 activity) activation was determined in nuclear extracts.  
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Figure 3.8 GR nuclear translocation after CS treatment. Beas-2B cells transfected 
with YFP-conjugated GR plasmid and treated with either FF (10
-10
 M) or FP (10
-10
 M), 
or left untreated (NT). Slides were fixed by cold methanol/acetone solution and YFP-
GR was visualised by fluorescent microscopy. GR positive cells were calculated. 
A549 cells were also transfected with YFP-GR and treated with FF or FP (both at 10
-9
 
M) for 4 and 16 hrs and harvested for nuclear extraction and nuclear GR was detected 
by western blot analysis. (A) Representative image of an experiment. (B) Plot 
shows % of GR positive cells, i.e. YFP-GR was detected in the nuclei. (C) 
Representative western blot analysis of nuclear GR protein levels.   
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Table 3.6. Nuclear translocation 30 hrs post CS treatment 
 
Treatment 
 
% GR Positive Cells 
 
Non-treated cells 
 
 
6.6 ± 1.6  
 
FF  
(10
-9
 M) 
 
30.8 ± 6.5 
 
FF  
(10
-10
 M) 
 
18.1 ± 4.5 
 
FP  
(10
-9
 M) 
 
9.8 ± 0.7 
 
FP  
(10
-10
 M) 
 
6.3 ± 2.2 
 
Values represent mean ± SEM 
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Similarly, FF inhibited IL-1β-induced NF-κB activation by 31 % and 56 % for 10-10 
M and 10
-9
 M, respectively (FF 10
-9
 M: 0.35 ± 0.038; FF 10
-10
 M: 0.26 ± 0.086). 
However, these CS-dependent inhibitory effects of NF-κB activation were not 
significant. On the other hand, after 16 hrs treatment, FF (10
-9
 M) significantly 
decreased NF-κB activation (FF-treated cells: 0.17 ± 0.04; IL-1β-treated cells: 0.53 ± 
0.09), but FP had no significant effects after 16 hrs (Fig. 3.9, Panel A, Table 3.7).  
As shown in Fig. 3.9, Panel B, IL-1β also significantly induced AP-1 (c-fos) 
activation by 5.3-fold after 30 min incubation (IL-1β treated cells: 0.44 ± 0.12; non-
treated cells: 0.08 ± 0.02). AP-1 activation was inhibited by 24 % and 52 % at 10
-10
 M 
and 10
-9
 M FP (FP 10
-9
 M: 0.35 ± 0.04; FP 10
-10
 M: 0.2 ± 0.06), respectively and by 
37 % and 54 % at 10
-10
 M and 10
-9
 M FF (FF 10
-9
 M: 0.31 ± 0.05; FF 10
-10
 M: 0.25 ± 
0.01), after 4 hrs treatment. These effects were not significant either.  
At 16 hrs after CS treatment, FF (10
-9
 M) significantly inhibited AP-1 activation (FF-
treated cells: 0.17 ± 0.010; IL-1β-treated cells: 0.34 ± 0.04), as previously shown for 
NF-κB (Fig. 3.9, Panel A). Once more FP had no significant effect on the inhibition 
of AP-1 activation.  
Furthermore, I assessed whether the increased AP-1 activation observed is a result of 
increased p38 MAPK phosphorylation. In addition, mRNA levels of MKP-1, a 
phosphatase which controls phosphorylation of p38 MAPKα, was also evaluated 
under oxidative stress.  
As shown in Fig. 3.10, Panel B, both FF and FP inhibited H2O2-induced p38 
phosphorylation at 4 and 24 hrs to a similar extent, (fold from H2O2-treated cells: FF 
(4hrs): 0.77 ± 0.17; FP (4 hrs): 0.74 ± 0.13; FF (24 hrs): 0.71 ± 0.18; FP (24 hrs): 0.64 
± 0.20). However, at 48 hrs, only FF was able to further inhibit H2O2-induced p38 
phosphorylation compared to FP (fold from H2O2-treated cells: FF: 0.54 ± 0.09; FP: 
0.95 ± 0.08). These findings correlated well with the increased FF-induced MKP-1 
mRNA expression at 48 hrs (Fig. 3.10, Panel C), under oxidative stress conditions 
compared to induction by FP (FF: 0.007 ± 0.0009; FP: 0.004 ± 0.0003). 
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Figure 3.9 Effect of CSs on transcription factor activation. A549 cells were treated 
with either FF (10
-10
 and 10
-9
 M) or FP (10
-10
 and 10
-9
 M), or left untreated (NT), prior 
to IL-1β stimulation (1 ngml-1). Cells were harvested for nuclear extraction. Nuclear 
extracts were used to measure the activities of NF-κB and AP-1 transcription factors. 
(A) Graph shows the effect of either FF or FP on IL-1β-induced NF-κB (p65) 
activation. (B) Graph shows the effect of either FF or FP on IL-1β-induced AP-1 (c-
fos) activation. Values represent mean ± SEM of three individual experiments. 
* Significant difference from IL-1β-treated cells, p < 0.05 
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Table 3.7. Summary of results of IL-1β-induced p65 and c-fos activation 
 
Treatment 
 
p65 Activation 
 
c-fos Activation  
4 hrs 16 hrs 4 hrs 16 hrs 
 
Non-treated 
cells 
 
0.10 ± 0.01 
 
 
0.10 ± 0.02 
 
0.08 ± 0.02 
 
0.09 ± 0.03 
 
IL-1β-treated 
cells 
 
0.46 ± 0.06 
 
 
0.53 ± 0.09 
 
0.44 ± 0.12 
 
0.34 ± 0.04 
 
 
FF  
(10
-9
 M) 
 
0.26 ± 0.06 
 
0.16 ± 0.04 
 
0.25 ± 0.01 
 
0.17 ± 0.01* 
 
FF  
(10
-10
 M) 
 
0.35 ± 0.04 
 
0.27 ± 0.02 
 
0.31 ± 0.05 
 
0.24 ± 0.02* 
 
FP  
(10
-9
 M) 
 
0.27 ± 0.07 
 
0.30 ± 0.03 
 
0.25 ± 0.06 
 
0.25 ± 0.03 
 
FP  
(10
-10
 M) 
 
0.35 ± 0.06 
 
0.41 ± 0.02 
 
0.35 ± 0.04 
 
0.30 ± 0.06 
 
Transcription factor activity is shown as optical density (OD) of an ELISA based 
assay. 
Values represent mean ± SEM of OD. 
* Significant difference from IL-1β-treated cells, p < 0.05 
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Figure 3.10 Effect of H2O2 on p38 phosphorylation and CS-dependent MKP-1 
mRNA expression. U937 cells were treated with either FF (10
-8
 M) or FP (10
-8
 M) at 
different time points (4, 24 and 48 hrs), prior to 1 hr stimulation with H2O2 (200 μM). 
Cells were harvested for RNA extraction or whole cell extraction. Phosphorylated 
levels of p38 were detected by western blot analysis and were normalised to β actin 
protein levels. MKP-1 mRNA expression levels were quantitated by real-time PCR 
and were normalised to GNB2L1 housekeeping gene. (A) Representative experiment 
of a western blot showing phosphorylation levels of p38. β Actin is shown as a 
loading control. (B) Graph shows fold change of p38 phosphorylation of H2O2-treated 
 108 
cells. (C) Graph shows relative levels of MKP-1 mRNA. Values represent mean ± 
SEM of 2 – 3 individual experiments.  
3.3.6 FF is Oxidative Stress Insensitive Compared to FP 
 
CS insensitivity is a major barrier to treating airway inflammatory diseases associated 
with oxidative stress (Ito et al., 2005). This includes COPD patients and some patients 
with severe asthma. FF is under development for inhaled once daily administration in 
combination with a LABA (Vilanterol trifenatate (VT)), for the treatment of COPD 
and asthma. As shown in Fig. 3.3, the efficacy of FF was similar in healthy volunteers 
and COPD patients, whereas FP was less potent in PBMCs from COPD patients. As 
COPD is associated with high levels of oxidative stress, the aim of this part of the 
study was to assess the potency of FF (alone) under simulated conditions of oxidative 
stress and compare it with that of FP.  
A549 cells were stimulated with H2O2 for 4 hrs. Cells were then treated with 
increasing concentrations of either FF or FP, for 1 hr, prior to overnight stimulation 
with IL-1β.  
As shown in Fig. 3.11, Panel B, the concentration response curve of FP shifted 
rightwards in the presence of H2O2 and increased the IC50 value by 35-fold (IC50 
(nM): no H2O2-treated cells: 0.034; H2O2-treated cells: 1.2). This suggests that 
oxidative stress reduced the efficacy of FP to inhibit cytokine release. Oxidative stress 
also reduced the effect of Dex (data not shown). On the contrary, FF (Fig. 3.11, Panel 
A) did not have a significant change in its efficacy under oxidative stress conditions 
(IC50 (nM): no H2O2 treated cells: 0.016; H2O2 treated cells: 0.064). 
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Figure 3.11 Effect of H2O2 on the efficacy of CSs to inhibit IL-1β-induced GM-
CSF production.  A549 cells were pre-treated with H2O2 (200 μM) for 4 hrs and then 
with increasing concentrations of either FF or FP for 1 hr, prior to overnight 
stimulation with IL-1β (1 ngml-1). Supernatants were collected for GM-CSF analysis 
by ELISA. Graphs show the inhibitory concentration response curve of (A) FF (red, 
closed circles) and the effect of H2O2 (red, open circles) (B) FP (green, closed 
rhombus) and the effect of H2O2 (green, open rhombus). Values represent mean ± 
SEM of three individual experiments.  
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3.4 Discussion 
 
In this chapter, superior effects of FF, a novel enhanced affinity CS, to currently 
available CSs, FP, Bud and MF have been assessed using molecular and 
pharmacological approaches. FF was initially developed as a topical CS for the 
treatment of allergic rhinitis (Salter et al., 2007). Previous human GR binding kinetics 
studies have shown a faster association of FF with the human GR and simultaneously 
demonstrated slow dissociation (Valotis and Hogger, 2007). X-ray crystallographic 
studies have revealed the crystal structure of FF (Biggadike et al., 2008). FF acquires 
the fluticasone backbone, which contains the 17-fluoromethylthioester that in 
combination with the metabolically stable 17R furoate ester, grant efficient systemic 
inactivation and enable better H-bonding and Van der Waals interactions with amino 
acid residues inside the ligand-binding site of the GR (Biggadike et al., 2008). The 
structure of ligand-binding domain of the GR was first identified by X-ray 
crystallography and Dex was used at the time as the CS that binds to the complex. 
This complex provided evidence and information for interactions between new 
ligands and GR. The 17R furoate group, which replaced the simpler propionate ester 
of the FP molecule, confers enhanced respiratory tissue retention as well as receptor 
binding (Salter et al., 2007).   
In this study, the potency and duration of action of FF were evaluated in several 
human airway cell lines and were compared to other CSs, FP, Bud and MF. FF was 
more potent than FP and Bud in all cell lines tested. Similarly, findings by Salter et al 
showed that all the CSs tested, demonstrated concentration-dependent reduced 
epithelial permeability to dextran with the rank order of potency FF > FP > Bud 
(Salter et al., 2007).  FF was also shown to have longer duration of action compared 
to FP and Bud as fluorescent microscopy revealed that GRs were still present in the 
nuclei even after 30 hrs pre-treatment of Beas-2B cells with FF, whilst in FP-treated 
cells the GR was diffused in the cytoplasm. Salter et al demonstrated that the rate of 
transport of FF across a basal aqueous cell layer using a monolayer human lung 
epithelial cell line was lower compared to other CSs. They also showed that retention 
in respiratory tissue was longer (Salter et al., 2007). FF was further revealed to have 
longer retention and tissue binding compared to FP or MF. Absorption to human lung 
tissue in vitro was attained within 20 min and after 60 min incubation with the CS-
containing buffer, FF showed the highest tissue binding. The lung tissue binding of 
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FF was statistically significantly higher than FP’s (Valotis and Hogger, 2007). These 
findings on cell retention and longer duration of GR binding might clarify the 
extended duration of anti-inflammatory action of FF seen in this study. 
Furthermore, both FF and FP inhibited IL-1β-induced NF-κB and AP-1 activation, 
however their effect was weak. This is in agreement with other studies demonstrating 
that CSs inhibit NF-κB and AP-1 activation directly but with low efficacies. Newton 
et al showed that A549 cells pre-treated with IL-1β followed by Dex had little or no 
effect on p65 mRNA or protein levels (Newton et al., 1998). As FF is more potent 
than Dex, this might explain the slightly greater inhibition on IL-1β-induced p65 or c-
fos activation. Although p65 and c-fos activation was not greatly reduced by FF or FP 
at shorter incubation, only FF pre-treatment for 16 hrs was able to significantly inhibit 
NF-κB and AP-1 activity. This can be due to the prolonged induction of endogenous 
inhibitors of these transcription factors, such as MKP-1, which will inhibit AP-1 
activity via inhibition of p38 MAPK phosphorylation. In fact, as shown in Fig. 3.10, 
in U937 cells, FF was able to inhibit H2O2-induced p38 MAPK phosphorylation, after 
48 hrs treatment, but FP did not.  
COPD is characterised by high levels of oxidative stress and poor response to CS 
treatment (Barnes et al., 2004). My findings are in agreement, as the IC50 value for FP 
in PBMCs from COPD patients was 31-fold higher than when evaluating the IC50 
value in PBMCs from healthy volunteers.  In contrast, FF sensitivity was similar in 
PBMCs from both healthy volunteers and COPD patients. Furthermore, FP sensitivity 
was also reduced in U937 cells under oxidative stress conditions, whereas FF 
sensitivity was slightly but not significantly reduced in cells treated with H2O2.  
According to the report by Biggadike et al, the 17R elaboration with the furoate ester 
allows greater binding of FF to the 17α pocket of the GR ligand binding site 
(Biggadike et al., 2008). Similarly, crystallographic analysis of the progesterone 
ligand-binding domain (PR-LBD) showed that the 17α pocket can accommodate 
larger molecules, such as the furoate group of MF (Wang et al., 2008). This 
phenomenon might confer a different conformational change of the GR that would 
allow for the improved FF sensitivity in COPD or under conditions of oxidative stress 
when compared to FP. Further studies are required to clarify the molecular 
mechanism involved in the different behaviour of FF and FP under oxidative stress. 
Regarding FF and MF, the two drugs share the common feature of accommodating a 
furoate salt in their structure. The furoate salt explains their longer duration of action. 
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Also, GSK has informed us that the furoate group will be inserted in depth in GR. 
However, more data is confidential and I cannot explain which structure is 
responsible for the different potency. 
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Reversed by Formoterol via PI3K Signalling Inhibition 
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4.1 Introduction 
 
In the previous chapter, the effect of oxidative stress on CS function was evaluated. 
As mentioned earlier in this thesis, oxidative stress may account for the CS 
insensitivity in COPD as well as severe and smoking asthma. In this chapter, the 
impact of oxidative stress on β2AR signalling and β2 agonists’ effects were evaluated.  
According to both GINA and GOLD guidelines, LABAs are used as a regular 
treatment to most stages of both diseases, on demand (Global Initiative for Asthma 
(GINA), 2009; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
2009). LABAs are bronchodilators that are important in ASM relaxation and provide 
patient relief. But the strength of bronchodilating effects is relatively weaker in COPD 
than in asthma. This might be due to the different targets in the lung between the 
diseases.  COPD targets the small airways; in contrast asthma targets the upper 
airways. I hypothesise that oxidative stress affects β2AR signalling or the β2 agonist 
itself, hence the weaker efficacy of LABAs in COPD. This hypothesis is unique and 
has not been tested. 
In this chapter, I aimed to study the effect of oxidative stress on β2AR signalling. In 
particular, I evaluated the potency of LABAs to produce cAMP under conditions of 
oxidative stress. Furthermore, the effect of LABAs on H2O2-induced Akt 
phosphorylation was studied, as well as the effect of H2O2 on LABA-induced β2AR 
internalisation. Finally, I tested the effect of LABAs on CS anti-inflammatory action 
under oxidative stress. 
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4.2 Methods 
 
4.2.1 TNFα-induced IL-8 Release in PBMCs 
 
PBMCs were isolated from whole blood from healthy volunteers, healthy smokers, 
patients with mild to severe asthma and patients with moderate to severe COPD, after 
giving written informed consent.  
PBMCs were seeded at a density of 100,000 cells/well on a 96-well plate and were 
pre-treated with either FM (10
-9
 M) or SM (10
-8
 M) for 20 min prior to Dex treatment 
at different concentrations for 1hr, or left untreated. PBMCs were then stimulated 
overnight with TNFα (10 ngml-1) and supernatants were collected for IL-8 analysis by 
ELISA.  
 
4.2.2 GR Nuclear Translocation in PBMCs from COPD Patients  
 
As a marker of GR nuclear translocation after ligand binding FITC-Dex incorporation 
was evaluated in PBMCs from COPD patients. PBMCs were incubated with FITC-
conjugated Dex (FITC-Dex at 10
-6
 M) for 30 min. Prior to FITC-Dex incubation FM 
(10
-9
 and 10
-8
 M) and SM (10
-7
 M) were added to the PBMCs. As a negative control, 
in order to determine non-specific translocation of FITC-Dex, non conjugated Dex at 
10
-5
 M was added to the cells. Cells were harvested for nuclear extraction using the 
Active motif kit. FITC fluorescent levels were determined in the nuclear protein 
fragments.  
 
4.2.3 TNFα-induced IL-8 Release in U937 Cells under Oxidative Stress 
 
U937 cells were pre-treated with either Bud or FP at different concentrations for 30 
min prior to overnight stimulation with TNFα (1 ngml-1). When required, cells were 
stimulated with H2O2 (100 μM), 10 min prior to CS treatment, whilst add-on 
treatment with either FM (10
-9
 M) or SM (10
-7
 M) was added 20 min prior to CS 
treatment. Supernatants were collected for IL-8 analysis by ELISA.  
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4.2.4 LABA-induced cAMP Production under Oxidative Stress in U937 
Cells  
 
U937 cells were seeded at a density 50,000 cells/treatment in a 6-well plate and were 
treated with H2O2 (100 μM) for 30 min, when needed, prior to treatment with 
increasing concentrations of either FM or SM for 30 min.  Cells were harvested, lysed 
and supernatants were collected for cAMP production, using a cAMP EIA kit.   
 
4.2.5 LABA-induced cAMP Production in PBMCs from COPD Patients 
and Healthy Volunteers 
 
PBMCs were isolated from whole blood from healthy volunteers (n = 6), healthy 
smokers (n = 7) and COPD patients (n = 6). PBMCs were treated with either FM (10-9 
M) or SM (10
-7
 M) for 15 min, followed by a lysis step and supernatants were 
collected for a cAMP ELISA based assay. 
 
4.2.6 Human phospho-MAPK and other Serine/Threonine Kinase 
Activation 
 
U937 cells were seeded at a density of 1 X 10
7
 cells/treatment, in a 150 cm
2
 flask, and 
were stimulated with H2O2 (200 μM) for 7.5 min, followed by 15 min treatment with 
either FM (10
-8
 M) or SM (10
-7
 M) for 15 min, or left untreated. Cells were harvested 
and solubilised in lysis buffer. Lysates (200 μg) were incubated on nitrocellulose 
membranes, which were incubated with a cocktail of phospho-site specific 
biotinylated antibodies to detect phosphorylated kinases via streptavidin-HRP and 
chemiluminescence. 
 
4.2.7 H2O2-induced Akt Phosphorylation by Western Blot Analysis 
 
U937 cells were seeded at a density of 2.5 – 3 X 106 cells/treatment, in a 150 cm2 
flask, and treated with increasing concentrations of either FM or SM or VT (10
-8
 M) 
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for 20 min prior to 5 min stimulation with H2O2 (200 μM), or left untreated. In 
subsequent experiments, in order to determine whether the effect of FM                                                                                                                                                 
was PKA-driven or not, U937 cells were treated with 1 μM H-89, PKA inhibitor 
(PKAi) for 15 min followed by FM (10
-8
 M) or EPAC agonist (10
-6
 M) for 30 min 
prior to 5 min stimulation with H2O2 (200 μM). Cells were harvested for whole cell 
extraction and immunoreactive bands were detected by ECL chemiluminescence. 
Relevant band intensities of phosphorylation levels of Akt1 at Ser 473 were quantified 
by densitometric analysis. Total Akt1/PKBα levels were also quantified and were 
used as loading control.   
 
4.2.8 β2AR-induced Internalisation under Oxidative Stress 
 
U937 cells were seeded at a density of 1 – 5 X 107 cells/treatment, in a 150 cm2 flask, 
and treated with H2O2 (200 μM) at different time points (30, 60 and 240 min). After 
H2O2 stimulation cells were treated with either FM (10
-8
 M) or SM (10
-7
 M) for 30 
min or salbutamol (SLB) (100 μM) for 5 min. Cells were harvested and membrane 
fractions were isolated using the ProteoExtract® Transmembrane protein extraction 
kit following a two-step protocol to allow for the enrichment of transmembrane 
proteins. Membrane proteins were size-fractionated by SDS-PAGE and β2AR protein 
levels were detected by western blotting analysis.
 
  
 
Each methodology above, required a different number of cells, 50,000 cells/treatment 
for cAMP release, 100,000 cells/well for ELISA, 2.5 – 3 X 106 cells/treatment for 
whole cell extraction, 1 – 5 X 107 cells/treatment for membrane fraction separation, 1 
X 10
7
 cells/treatment for the human phospho-MAPK arrays. This was done for 
practical reasons. Cytokine release and cAMP release can be measured in a 96-well 
plate format. However extractions require 6-well plates or flasks and require greater 
number of cells. Essential was to keep the same final DMSO concentrations in all 
treatments (i.e. 0.05 %); therefore I do not think that the different cell numbers affect 
the results.  
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4.3 Results 
 
4.3.1 Effect of LABAs on CS Insensitivity in PBMCs  
 
PBMCs were isolated from whole blood from healthy volunteers, healthy smokers, 
patients with mild to severe asthma and patients with moderate to severe COPD, after 
giving informed consent. Subject demographics are listed in tables 4.1 and 4.2.  
PBMCs were pre-treated with either FM or SM prior to Dex treatment followed by 
overnight stimulation with TNFα. Supernatants were collected for IL-8 analysis by 
ELISA and the IC50 value of Dex was calculated from the concentration response 
curves generated and this was used as a marker of Dex sensitivity. 
The IC50 value for severe asthma patients was 173.8 ± 31.4 nM, significantly higher 
than the IC50 values for healthy volunteers (26.6 ± 9. 2 nM) and mild asthmatics (20.0 
± 3.8. nM) (Fig. 4.1, Table 4.3). The IC50 for COPD patients was 210.9 ± 63.8 nM, 
significantly higher than healthy volunteers (37.1 ± 10.1 nM) and healthy smokers 
(47.5 ± 19.6 nM) (Fig. 4.1, Table 4.3). Thus PBMCs from severe asthma and COPD 
patients are less sensitive to Dex. 
Add-on treatment with either FM (10
-9
 M) or SM (10
-7
 M) had no effect on Dex 
sensitivity in PBMCs from healthy volunteers (IC50 (nM): FM = 27.4 ± 10.9; SM = 
27.4 ± 12.8) (Table 4.3). However, Dex sensitivity was significantly improved by all 
treatments (IC50 (nM): FM = 40.8 ± 12.3; SM (10
-7 
M) = 63.7 ± 16.0; SM (10
-8
 M) = 
10.8 ± 6.0) in PBMCs from severe asthmatics (Table 4.3).  
Dex sensitivity in PBMCs from COPD patients was significantly improved by FM 
add-on treatment (IC50 (nM): 75.6 ± 20.8) whereas SM (10
-8
 or 10
-7
 M) partially, but 
not significantly reversed the IC50 values for Dex (IC50 (nM): SM (10
-7
 M) = 126.2 ± 
38.2; SM (10
-8
 M) = 157.7 ± 54.0) (Fig. 4.2, Table 4.3).  
Thus, FM improved Dex sensitivity in PBMCs from both severe asthma and COPD 
patients, whereas SM add-on treatment only in severe asthma patients. This suggests 
that SM and FM behave differently in COPD but not in severe asthma. 
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Table 4.1. Subject demographics from asthma study   
 
  
Healthy 
Volunteers 
 
Mild 
Asthmatics 
 
Severe  
Asthmatics 
 
N 
 
 
7 
 
 
6 
 
 
7 
 
 
Gender 
(M / F) 
 
3 / 4 
 
2 / 4 
 
1 / 6 
 
Age 
(yrs) 
 
36.5 ± 3.6 
 
40.5 ± 2.2 
 
30.8 ± 3.8 
 
FEV1 
(% pred.) 
 
94.8 ± 4.8 
 
84.1 ± 5.5* 
 
59.3 ± 6.5** 
 
FEV1/FVC 
(% pred.) 
 
96.6 ± 2.9 
 
n/a 
 
77.9 ± 4.2** 
 
Values represent mean ± SEM 
FEV1: Forced expiratory volume in the 1
st
 sec of exhalation 
FVC:  Forced vital capacity 
n/a: not available 
* Significant difference from healthy volunteers, p < 0.05 
** Significant difference from healthy volunteers, p < 0.01 
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Table 4.2. Subject demographics from COPD study  
 
  
Healthy 
Volunteers 
 
Healthy 
Smokers 
 
COPD  
Patients 
 
N 
 
 
9 
 
 
7 
 
 
13 
 
 
Gender 
(M / F) 
 
3 / 6 
 
4 / 3 
 
5 / 8 
 
Age 
(yrs) 
 
56.6 ± 1.8 
 
56.1 ± 3.6 
 
65.6 ± 1.9 
 
FEV1 
(% pred.) 
 
87.4 ± 5.2 
 
96.3 ± 3.4 
 
41.6 ± 3.5** 
 
FEV1/FVC 
(% pred.) 
 
78.0 ± 2.2 
 
73.8 ± 1.6 
 
39.6 ± 3.0** 
 
Values represent mean ± SEM 
FEV1: Forced expiratory volume in the 1
st
 sec of exhalation 
FVC:  Forced vital capacity 
** Significant difference from healthy volunteers, p < 0.01 
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Figure 4.1 Dex sensitivity in severe asthma and COPD. PBMCs were isolated from 
whole blood from healthy volunteers (n = 7 – 9), mild asthmatics (n = 6), severe 
asthmatics (n = 8), healthy smokers (n = 7) and COPD patients (n = 13).  PBMCs 
were treated with increasing concentrations of Dex for 1 hr, prior to overnight 
stimulation with TNFα (1 ngml-1). Supernatants were collected for IL-8 analysis by 
ELISA and IC50 values were calculated from the concentration response curves. (A) 
IC50 values calculated from PBMCs from healthy volunteers (red), mild asthmatics 
(blue) and severe asthmatics (green) in response to Dex treatment. (B) IC50 values 
calculated from PBMCs from healthy volunteers (red), healthy smokers (blue) and 
COPD patients (green) in response to Dex treatment. Values represent mean ± SEM 
of each subject group. 
* Significant difference from either healthy or mild asthma patients, p < 0.05 
** Significant difference from either healthy or smokers, p < 0.01 
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Table 4.3. Dex sensitivity in healthy volunteers and patient groups (IC50 values)  
 
 
 
IC50 of Dex 
(nM) 
 
Dex 
 
Dex +  
FM (1 nM) 
 
Dex + 
SM (10 nM) 
 
Dex+ 
SM (100 nM) 
 
Healthy 
Volunteers 
 
26.6 ± 9.2 
 
27.4 ± 10.9 
 
22.8 ± 3.8 
 
27.4 ± 12.8 
 
Mild 
Asthmatics 
 
20.0 ± 3.8 
 
n/d 
 
n/d 
 
14.7 ± 3.5 
 
Severe 
Asthmatics 
 
173.8 ± 31.4 
 
40.8 ± 12.3* 
 
30.8 ± 6.0* 
 
63.7 ± 16.0* 
 
Healthy 
Volunteers 
 
37.1 ± 10.1 
 
24.3 ± 5.4 
 
23.3 ± 7.9 
 
25.9 ± 6.4 
 
Healthy 
Smokers 
 
47.5 ± 19.6  
 
18.2 ± 6.2 
 
28.4 ± 9.2 
 
27.9 ± 6.4 
 
COPD 
patients 
 
210.9 ± 63.8 
 
75.6 ± 20.8* 
 
157.7 ± 54.0 
 
126.2 ± 38.2 
 
Values represent mean ± SEM  
n/d: not determined 
* Significant difference from Dex treatment, p < 0.05 
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Figure 4.2 Effect of LABA add-on treatment on Dex sensitivity in COPD. PBMCs 
were isolated from whole blood from COPD patients (n = 13) and were pre-treated 
with either FM (10
-9
 M) or SM (10
-7
 M) for 20 min, or left untreated (NT) prior to 
Dex treatment at different concentrations, followed by overnight stimulation with 
TNFα (1 ngml-1). Supernatants were collected for IL-8 analysis by ELISA and IC50 
values were calculated from concentration response curves. (A) IC50 values of Dex 
treatment (grey open circles) and the effect of FM (blue stars). (B) IC50 values of Dex 
treatment (grey open circles) and the effect of SM (green stars). Lines represent mean 
values for each subject group. 
* Significant difference from NT, p = 0.0246 
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4.3.2 Effect of LABA Add-on Treatment on GR Nuclear Translocation 
 
As a marker of GR nuclear translocation after ligand binding FITC-Dex incorporation 
was evaluated in PBMCs from COPD patients. PBMCs were treated with either FM 
(10
-9
 and 10
-8
 M) or SM (10
-7
 M) prior to treatment with FITC-conjugated Dex 
(FITC-Dex at 10
-6
 M) for 30 min. As a negative control, in order to determine non-
specific translocation of FITC-Dex, non conjugated Dex at 10
-5
 M was added to the 
cells. FITC fluorescent levels were determined in the nuclear protein fragments.  
GR nuclear translocation was significantly impaired in PBMCs from COPD patients 
(FITC-Dex in nuclei in COPD, 4.4 ± 2.8 nM, n = 13), compared to healthy volunteers 
(7.7 ± 1.8 nM, n = 8) and healthy smokers (6.0 ± 3.6 nM, n = 7). When FM was added 
to the PBMCs GR nuclear translocation was enhanced (FITC-Dex (nM): FM (10
-8 
M) 
8.2 ± 1.2; FM (10
-9
 M) 7.4 ± 1.7) (Fig. 4.3). On the other hand, even at a higher 
concentration, SM (10
-7
 M) did not significantly enhance GR nuclear translocation 
(FITC-Dex (nM): SM 6.4 ± 0.58).  
 
4.3.3 Effect of LABAs on Oxidative Stress-induced CS Insensitivity 
 
Different efficacies of FM and SM on enhancement of CSs’ effects were found in 
PBMCs from COPD patients. In this study, the impact of oxidative stress on FM and 
SM effects was evaluated in U937 cells by either the absence or presence of H2O2.   
U937 cells were stimulated with H2O2 (100 μM), followed by a 20 min add-on 
treatment with either FM (10
-9
 M) or SM (10
-7
 M). Cells were then treated with either 
Bud or FP at different concentrations for 30 min prior to overnight stimulation with 
TNFα (1 ngml-1). Supernatants were collected for IL-8 analysis by ELISA.  
Both Bud and FP (Fig. 4.4) inhibited TNFα-induced IL-8 release in a concentration-
dependent manner. The EC50 and Emax values for Bud were 0.38 ± 0.08 nM and 87.1 ± 
2.8 %, respectively. Regarding FP, these values were 0.074 ± 0.02 nM and 85.0 ± 
0.7 %, respectively (Table 4.4). 
CS sensitivity was significantly induced by H2O2, as TNFα-induced IL-8 production 
was higher in U937 cells pre-treated with H2O2 (IL-8 (ngml
-1
): TNFα only: 1977 ± 
101; TNFα + H2O2: 3000 ± 439). The EC50 values were increased and the maximum  
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Figure 4.3 Effect of LABA add-on treatment on GR nuclear translocation. 
PBMCs were isolated from whole blood from COPD patients (n = 13). PBMCs were 
pre-treated with either FM (10
-9
 and 10
-8
 M) or SM (10
-7
 M) prior to treatment with 
10
-6
 M FITC-conjugated Dex (NT). GR nuclear translocation was evaluated by the 
amount of FITC-Dex in the nuclei. Graph represents the effect of either FM (10
-9
 and 
10
-8
 M) or SM (10
-7
 M) as add-on treatment to FITC-Dex. FITC fluorescent levels 
were detected in nuclear extracts. Data represent median ± interquartile range in each 
group 
** Significant difference from FITC-Dex treated cells (NT), p < 0.01 
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Figure 4.4 Effect of H2O2 on CS insensitivity in U937 cells. U937 cells were treated 
with either Bud or FP at different concentrations for 30 min prior to overnight 
stimulation with TNFα (1 ngml-1). Cells were also stimulated with H2O2 (100 μM) for 
10 min or FM (10
-9
 M) as add-on treatment for 20 min prior to CS treatment. (A) 
Graphs represent concentration response curves for Bud alone (purple closed squares), 
under oxidative stress conditions (purple open squares) and in combination with FM 
under oxidative stress conditions (purple crosses). (B) Graphs represent concentration 
response curves for FP alone (green closed squares), under oxidative stress conditions 
(green open squares) and in combination with FM under oxidative stress conditions 
(green crosses). Values represent mean ± SEM of three individual experiments.   
* Significant difference from NT, p < 0.05 
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Table 4.4. Efficacy of CS under oxidative stress and the effect of add-on treatment 
 
 Bud 
 
FP 
 EC50 
 (nM) 
Emax  
(%) 
EC50  
(nM) 
Emax  
(%) 
 
NT 
 
 
0.38 ± 0.08 
 
87.0 ± 2.8 
 
0.07 ± 0.02 
 
85.0 ± 0.7 
 
H2O2 
(100 μM) 
 
1.50 ± 0.14 
 
60.0 ± 1.8 
 
0.68 ± 0.11 
 
68.0 ± 3.4 
 
H2O2 +  
FM (10
-9
 M) 
 
0.23 ± 0.03* 
 
77.0 ± 7.3 
 
0.15 ± 0.03 
 
73.0 ± 8.2 
 
H2O2 +  
SM (10
-7
 M) 
 
1.00 ± 0.21 
 
66.0 ± 1.6 
 
0.48 ± 0.11 
 
69.0 ± 2.5 
 
* Significant difference from H2O2 treatment, p < 0.05  
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inhibition was reduced for both CS (EC50 (nM): Bud: 1.5 ± 0.14; FP: 0.68 ± 0.11) 
(Emax (%): Bud: 60.0 ± 1.8; FP: 68.0 ± 3.4) (Table 4.4). 
Addition of FM significantly improved Bud sensitivity in U937 cells (EC50 (nM): 
Bud: 0.23 ± 0.03; FP: 0.15 ± 0.03), as is also seen by the leftward shift of the Bud 
concentration response curve (Fig. 4.4). In contrast, SM did not significantly restore 
Bud sensitivity under oxidative stress (EC50 (nM): Bud: 1.0 ± 0.21; FP: 0.48 ± 0.11) 
(Table 4.4).  
 
4.3.4 Effect of H2O2 on LABA-induced cAMP Production in U937 Cells 
 
The effect of oxidative stress on LABA-induced cAMP release was further 
investigated.  
U937 cells were treated with H2O2 (100 μM) for 30 min, prior to treatment with 
increasing concentrations of either FM or SM for 30 min.  Cells were harvested and 
supernatants were collected for cAMP production. The 30 min incubation selected 
was optimal for SM rather than FM, as SM has slower onset of action than FM.  
Both FM and SM increased cAMP production in a concentration-dependent manner, 
in U937 cells, with concentrations that showed 50 % induction compared to baseline 
(IndC50) were 0.37 ± 0.22 and 9.9 ± 1.0 nM, respectively (Fig. 4.5). H2O2 pre-
treatment significantly reduced the ability of SM to produce cAMP (IndC50 (nM): SM 
+ H2O2: 223 ± 96; SM alone: 9.9 ± 1.0), whilst the effect was weaker and non 
significant for FM (IndC50 (nM): FM + H2O2:  1.1 ± 0.65; FM alone: 0.37 ± 0.22). 
Pre-treatment of U937 cells with a PI3K inhibitor, LY294002 (3.3 μM), 20 min prior 
to H2O2 exposure, restored the ability of SM to produce cAMP under oxidative stress 
(SM IndC50 (nM): + H2O2:  223 ± 96; + H2O2/LY294002: 11.1 ± 4.6) (Fig. 4.5, Panel 
B). The inhibitor had no significant effect on FM-treated cells as H2O2 did not affect 
FM induced cAMP release (FM IndC50 (nM): + H2O2:  1.1 ± 0.65; + 
H2O2/LY294002: 1.1 ± 0.03) (Fig. 4.5, Panel A).   
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Figure 4.5 Effect of H2O2 on LABA-induced cAMP production. U937 cells were 
treated with a PI3K inhibitor, LY294002 (3.3 μM) for 20 min and then treated with 
H2O2 (100 μM) for 30 min followed by 30 min treatment with increasing 
concentrations (10
-11
 – 10-7 M) of either FM or SM. Supernatants were collected for a 
cAMP ELISA based assay.  (A) Graph represents the concentration response curve 
for FM (closed squares), the effect of H2O2 (open squares) and the effect of PI3K 
Inhibitor (LY) (crosses). (B) Graph represents the concentration response curve for 
SM (closed squares), the effect of H2O2 (open squares) and the effect of PI3K 
Inhibitor (LY) (crosses). Values represent mean ± SEM of three individual 
experiments.  
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4.3.5 Effect of LABAs on cAMP Production in PBMCs from COPD 
Patients and Healthy Volunteers 
 
Having established the effect of oxidative stress on LABA-induced cAMP production 
in U937 cells, the next step involved the investigation into the effect of LABAs on 
cAMP production in PBMCs from healthy volunteers and COPD patients. 
PBMCs from healthy volunteers (n = 6), healthy smokers (n = 7) and COPD patients 
(n = 6) were treated with either FM (10-9 M) or SM (10
-7
 M) for 15 min and cAMP 
was measured in supernatants.   
Both FM and SM significantly increased cAMP release in PBMCs from healthy 
volunteers (Induction from baseline (%): FM: 391 ± 73; SM: 348 ± 58) (Fig. 4.6, 
Panel A). FM had an enhanced and significant effect on cAMP production in PBMCs 
from COPD patients compared to SM (Induction from baseline (%): FM: 268 ± 25; 
SM: 230 ± 60) (Fig. 4.6, Panel C). A similar picture was seen in healthy smokers 
(Induction from baseline (%): FM: 177 ± 20; SM: 150 ± 14) (Fig. 4.6, Panel B).  
Hence, FM was more potent in producing cAMP in primary cells.  
 
4.3.6 Effect of LABAs on Phosphorylation of MAPKs and other 
Serine/threonine Kinases  
   
So far, I have shown that PI3K is likely to be involved in oxidative stress-dependent 
defects of SM; however, FM effects seem not to be affected by oxidative stress. The 
next step was to investigate further the effect of PI3K and other kinases on the β2AR-
dependent signalling. Initially a screening process was carried out in order to identify 
candidate kinases that would be studied further by more quantitative (semi-
quantitative) techniques. Of special interest was PKB/Akt kinase as it is a downstream 
substrate of the PI3K cascade. 
For this, the human phospho MAPK array kit was used, which is a rapid and sensitive 
tool that can simultaneously detect the relative levels of phosphorylation of nine 
MAPKs and nine other serine/threonine kinases. Of main interest were the activation 
of kinases under oxidative stress and the effect of LABAs; however firstly the effects 
of LABAs on basal levels of kinase phosphorylation were examined. 
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Figure 4.6 Effect of LABAs on cAMP production in PBMCs. PBMCs were 
isolated from whole blood from healthy volunteers (n = 6), healthy smokers (n = 7) 
and COPD patients (n = 6). PBMCs were treated with FM (10
-9
 M) or SM (10
-7
 M) 
for 15 min, or left untreated (NT). cAMP release was assessed by an ELISA based 
assay. Graph shows cAMP production in PBMCs from (A) Healthy volunteers, (B) 
Healthy smokers and (C) COPD patients. Values represent mean ± SEM of each 
subject group.  
* Significant difference from NT, p < 0.05 
** Significant difference from NT, p < 0.01 
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Briefly, U937 cells were treated with either FM or SM for 15 min. Cells were 
harvested and lysates were incubated on nitrocellulose membranes, which had capture 
and control antibodies for the different kinases spotted in duplicate. Membranes were 
incubated with a cocktail of phospho-site specific biotinylated antibodies to detect 
phosphorylated kinases via streptavidin-HRP and chemiluminescence (Fig. 4.7, Panel 
A). 
As shown in Fig. 4.7, Panel B, FM resulted in an increase in phosphorylation of a few 
kinases, such as p38α (104 ± 42 % induction from NT) and HSP27 (268 ± 179 % 
induction from NT) (Fig. 4.7, Panel B, Table 4.5). SM had no effect on kinase 
phosphorylation (Fig. 4.7, Panel B, Table 4.5). Due to the variability between 
experiments, no significant difference of LABA efficacies on kinase phosphorylation 
could be determined.  
 
4.3.7 Effect of H2O2 on Phosphorylation of MAPKs and other 
Serine/threonine Kinases 
 
The effect of H2O2 on the phosphorylation of MAPKs and other Ser/Thr kinases was 
investigated. The experimental procedure followed was similar to that explained in 
section 4.2.6.  
H2O2 induced the phosphorylation of several kinases (Fig. 4.8, Table 4.6). Notably, 
were the induction of Akt kinases, p38γ, p38α and its downstream substrates MSK2 
and HSP27, JNK pan and ERK1 (% induction from NT: Akt pan: 72 ± 12; Akt2: 107 
± 25; ERK1: 150 ± 50; JNK pan: 130 ± 77; p38γ: 682 ± 463; p38α: 250 ± 52; MSK2: 
92 ± 27; HSP27: 1400 ± 722).  
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Figure 4.7 Effect of LABAs on the phosphorylation of MAPKs and other 
serine/threonine kinases (baseline). U937 cells were treated with either FM (10
-8
 M) 
or SM (10
-7
 M) for 15 min, or left untreated (NT). Cells were harvested and 
solubilised in lysis buffer. Each lysate was incubated with human phospho-MAPK 
array and phosphorylated kinases were detected by streptavidin-HRP and 
chemiluminescence. (A) Representative human phospho-MAPK array (dot-blot). (B) 
Graphs show % induction of kinase phosphorylation levels compared to non-treated 
cells. 
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Table 4.5. Panel of kinases activated by LABA treatment (basal levels) 
 
Kinase 
 
Kinase phosphorylation 
(% induction from NT) 
[Formoterol] 
Kinase phosphorylation 
(% induction from NT) 
[Salmeterol] 
 
Akt pan 0.3 ± 26 33 ± 37 
 
Akt1 -6 ± 7 -19.0 ± 10 
 
Akt2 -18 ± 49 44.3 ± 63 
 
Akt3 -17 ± 15 -4.0 ± 19 
 
ERK1 601 ± 621 391 ± 456 
 
ERK2 -8 ± 6 -12 ± 11 
 
HSP27 268 ± 179 23 ± 33 
 
JNK pan 37 ± 51 -2 ± 33 
 
JNK1 72 ± 83  11 ± 15 
 
JNK2 -22 ± 11  -21 ± 16  
 
JNK3 13 ± 17  35 ± 46 
 
MSK2 52 ± 45  8 ± 6 
 
p38α 104 ± 42 29 ± 15 
 
p38β -43± 47 -0.4 ± 10 
 
p38γ 912 ± 942 -0.2 ± 23 
 
p38δ 12 ± 40 14 ± 31 
 
Note: Values are presented as % induction of kinase phosphorylation from non-
treated cells. Values represent mean ± SEM of 3 – 4 individual experiments.  
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Figure 4.8 Effect of H2O2 on the phosphorylation of MAPKs and other 
serine/threonine kinases. U937 cells were stimulated with H2O2 (200 μM) for 7.5 
min, or left untreated (NT). Cells were harvested and solubilised in lysis buffer. Each 
lysate was incubated with human phospho-MAPK array and phosphorylated kinases 
were detected by streptavidin-HRP and chemiluminescence. (A) Representative 
human phospho-MAPK array (dot-blot). (B) Graph show % induction of kinase 
phosphorylation levels compared to non-treated cells. 
 136 
 
 
 
 
 
Table 4.6. Panel of kinases phosphorylated by H2O2 stimulation  
 
Kinase 
 
Kinase phosphorylation 
(% Induction from NT) 
[H2O2] 
 
Akt pan 72 ± 12  
 
Akt1 44 ± 45  
 
Akt2 107 ± 25  
 
Akt3  38 ± 29  
 
ERK1 150 ± 50 
 
ERK2 38 ± 16 
 
HSP27 1400 ± 722 
 
JNK pan 130 ± 77  
 
JNK1  76 ± 47  
 
JNK2 42 ± 67 
 
JNK3 80 ± 62 
 
MSK2 92 ± 27 
 
p38α 250 ± 52 
 
p38β 15 ± 77 
 
p38γ 682 ± 463 
 
p38δ 68 ± 46 
 
Note: Values are presented as % induction of kinase phosphorylation from non-
treated cells. Values represent mean ± SEM of four individual experiments. 
 137 
4.3.8 Effect of LABAs on H2O2-induced MAPK and Akt Phosphorylation 
 
As FM showed superior effects to SM under oxidative stress in both PBMCs and cell 
lines, the effect of FM on oxidative stress-induced kinase phosphorylation was 
evaluated. As before, U937 cells were incubated with H2O2, prior to 20 min FM 
treatment. Lysates were then incubated with the phospho MAPK arrays and kinase 
phosphorylation levels were detected by chemiluminescence.  
FM either inhibited or further enhanced H2O2-induced kinase phosphorylation (Table 
4.7). H2O2-induced p38α (% induction from NT: H2O2 alone: 250 ± 52; H2O2 + FM: 
338 ± 55) and HSP27 (% induction from NT: H2O2 alone: 1400 ± 722; H2O2 + FM: 
3593 ± 1494) phosphorylation was not inhibited by FM (Fig. 4.9, Table 4.7). 
On the other hand, H2O2-induced Akt pan and JNK pan phosphorylation was inhibited 
by FM (Table 4.7). Akt pan was inhibited by ~ 83 % (% induction from NT: H2O2 
alone: 72 ± 12; H2O2 + FM: 12 ± 33). For JNK pan the inhibition on phosphorylation 
was ~ 70 (% induction from NT: H2O2 alone: 130 ± 77; H2O2 + FM: 44 ± 8).  
 
4.3.9 Effect of H2O2 on Akt Phosphorylation 
 
The human phospho-MAPK arrays had a high degree of variability between 
experiments. This method was used only as a screening process and candidate kinases 
were selected for further experiments. Akt was one of the candidate kinases that its 
activation was altered by the stimulus and/or in combination with a LABA, therefore I 
further investigated this kinase using more quantitative techniques, such as western 
blotting.  
U937 cells were treated for 5 min with H2O2 (200 μM) and were harvested for whole 
cell extraction. Phosphorylation levels of Akt1 at Ser 473 were quantified by western 
blot analysis, using total Akt1/PKBα as a loading control. 
H2O2 significantly induced a 5-fold increase in Akt phosphorylation (Fig.4.10), which 
confirms the findings obtained from the screening with the phospho-MAPK arrays. 
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Table 4.7. Panel of kinases phosphorylated by H2O2 and the effect of FM 
 
 
Kinase 
 
Kinase phosphorylation 
(% Induction from NT) 
[H2O2] 
Kinase phosphorylation 
(% Induction from NT) 
[Formoterol + H2O2] 
 
Akt pan 
 
72 ± 12 
 
12 ± 33  
 
 
Akt1 
 
 
44 ± 45 
 
15 ± 25  
 
 
ERK1 
 
150 ± 50 
 
410 ± 351  
 
 
ERK2 
 
38 ± 16 
 
-3 ± 16  
 
 
HSP27 
 
1400 ± 722 
 
3593 ± 1494  
 
 
JNK pan 
 
130 ± 77 
 
44 ± 8 
 
 
JNK1 
 
76 ± 47 
 
43 ± 45 
 
 
p38α 
 
250 ± 52 
 
338 ± 55 
 
 
p38γ 
 
682 ± 463 
 
891 ± 660 
 
 
Note: Values are presented as % induction of kinase phosphorylation from non-
treated cells. Values represent mean ± SEM of four individual experiments. 
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Figure 4.9 Effect of FM on H2O2-induced MAPK and PKB/Akt phosphorylation. 
U937 cells were treated with FM (10
-8
 M) for 15 min, prior to 7.5 min stimulation 
with H2O2 (200 μM), or left untreated (NT). Cells were harvested and solubilised in 
lysis buffer. Each lysate was incubated with human phospho-MAPK array and 
phosphorylated kinases were detected by streptavidin-HRP and chemiluminescence. 
(A) Human phospho-MAPK arrays (dot-blot). (B) Graph show % induction of kinase 
phosphorylation levels compared to non-treated cells. 
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Figure 4.10 Effect of H2O2 on Akt phosphorylation. U937 cells were treated with 
H2O2 (200 μM) for 5 min, or left untreated (NT). Cells were harvested for whole cell 
extraction. Proteins were size-fractionated by SDS-PAGE and phosphorylated levels 
of Akt (pAkt) were evaluated by western blotting. (A) Representative western blot 
experiment showing phosphorylation levels of Akt. Total Akt is shown as a loading 
control. (B) Graph shows Akt phosphorylation levels normalised to total Akt levels, 
analysed by densitometric analysis. Values represent mean ± SEM from six individual 
experiments. 
* Significant difference from NT, p = 0.03  
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4.3.10 Effect of LABAS on H2O2-induced Akt Phosphorylation 
 
The effects of Akt phosphorylation, as a marker of PI3K signalling were also 
confirmed by western blot analysis. 
U937 cells were treated with increasing concentration of either FM or SM or VT (10
-8
 
M) for 20 min prior to 5 min stimulation with H2O2. Phosphorylation levels of Akt 
were detected by western blotting analysis. 
As shown in Fig. 4.11, FM significantly and concentration-dependently inhibited the 
H2O2-induced Akt phosphorylation, with maximum inhibition ~ 54 % at 10
-8
 M (Fold 
change from H2O2: 0.46 ± 0.04). On the contrary, SM weakly inhibited H2O2-induced 
Akt phosphorylation (32.5 %) (Fold change from H2O2: 0.68 ± 0.11), only at the 
highest concentration (10
-6
 M), however, this was not significant. Pre-treatment with 
VT at 10
-8
 M, resulted in a significant inhibition of the H2O2-induced phosphorylation 
of Akt by 60 % (Fold change from H2O2: 0.39 ± 0.10) (Fig. 4.12). These data show 
that FM (or VT) is able to inhibit H2O2-induced Akt phosphorylation, but SM not.  
 
4.3.11 Inhibition of H2O2-induced Akt Phosphorylation by FM is PKA-
driven  
 
As shown in Fig. 1.6, upon binding of the β2 agonist to the β2AR, a β2AR-dependent 
signalling cascade is activated. Elevated levels of cAMP activate a downstream 
pathway that involves either PKA or Epac. Therefore, the next experiments would 
clarify whether inhibition of H2O2-induced phosphorylation of Akt by FM was a 
PKA-dependent effect or not.  
The experiment detailed in section 4.3.10 was repeated either in the presence or 
absence of a PKA inhibitor (PKAi) at 1 μM for 15 min, under oxidative stress. 
Phosphorylation levels of Akt were detected in whole cell extracts by western blot. 
The inhibitory effect of FM was reversed by the addition of PKAi (fold change from 
H2O2 treatment: FM alone: 0.64 ± 0.06; FM + PKAi: 1.12 ± 0.31) (Fig. 4.13). Epac 
agonist (1 μM) or PKAi did not have any effect on H2O2-induced Akt 
phosphorylation (data not shown). These data show that FM-induced inhibition of 
H2O2-induced Akt phosphorylation was a PKA-dependent effect. 
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Figure 4.11 Effect of LABAs on H2O2-induced Akt phosphorylation. U937 cells 
were treated with increasing concentrations of either FM or SM for 30 min prior to 
H2O2 (200 μM) stimulation for 5 min, or left untreated (NT). Cells were harvested for 
whole cell extraction and proteins were size-fractionated by SDS-PAGE and 
phosphorylation levels of Akt (pAkt) were evaluated by western blot analysis. (A) 
Representative experiment of western blot showing phosphorylation levels of Akt. 
Total Akt is shown as a loading control. (B) Graph shows fold change of Akt 
phosphorylation levels from H2O2 treatment alone, normalised to total Akt levels. FM 
doses used: 10
-10
 – 10-8 M; SM doses used: 10-8 – 10-6 M. Values are a mean ± SEM 
from three individual experiments.  
** Significant difference from H2O2 treatment, p < 0.01 
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Figure 4.12 Effect of VT on H2O2-induced Akt phosphorylation. U937 cells were 
treated with VT (10
-8
 M) for 30 min prior to H2O2 (200 μM) stimulation for 5 min, or 
left untreated (NT). Cells were harvested for whole cell extraction and proteins were 
size-fractionated by SDS-PAGE and phosphorylation levels of Akt (pAkt) were 
evaluated by western blot analysis. (A) Representative experiment of a western blot 
showing phosphorylation levels of Akt. Total Akt is shown as a loading control. (B) 
Graph shows fold change of Akt phosphorylation levels from H2O2 treatment alone, 
normalised to total Akt levels. Values are a mean ± SEM from four individual 
experiments.  
** Significant difference from H2O2 treatment, p < 0.01 
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Figure 4.13 Effect of FM on H2O2-induced Akt phosphorylation is a PKA-
dependent effect. U937 cells were treated with a PKA inhibitor (PKAi) (1 μM) for 
15 min followed by treatment with FM (10
-8
 M) for 30 min before being treated with 
H2O2 (200 μM) for 5 min or left untreated (NT). Cells were harvested and whole cell 
extraction was performed. Proteins were size fractionated by SDS-PAGE and the 
levels of phospho-Akt (pAkt) were evaluated by western blotting. (A) Representative 
experiment of western blot showing phosphorylation levels of Akt. Total Akt is 
shown as a loading control. (B) Graph shows fold change of Akt phosphorylation 
from H2O2 treatment alone, normalised to total Akt level. Values represent mean ± 
SEM from 3 – 4 individual experiments.  
 
 
 
 145 
4.3.12 Effect of Oxidative Stress on LABA-induced β2AR Internalisation 
 
Chronic exposure of the β2ARs to β2 agonists triggers the translocation of the receptor 
from the cell membrane into the cytoplasm, a process known as internalisation. 
However, the effect of oxidative stress on internalisation has yet to be established. 
Having seen that FM and SM behave differently with respect to β2AR-dependent 
signalling, their effect on β2AR internalisation, under H202 conditions was also 
evaluated. 
U937 cells were stimulated with H2O2 for 4 hrs on cells followed by 30 min treatment 
with either FM or SM or salbutamol (SLB) for 5 min. β2AR protein levels were 
detected in membrane fractions by western blot analysis.
 
Neither FM nor SM altered β2AR protein levels in membrane fractions of U937 cells 
after 30 min incubation; however SLB reduced β2AR protein at cell membrane, after 5 
min incubation (data not shown), suggesting that SLB induced β2AR internalisation. 
H2O2 slightly induced internalisation, as membrane β2AR was reduced after 240 min 
exposure (Fig. 4.14). FM treatment under oxidative stress conditions did not alter 
membrane β2AR protein levels even after 240 min H2O2 exposure (Fig. 4.14). In 
contrast, SM induced β2AR internalisation, starting at 30 min incubation and was 
reduced ~ 57 % by 240 min H2O2 incubation; however SM did not induce 
internalisation of β2AR under normal conditions, i.e. no H2O2 conditions.  
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Figure 4.14 Effect of H2O2 on LABA-induced β2AR internalisation. U937 cells 
were treated with H2O2 (200 μM) at different time points (30, 60 and 240 min), 
followed by 30 min incubation with either FM (10
-8
 M) or SM (10
-7
 M), or left 
untreated (NT). Cells were harvested for membrane isolation and β2AR protein levels 
in the membrane fractions were evaluated by western blotting analysis. (A) 
Representative experiment of western blot showing β2AR protein levels in membrane 
fractions (B) Graph shows % change from non-treated cells of membrane β2AR 
protein levels under H2O2 for 240 min. Membrane β2AR protein levels were 
normalised to protein concentrations. Values represent mean ± SEM of three 
individual experiments. 
* Significant difference from NT, p < 0.05 
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4.4 Discussion 
 
CSs are essential for the treatment of asthma, however, only a 70 % of the general 
asthma population respond to CS treatment (Holgate and Polosa, 2006).  Concurrently 
with CS refractory asthma, inflammation in COPD shows little response to CSs 
(Stockley et al., 2009). In this study, CS insensitivity was evident in PBMCs from 
patients with severe asthma or COPD. PBMCs were insensitive to Dex on TNFα-
induced IL-8 release and the effect in COPD was 5 – 7-fold weaker than that seen on 
healthy volunteers or healthy smokers. More importantly, in this system, although SM 
and FM restored Dex sensitivity on TNFα-induced IL-8 release in PBMCs from 
severe asthma patients, only FM was able to restore Dex sensitivity in PBMCs from 
COPD patients.  
Oxidative stress (i.e. H2O2) has been previously reported to induce CS insensitivity in 
cultured cells (Ito et al., 2004). In fact, H2O2 decreased the sensitivity of both Bud and 
FP in U937 cells (Fig. 4.4, Table 4.4). The EC50 values for both Bud and FP had 
increased 4- and 10-fold, respectively, as well as their maximum effect (Emax) on 
TNFα-induced IL-8 production was reduced by 20 %.  In the same system, FM 
reversed Bud and FP sensitivity in H2O2-treated U937 cells. In contrast, even though 
100-fold higher concentration was used, SM did not significantly restore sensitivity in 
H2O2-treated U937 cells. Under oxidative stress, there is a defect on GR nuclear 
translocation. A possible molecular mechanism involved is GR phosphorylation. 
Especially phosphorylation at Ser 226 is reported to cause an increase of export of GR 
from cells, leading to the weakening of steroid activity. The kinase responsible for 
this phosphorylation is JNK. In fact, in this thesis, H2O2 activated JNK 
phosphorylation (human phospho MAPK arrays), which was inhibited by FM.  Thus, 
I hypothesise that FM inhibits GR phosphorylation under oxidative stress by 
inhibiting JNK activation and enhancing CS function. Ito et al have shown that FM 
inhibits JNK phosphorylation via enhancement by a phosphatase (in preparation). 
Additionally, H2O2 reduced SM-induced cAMP production. In consequence, it seems 
that SM is oxidative stress sensitive, thus its efficacy is reduced in COPD. 
Screening of MAPK and other serine/threonine kinase activation revealed that H2O2 
induced the phosphorylation of several kinases, including p38 MAPKs, JNK and the 
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Akt family of kinases. FM did not inhibit the H2O2-induced phosphorylation of p38α 
and its downstream substrates, HSP27 and MSK2.  
However, there was an effect on Akt (a downstream kinase of the PI3K pathway) 
phosphorylation, which was confirmed by western blot analysis (Fig. 4.11). It has 
been previously reported that oxidative stress, i.e. cigarette smoke, is able to activate 
this pathway in U937 cells (Marwick et al., 2009). Addition of FM significantly 
inhibited H2O2-induced Akt phosphorylation in a concentration-dependent manner 
with a maximum inhibitory effect of 54 % at 10
-8
 M. On the contrary, SM, even at 
100-fold higher concentration (10
-6
 M) had a weaker effect, as it inhibited H2O2-
induced Akt phosphorylation by only 35 %, which was not statistically significant. A 
novel LABA, VT (10
-8
 M), also inhibited Akt phosphorylation by 60 % under 
conditions of oxidative stress. Furthermore, the reduction observed in SM-induced 
cAMP production by H2O2 was reversed by the PI3K inhibitor, LY294002. These 
data show that PI3K leads to reduced efficacy of LABAs. Besides, it has been 
reported that PI3K signalling is involved in β2AR endocytosis (Naga Prasad et al., 
2002). Therefore, Akt phosphorylation by oxidative stress might explain the SM-
induced β2AR-induced internalisation after 4 hrs pre-treatment with H2O2 in U937 
cells observed in this study. However, the latter finding needs to be further evaluated 
as a membrane loading control was not used for this study. At the time of this thesis it 
was not able to identify in the market a membrane loading control that is not affected 
by oxidative stress and the results were normalised to the protein concentrations and 
an equal amount (30 μg) of protein was used for each membrane fraction. β2-AR 
internalisation can also be studied by FACS analysis in membrane fractions. 
In fact, FM and SM are two different pharmacological entities. The different 
properties they entail might be important for the inhibition by PI3K signalling, 
however further experiments are required to dissect the molecular mechanism 
involved. FM is cationic and a full agonist, and a good agonist clinically. On the other 
hand, SM is more lipophilic and a partial agonist; however it has a proven efficacy 
clinically. Being a partial agonist it is not a great tool for pharmacological research. 
Therefore I used FM in most of the experiments as it is a better tool for research and 
confirmed SM effects in key experiments.  
Furthermore, VT was more effective than SM. According to the manuscript by 
Procopiou e.t al., VT is the triphenylacetate salt of the 2,6-dichlorobenzyl analogue of 
a series of novel β2AR agonists obtained by the incorporation of an oxygen atom at 
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the homobenzylic position of the right hand side phenyl ring of (R)-SM (Procopiou et 
al., 2010). The triphenylacetate salt was found to have suitable properties for inhaled 
administration. Therefore VT is an agonist with improved pharmacological properties. 
From personal communication with GSK, VT is an agonist between a full and a 
partial one (no access to other confidential information). Regarding the resistance of 
VT to oxidative stress is a novel finding in this thesis; however the molecular 
mechanism involved has not been explored. Nonetheless, I hypothesise that oxidative 
stress affects the lipid oxidation of membrane receptors. Furthermore, cysteine 
oxidation of either SM or VT binding site will be different. In the future, I would like 
to work more on the molecular mechanism implicated. 
These data suggest that FM (and VT) is more potent and less sensitive to oxidative 
stress compared to SM (i.e. the drug is loosing pharmacological effects, e.g. potency, 
under oxidative stress conditions). These data are in agreement with several in vivo 
and in vitro studies that showed FM’s efficacy to be greater than other LABAs’. For 
example, Cote et al proposed that FM has a faster onset of action, as 5 and 30 min 
post treatment, COPD patients showed significant greater improvements from 
baseline in FEV1 compared to SM (Cote et al., 2009). Partridge and colleagues also 
showed that FM/Bud had a faster onset of effect compared to SM/FP, as greater 
improvements were evident in COPD patients that were able to perform morning 
activities regardless of the lower dose of ICS (Partridge et al., 2009).   This is 
reflected by in vitro studies, where it is shown that FM enhanced cAMP production in 
monocyte-derived macrophages greater than SM (Donnelly et al., 2009). Rabe et al 
showed that FM inhibited LTB4-induced H2O2 generation in peritoneal eosinophils 
from guinea pigs, however SM being a partial agonist did not, behaving more as an 
antagonist (Rabe et al., 1993). In mouse trachea, FM’s maximal relaxation (Rmax) was 
not impaired after concomitant treatment with cytokines and Bud, whereas Rmax for 
SM was impaired. A similar pattern was seen in LABA-induced cAMP production 
(Adner et al., 2010). 
Therefore, FM behaves differently from SM in vitro, under oxidative stress conditions 
or in primary cells from COPD patients, due to a partial inhibition of PI3K signalling 
triggered by oxidative stress. 
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Chapter 5,  
Optimisation of Combination Therapy of a Long-acting β2 
Agonist with a Corticosteroid for the Treatment of COPD 
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5.1 Introduction 
 
CSs in combination with LABAs are the first-line treatment administered to patients 
with mild to moderate asthma.  These patients show good control of asthma therefore 
the combination has become the mainstay of asthma therapy. Several clinical studies 
demonstrated the beneficial effect of combination inhalers of CSs and LABAs. They 
showed better efficacy than ICS alone on lung function and other clinical related 
symptoms. COPD is a CS insensitive disease and the combination inhalers do not 
seem to be effective enough to control its symptoms as well as they do in asthma. The 
numbers of studies with COPD patients are still limited compared with asthma and 
the long term benefits of CS/LABA combination have not been clarified yet.  
In the previous chapters, the impact of oxidative stress on the efficacy of CSs and 
LABAs was evaluated. FF and FM (or VT) were shown to be oxidative stress 
insensitive CS and LABAs, respectively. In this chapter, an attempt was made to 
identify the combination of a CS with a LABA, either in cell lines under simulative 
conditions of oxidative stress or in PBMCs from COPD patients and healthy 
volunteers.  
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5.2 Methods 
 
5.2.1 TNFα-induced IL-8 Production  
 
U937 cells were seeded at a density of 200,000 cells/ well in a 96-well plate and were 
treated with various LABAs (VT: 10
-8
 M; FM: 10
-8
 M; SM: 10
-7
 M) for 30 min, 
followed by 4 hrs treatment with CS (FF, FP, MF and Bud: 10
-14 – 10-6 M), prior to 
overnight TNFα (1 ngml-1) stimulation, or left untreated. Supernatants were collected 
for analysis of IL-8 by ELISA. The combinations used are shown in table 5.1. 
 
Table 5.1. CS/LABA combinations used in this chapter 
 
CS / LABA Name Company Clinical Trial Status 
FF / VT Relovair GSK Phase II 
FP / SM Seretide GSK Launched 
MF / FM Dulera Schering Corporation Launched 
Bud / FM Symbicort AstraZeneca Launched 
 
5.2.2 TNFα-induced IL-8 Production under Oxidative Stress 
 
The same methodology was used as shown in section 5.2.1. The only difference was a 
stimulation with H2O2 (100 μM) for 1 hr prior to LABA treatment. 
 
5.2.3 MKP-1 mRNA Expression in U937 Cells 
 
U937 cells were seeded at a density of 1 x 10
6
 cells/treatment and were treated with 
either SM (10
-7
 M) or VT (10
-8
 M) for 30 min, prior to FP (10
-8
 M) and FF (10
-8
 M) 
treatment, respectively, for 4 hrs. Cells were harvested for RNA extraction and 
reverse transcription. MKP-1 mRNA levels were quantified by real-time PCR and 
were normalised to GNB2L1 mRNA levels.  
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5.2.4 MKP-1 mRNA Expression in U937 Cells under Oxidative Stress 
 
The same methodology was used as explained in section 5.2.3. However, prior to 
LABA treatment cells were stimulated with H2O2 (200 μM) for 1 hr. 
 
5.2.5 Effect of “Pre-incubation” Mixture of FP and SM on MKP-1 mRNA 
Expression  
 
SM (10
-7
 M) was mixed with FP (10
-8
 M) in a test tube for either 15 or 60 min at room 
temperature. At t = 0 min, U937 cells were treated with either drug alone, the pre-
incubated mixture and the combination of each drug added separately to the 
appropriate wells, or left untreated. After 4 hrs incubation, cells were harvested and 
RNA extraction and reverse transcription were carried out. MKP-1 and GNB2L1 
mRNA levels were quantitated by real-time PCR.  
 
5.2.6 TNFα-induced IL-8 Release in PBMCs from COPD Patients and 
Healthy Volunteers 
 
Whole blood was taken after subjects had given informed consent. PBMCs were 
isolated from whole blood and were seeded at a density of 100,000 cells/well at a 96-
well plate. PBMCs were treated with increasing concentrations of FF, FP and MF for 
24 hrs, or left untreated, prior to overnight stimulation with TNFα (10 ngml-1). 
Supernatants were collected for IL-8 analysis by ELISA. 
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5.3 Results 
 
5.3.1 Effect of LABA Addition on CS Anti-inflammatory Action  
 
In previous chapters the potency of CSs in both normal and oxidative stress 
conditions was evaluated. The next step was to assess the effect of combinations of 
CSs with LABAs on anti-inflammatory action.  
The effects of CS/LABA combination on TNFα-induced IL-8 release were tested in 
U937 cells. U937 cells were treated with different LABAs, followed by CSs prior to 
overnight stimulation with TNFα, or left untreated. Supernatants were collected for 
IL-8 analysis by ELISA.   
As shown in Fig. 5.1 all CSs inhibited TNFα-induced IL-8 release in a concentration-
dependent manner. FF was more potent than all other steroids with maximum effect 
(Emax) at 71.7 ± 6.1 % (FP: 51.5 ± 3.6; MF: 70.2 ± 4.0; Bud: 57.6 ± 2.2) (Table 5.2). 
Addition of VT to FF treatment vaguely reduced the IC50 value (IC50 (nM); FF: 0.4; 
FF/VT: 0.3). Addition of SM to FP or FM to either MF or Bud resulted in an 
enhancement of the maximum effect on all CSs. Thus, Emax of CSs was enhanced by 
LABAs; however, the potency of CSs, evaluated by the IC50 value, was not changed 
although MF concentration response curve shifted leftwards after add-on treatment of 
FM (Fig. 5.1). The IC50 value of Bud in the presence of FM was ~ 21-fold weaker 
than FF/VT, and ~ 12-fold weaker than both FP/SM and MF/FM combinations.  
 
5.3.2 Effect of LABA on Anti-inflammatory Action of CSs under Oxidative 
Stress 
 
Similarly, as described in section 5.3.1, experiments were repeated under oxidative 
stress. Briefly, U937 cells were treated with H2O2 prior to LABA treatment followed 
by CS treatment and an overnight TNFα stimulation, or left untreated.  
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Figure 5.1 Effect of LABA addition to CS treatment on TNFα-induced IL-8 
release. U937 cells were treated with vilanterol (VT) (10
-8
 M), formoterol (FM) (10
-8
 
M) or salmeterol (SM) (10
-7
 M) for 30 min. Cells were then treated with increasing 
concentrations of fluticasone furoate (FF), fluticasone propionate (FP), mometasone 
furoate (MF) or budesonide (Bud) for 4 hrs,  prior to overnight stimulation with TNFα 
(1 ngml
-1
). Supernatants were collected for IL-8 analysis by ELISA. Graphs show the 
inhibitory concentration response curve of (A) FF (red, circle) and the effect of VT 
addition (red, cross) (B) FP (green, rhombus) and the effect of SM addition (green, 
cross). (C) MF (blue, square) and the effect of FM addition (blue, cross) (D) Bud 
(purple, triangle) and the effect of FM addition (purple, cross).  Values represent 
mean ± SEM of 4 – 5 individual experiments.  
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Table 5.2. Summarised data of CS/LABA combination experiments and the effect of 
the combination on TNFα-induced IL-8 release 
 
 
 IC50 
(nM) 
Emax 
(%) 
N 
 
FF 
 
 
0.4 
 
71.7 ± 6.1 
 
5 
 
FF + VT 
 
 
0.3 
 
80.1 ± 3.8 
 
5 
 
FP 
 
 
1.4 
 
51.5 ± 3.6 
 
5 
 
FP + SM 
 
 
0.5 
 
77.4 ± 2.2 
 
5 
 
MF 
 
 
5.2 
 
70.2 ± 4.0 
 
4 
 
MF + FM 
 
 
0.5 
 
84.1 ± 1.0 
 
4 
 
Bud 
 
 
10.2 
 
57.6 ± 2.2 
 
4 
 
Bud + FM 
 
 
6.2 
 
73.3 ± 6.0 
 
4 
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H2O2 did not have high impact on maximum effect (Emax) of FF, FP, MF and Bud on 
TNFα-induced IL-8 release (Emax (%): FF: 84.7 ± 8.0; FP: 71.6 ± 5.6; MF: 85.5 ± 5.1; 
Bud: 74.1 ± 10.0) (Table 5.3, Fig. 5.2). 
Addition of VT to FF treatment did not have any effect on the IC50 value (IC50 (nM); 
FF: 0.4; FF/VT: 0.8), however it increased the maximum effect to 93.9 ± 11.7. 
Addition of SM to FP or FM to either MF or Bud, resulted in an enhancement of the 
maximum effect an all CSs (Emax (%): FP/SM: 86.0 ± 7.1; MF: 99.5 ± 7.4; Bud: 83.8 
± 9.1).  in all combinations tested, the most potent combinations were FF/VT and 
MF/FM in terms of the Emax.  
 
5.3.3 LABAs Enhances CS-dependent Transactivation (MKP-1 mRNA 
Induction) 
 
U937 cells were treated with either SM or VT for 30 min, prior to FP and FF 
treatment, respectively, for 4 hrs. MKP-1 and GNB2L1 mRNA levels were quantified 
by real-time PCR.  
FF increased MKP-1 mRNA expression ~ 4-fold compared to non-treated cells (Ratio 
of MKP-1/GNB2L1; NT: 0.0019 ± 0.0003, FF: 0.0081 ± 0.0034). VT treatment alone 
did not induce MKP-1 mRNA expression compared to non-treated cells, however, 
addition to FF treatment resulted in a 6.5-fold increase of MKP-1 mRNA levels (Ratio 
of MKP-1/GNB2L1; VT: 0.0019 ± 0.0003; FF/VT: 0.0125 ± 0.0026) (Fig. 5.3, Panel 
A). 
FP significantly enhanced MKP-1 mRNA expression by 5-fold compared to non-
treated cells (Ratio of MKP-1/GNB2L1: NT:  0.001 ± 0.0002; FP: 0.005 ± 0.0006). 
SM on its own slightly increased MKP-1 mRNA expression (Ratio of MKP-
1/GNB2L1: SM: 0.002 ± 0.0005), but this change was not significant. Nonetheless, 
addition of SM to FP significantly augmented MKP-1 mRNA expression (Ratio of 
MKP-1/GNB2L1: FP/SM 0.012 ± 0.0009) (Fig. 5.3, Panel B). 
Furthermore, these combinations were tested under H2O2 conditions. As shown in Fig. 
5.4, Panel A, FF/VT combination was 3.5-fold more potent than FP/SM combination 
in enhancing MKP-1 mRNA expression under oxidative stress (Ratio of MKP-
1/GNB2L1: FF/VT: 0.093 ± 0.004; FP/SM: 0.026 ± 0.019). More interestingly, under 
oxidative stress conditions, FF/VT combination showed greater improvement than its  
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Table 5.3. Summarised data of CS/LABA combination experiments and the effect of 
the combination on TNF-α-induced IL-8 release, under oxidative stress conditions 
 
 
 
 IC50 
(nM) 
Emax 
(%) 
n 
 
FF 
 
 
0.4 
 
84.7 ± 8.0 
 
5 
 
FF + VT 
 
 
0.8 
 
93.9 ± 11.7 
 
5 
 
FP 
 
 
1.2 
 
71.6 ± 5.6 
 
5 
 
FP + SM 
 
 
0.5 
 
86.0 ± 7.1 
 
5 
 
MF 
 
 
1.9 
 
85.5 ± 5.1 
 
4 
 
MF + FM 
 
 
0.5 
 
99.5 ± 7.4 
 
4 
 
Bud 
 
 
4.8 
 
74.1 ± 10.0 
 
4 
 
Bud + FM 
 
 
1.7 
 
83.8 ± 9.1 
 
3 
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Figure 5.2 Effect of LABA addition to CS treatment on TNFα-induced IL-8 
release in the presence of H2O2. U937 cells were pre-treated with H2O2 (200 μM) 
prior to treatment with vilanterol (VT) (10
-8
 M), formoterol (FM) (10
-8
 M) or 
salmeterol (SM) (10
-7
 M) for 30 min. Cells were further treated with increasing 
concentrations of fluticasone furoate (FF), fluticasone propionate (FP), mometasone 
furoate (MF) or budesonide (Bud) for 4 hrs, prior to overnight stimulation with TNFα 
(1 ngml
-1
). Supernatants were collected for IL-8 analysis by ELISA. Graphs show the 
inhibitory concentration response curve of (A) FF (red, circle) and the effect of VT 
addition (red, star). (B) FP (green, rhombus) and the effect of SM addition (green, 
star). (C) MF (blue, square) and the effect of FM addition (blue, star) (D) Bud (purple, 
triangle) and the effect of FM addition (purple, star).  Values represent mean ± SEM 
of 3 – 5 individual experiments.  
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Figure 5.3 Effect of LABA addition to CS-dependent MKP-1 mRNA expression. 
U937 cells were treated with either VT (10
-8
 M) or SM (10
-7
 M) for 30 minutes prior 
to treatment with FF (10
-8
 M) or FP (10
-8
 M), respectively for 4 hrs, or left untreated 
(NT). Cells were harvested for RNA extraction and reverse transcription was carried 
out. Relative levels of MKP-1 mRNA were measured by real-time PCR and were 
normalised to GNB2L1, an endogenous housekeeping gene. Graphs show relative 
levels of MKP-1 mRNA in the presence of (A) FF alone, VT alone and FF/VT in 
combination. (B) FP alone, SM alone and FP/SM in combination. Values represent 
mean ± SEM from 5 – 6 individual experiments. 
* Significant difference from NT, p < 0.05 
** Significant difference from NT, p < 0.01  
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Figure 5.4 Effect of LABA addition to CS-dependent MKP-1 mRNA expression 
under oxidative stress. U937 cells were stimulated with H2O2 (200 μM) prior to 30 
min treatment with either VT (10
-8
 M) or SM (10
-7
 M) followed by FF (10
-8
 M) or FP 
(10
-8
 M), respectively for 4 hrs, or left untreated (NT). Cells were harvested for RNA 
extraction and reverse transcription was carried out. Relative levels of MKP-1 mRNA 
were measured by real-time PCR and were normalised to GNB2L1, an endogenous 
housekeeping gene. Graphs show relative levels of MKP-1 mRNA in the presence of 
(A) FF alone, VT alone and FF/VT in combination, under H2O2 conditions. (B) FP 
alone, SM alone and FP/SM in combination, under H2O2 conditions. Values represent 
mean ± SEM from 2 individual experiments of triplicate treatments. 
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subsequent combination in normal conditions (Ratio of MKP-1/GNB2L1: FF/VT (no 
H2O2): 0.007 ± 0.003; FF/VT (H2O2): 0.093 ± 0.004; FP/SM (no H2O2): 0.009 ± 0.004; 
FP/SM (no H2O2): 0.009 ± 0.004; FP/SM (H2O2): 0.026 ± 0.019). Comparing the fold 
difference of improvement, FF/VT anti-inflammatory action increased MKP-1 mRNA 
expression by 13.2-fold, whereas this increase was only 2.8-fold for the FP/SM 
combination (Table 5.4). 
These data demonstrate the positive impact of adding a LABA to a CS, which is in 
agreement with previous in vivo (Hanania et al., 2003; Ind et al., 2003) and in vitro 
(Usmani et al., 2005) studies.  
 
5.3.4 Confirmation of Superior Effects of FF/VT Combination in PBMCs 
from COPD Patients 
 
Having evaluated the potency of CS/LABA combination in cell lines and especially 
under oxidative stress, the next step was to confirm the results in primary cells, i.e. 
PBMCs. For this, PBMCs from both healthy volunteers and patients with COPD were 
used. Subject demographics are listed in table 5.5. 
PBMCs were incubated with CSs overnight and then stimulated with TNFα for 24 hrs. 
Supernatants were collected for IL-8 analysis by ELISA. 
Both FF and FP inhibited TNFα-induced IL-8 production in a concentration-
dependent manner, to a similar extent in PBMCs from healthy volunteers (Table 5.6), 
but the maximum effects were less than 50 %, confirming that this system is more CS 
insensitive than U937 cells. To determine the potency of each CS, EC50 values were 
calculated. As shown in table 5.6, MF was less potent than the other CS (EC50 (nM): 
MF: 3.54; FF: 0.24; FP: 0.16). Addition of VT to FF improved the EC50 value ~ 3.4-
fold (EC50 (nM): FF/VT: 0.07) and addition of FM to MF improved the EC50 value ~ 
25-fold (EC50 (nM): MF/FM: 0.14). SM did not improve EC50 values for FP. 
However, all LABAs improved the Emax (Table 5.6), with the FF/VT and FP/SM 
combinations showing greater enhancement.  
In PBMCs from COPD patients, all CSs tested, were less sensitive compared to their 
efficacy in PBMCs from healthy volunteers. Most interestingly, FP did not inhibit the 
TNFα-induced IL-8 release and the EC50 value could not be calculated. In contrast, FF 
was the most potent CS (EC50 (nM): FF: 0.06; FP: not calculated; MF: 7.64) in  
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Table 5.4. Summary of MKP-1 induction by CS and/or LABA compared to baseline 
 
   
MKP-1 induction vs. NT (baseline) 
 
  
H2O2 
 
CS alone 
 
 
LABA alone 
 
 
CS/LABA 
 
FF / VT 
 
- 
 
 
1.6 ± 0.55 
 
1.1 ± 0.17 
 
2.3 ± 0.87 
 
FF / VT 
 
+ 
 
 
2.0 ± 0.40 
 
2.2 ± 0.01 
 
18.9 ± 11.02 
 
FP / SM 
 
- 
 
 
1.8 ± 0.61 
 
1.1 ± 0.13 
 
3.4 ± 1.63 
 
FP / SM 
 
+ 
 
 
1.6 ± 0.44 
 
1.2 ± 0.08 
 
2.7 ± 0.69 
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Table 5.5. Subject demographics of COPD study (combination therapy) 
 
  Healthy 
Volunteers 
COPD 
patients 
 
N 
 
 
5 
 
 
15 
 
 
Gender 
(M / F) 
 
2 / 3 
 
8 / 7 
 
Age 
(yrs) 
 
55.2 ± 3.8 
 
65.0 ± 1.8 
 
FEV1 
(% pred.) 
 
89.7 ± 2.8 
 
55.8 ± 4.8 
 
FEV1/FVC 
(% pred.) 
 
100.3 ± 2.9 
 
71.8 ± 5.2 
 
Medication 
 
 
n/a 
 
ICS (7) 
 
FEV1: Forced expiratory volume in the 1
st
 sec of exhalation 
FVC:  Forced vital capacity 
ICS: Inhaled corticosteroid 
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Table 5.6. Summary of results from experiments of TNFα-induced IL-8 production in 
PBMCs from healthy subjects in response to CS/LABA treatment   
 
  
Emax (%) 
 
EC50 (nM) 
 
FF 
 
 
28. 5 ± 8.6 
 
 
0.24 
 
FF + VT 
 
 
60.8 ± 4.4 
 
0.07 
(x 3.4 vs. FF) 
 
FP 
 
 
31.8 ± 5.2 
 
0.16 
 
FP + SM 
 
 
72.3 ± 13.7 
 
0.16 
(x 1 vs. FP) 
 
MF 
 
 
41.9 ± 3.9 
 
3.54 
 
MF + FM 
 
 
49.9 ± 3.9 
 
0.14 
(x 25 vs. MF) 
 
Values represent mean ± SEM 
Values in brackets (x # vs. CS) represent fold induction of each CS by LABA add-on  
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PBMCs from COPD subjects. Although FF showed some effect, addition of VT 
improved the EC50 value (EC50 (nM): FF/VT: 0.04) by 1.5-fold (Table 5.7, Fig. 5.5).  
Surprisingly, the EC50 value of MF was reduced by 32-fold by the addition of FM 
(EC50 (nM): MF: 7.64; MF/FM: 0.24). Although the enhancement of VT was not 
strong, the FF/VT combination was more potent than any other combination tested, as 
suggested by the EC50 and Emax values. 
 
5.3.5 Optimisation of Treatment Conditions of FP/SM Combination 
Therapy 
 
The superior effects of LABA/CS combination rather than administering each drug 
separately has been studied in clinical trials (Chapman et al., 1999). Nevertheless, the 
probable mechanism of the improved effect of the combination needed to be studied 
in vitro in cultured cells or in primary cells from COPD patients. The main aim of this 
part of the study was to evaluate the impact of pre-mixture of SM with FP on CS-
induced MKP-1 mRNA expression. 
 
5.3.5.1 Effect of Pre-incubation of SM and FP Prior to Treatment 
 
SM (10
-7
 M) was mixed with FP (10
-8
 M) in a test tube for either 15 or 60 min at room 
temperature. At t = 0 min, U937 cells were treated with either drug alone, the pre-
incubated mixture, the combination of each drug added separately to the appropriate 
wells, or left untreated (NT) for 4 hrs. MKP-1 mRNA was quantified by real-time 
PCR and normalised to GNB2L1 mRNA levels (Fig. 5.6).  
Comparing to basal MKP-1 mRNA expression, FP or SM alone, increased MKP-1 
mRNA expression, 5-fold (Ratio of MKP-1/GNB2L1; NT: 0.001 ± 0.0002; FP: 0.005 
±.0006) and 2-fold (Ratio of MKP-1/GNB2L1; SM: 0.002 ± 0.0005), respectively. 
MKP-1 mRNA expression was further upregulated by the combination of the two 
drugs added separately at t = 0 min (Ratio of MKP-1/GNB2L1; FP/SM – 0 min: 0.012 
± 0.0009), as shown in Fig. 5.7. The 15 min pre-incubation mixture showed similar 
effect as the treatment at t = 0 min (Ratio of MKP-1/GNB2L1; FP/SM – 15 min:  
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Table 5.7. Summary of results from experiments of TNFα-induced IL-8 production in 
PBMCs from COPD subjects in response to CS/LABA treatment   
 
  
Emax (%) 
 
EC50 (nM) 
 
FF 
 
 
17.7 ±  5.6 
 
0.06 
 
 
FF + VT 
 
 
32.1 ± 3.9 
 
0.04 
(x 1.5 vs. FF) 
 
FP 
 
 
13.5 ± 3.7 
 
SR 
 
 
FP + SM 
 
 
26.9 ± 4.7 
 
1.38 
(n/a vs. FP) 
 
MF 
 
 
24.6 ± 4.9 
 
7.64 
 
MF + FM 
 
 
30.6 ± 4.5 
 
0.24 
(x 32 vs. MF) 
 
Values represent mean ± SEM 
Values in brackets (x # vs. CS) represent fold induction of each CS by LABA add-on  
SR: Steroid resistant (value could not be calculated) 
n/a: not available 
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Figure 5.5 Effect of CS/LABA combination in PBMCs from COPD patients. 
PBMCs were isolated from whole blood from COPD (n = 15) patients. PBMCs were 
treated with VT (10
-8
 M), SM (10
-7
 M) and FM (10
-8
 M) for 30 min prior to 24 hrs 
treatment with increasing concentrations of FF, FP or MF, followed by overnight 
stimulation with TNFα (10 ngml-1). Supernatants were collected for IL-8 analysis by 
ELISA and concentration response curves of TNFα-induced IL-8 release were 
generated. Graphs show % inhibition IL-8 release in response to (A) FF treatment (red, 
circle) and FF/VT combination (red, cross). (B) FP treatment (green, rhombus) and 
FP/SM combination (green, cross) (C) MF treatment (blue, square) and MF/FM 
combination (blue, cross).Values represent mean ± SEM at each concentration. 
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Figure 5.6 Schematic representation of protocol used for “pre-incubation” 
FP/SM mixture experiments. SM (10
-7
 M) was mixed with FP (10
-8
 M) in a test tube 
for either 15 or 60 min at room temperature. At t = 0 min, U937 cells were treated 
with either drug alone, the pre-incubated mixture, the combination of each drug added 
separately to the appropriate wells, or left untreated for 4 hrs. Cells were harvested for 
RNA extraction and reverse transcription and MKP-1 and GNB2L1 mRNA levels 
were quantitated by real-time PCR.  
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Figure 5.7 Pre-combining SM with FP has a superior anti-inflammatory effect 
than each drug added separately. At t = 0 min, U937 cells were treated with SM 
(10
-7
 M), FP (10
-8
 M) separately or in combination, or left untreated (NT). Some cells 
were also treated with the pre-combined mixture of FP/SM that had been mixed in a 
test tube for either 15 or 60 min at room temperature. Cells were incubated for 4 hrs 
and were harvested for RNA extraction and reverse transcription. Relative levels of 
MKP-1 mRNA were measured by real-time PCR and were normalised to GNB2L1 
(endogenous housekeeping gene) mRNA levels. Graph shows relative levels of 
MKP1 expression in the presence of FP alone, SM alone or FP/SM in combination. 
Values are a mean ± SEM from six individual experiments.  
** Significant difference from NT, p < 0.01 
# Significant difference from FP/SM – 0 min, p < 0.01 
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0.012 ± 0.0025). However, the 60 min pre-incubation mixture significantly 
augmented MKP-1 mRNA expression (Ratio of MKP-1/GNB2L1; FP/SM – 60 min: 
0.016 ± 0.0001) compared to when both drugs were added separately at t = 0 min (Fig. 
5.7).  
 
5.3.5.2 Effect of Temperature on the Pre-incubation Mixture of FP/SM 
 
Subsequently, I decided to investigate further whether the effect of the pre-incubated 
mixture was temperature-dependent. For this reason the FP/SM pre-mixture was 
incubated at room temperature (RT, 21 - 23 
o
C), 4 
o
C and 37 
o
C for 60 min.  
As previously described FP/SM were pre-incubated prior to addition to the cells. As 
shown in Fig. 5.8, the effect of 60 min pre-incubation mixture at 4 
o
C (Ratio of MKP-
1/GNB2L1; 0.012 ± 0.001) was similar to the treatment at t = 0 min (Ratio of MKP-
1/GNB2L1; 0.012 ± 0.0009) of both drugs applied separately at room temperature 
(RT). However, the efficacy of the 60 min pre-incubation at RT (Ratio of MKP-
1/GNB2L1; 0.016 ± 0.001) was superior to the treatment at t = 0 min. The effect of 60 
min pre-incubation mixture at 37 
o
C (Ratio of MKP-1/GNB2L1; 0.018 ± 0.004) was 
similar to the effect at RT, though this effect was not significant.  
These data suggest that there is an advantage of combining SM with FP prior to 
treatment, in in vitro setup. The effects are time- and temperature-dependent. This is 
in agreement with data by Chapman et al that showed combining SM with FP in a 
combination Diskus inhaler was as effective as when administering via separate 
Diskus inhalers. Besides, data from GlaxoSmithKline (data not shown) suggest that 
there is a 30 % binding of SM to FP in the combination Diskus inhaler. This finding 
could be important for optimising the formulation or dosing of combination therapy to 
maximise its efficacy in asthma and COPD. 
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Figure 5.8 Effect of temperature on the pre-incubation of SM and FP. U937 cells 
were treated with FP (10
-8
 M) and SM (10
-7
 M) separately (shown as 0 min), or a pre-
combined mixture of FP/SM at various temperatures (RT; 4 
o
C; 37 
o
C) for 60 min, or 
left untreated (NT) for 4 hrs. Cells were harvested for RNA extraction and reverse 
transcription. Relative levels of MKP-1 mRNA were measured by real-time PCR and 
were normalised to GNB2L1 mRNA levels. Graph shows the relative levels of MKP-
1 mRNA in the presence of FP alone, SM alone or FP/SM in combination at various 
temperatures. Values are a mean ± SEM from 4 – 6 individual experiments. 
** Significant difference from NT, p < 0.01 
# Significant difference from FP/SM – 0 min, p < 0.01 
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5.4 Discussion 
 
It is now well established that the most common therapy for asthma and COPD, 
according to GINA and GOLD guidelines, is the combination of ICS and LABA 
(Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2009; Global 
Initiative for Asthma (GINA), 2009). However, severe and smoking asthma as well as 
COPD patients are less sensitive to CS treatment (Barnes et al., 2004). Although the 
beneficial effects of ICS in reducing the rate of COPD exacerbations are well 
documented (Alsaeedi et al., 2002), the long term benefits of such medications and 
the risk for COPD patients is not clearly established.   
In the previous chapters, I have shown that FF is an oxidative stress insensitive CS 
and also that FM (or VT) is an oxidative stress insensitive LABA. Therefore, I was 
interested to further evaluate their combination, and in particular the FF/VT 
combination and compare it to combinations that are currently available (FP/SM, 
MF/FM, Bud/FM). Due to time limitations I only focused on these combinations as 
they were either clinically developed or being developed (see Table 5.1). Nowdays 
other generic companies are developing combinations as FP/FM, a very potent 
combination, however the duration of action would not be longer. Although, this 
would be an interesting combination to test in the future. 
Initially, the effect of LABA on CS-dependent anti-inflammatory action was 
evaluated in U937 cells. All CSs tested (FF, FP, MF and Bud) inhibited TNFα-
induced IL-8 release in a concentration-dependent manner. Addition of LABAs (VT, 
SM and FM) enhanced the efficacy of most CSs. The enhancement of CS effects by 
LABA was more impressive in terms of CS-induced MKP-1 mRNA expression. 
Usmani et al showed the beneficial effect of SM when it was combined with FP in 
both in vivo and in vitro (clinical study).  FP presented a clear dose-dependent 
increase of GR nuclear translocation in epithelial cells and SM significantly enhanced 
this increase. A similar pattern was seen in sputum macrophages (Usmani et al., 2005). 
In addition, the effects of two CS-inducible genes; MKP-1 and secretory leuko-
proteinase inhibitor (SLPI) in PMA-treated U937 and Beas-2B cells, respectively 
were also evaluated. SM in combination with FP significantly enhanced both MKP-1 
and SLPI mRNA expression in both cell systems, when compared to FP treated cells 
only (Usmani et al., 2005). 
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Moreover the impact of oxidative stress on the effects of CS/LABA combination in 
the same system, i.e. TNFα-induced IL-8 release and CS-induced MKP-1 mRNA 
expression in U937 cells, were evaluated. As seen in the previous chapters, FF as well 
as the LABAs, FM and VT were insensitive to oxidative stress; therefore their 
combination was expected to function in a similar way. The FF/VT combination was 
not affected by the addition of H2O2.  
PBMCs from COPD patients were totally resistant to FP and addition of SM 
enhanced the anti-inflammatory efficacy of FP. MF showed some anti-inflammatory 
action in PBMCs from COPD subjects, but FF was > 120-fold more potent than MF. 
Addition of VT slightly improved the efficacy of FF. As FF showed some effect on its 
own, the enhancement was not great. This is similar to that observed in U937 cells. 
Addition of FM also enhanced the efficacy of MF > 30-fold. Therefore LABAs 
improved the efficacy of the CSs in PBMCs from COPD patients. As well as potency 
(EC50), LABAs also enhanced the maximum effect of the CSs (Table 5.7). 
The beneficial effect of ICS/LABA combination therapy has been reported in several 
clinical studies in COPD. Mahler et al reported that SM/FP combination improved the 
FEV1 of COPD patients (Mahler et al., 2002). Similarly, in a large clinical trial by 
Calverley et al, even if they failed to show the effect of SM/FP combination on 
survival rate in COPD patients, their results were consistent with other studies, 
showing improved lung function and reduced rate of exacerbations (Calverley et al., 
2007).  
In respect to combinations of ICS with FM, Cazzola et al reported that addition of 
Bud to FM treatment influenced the fast onset of action of FM. The change in FEV1 
15 min after inhalation of the combination was significantly greater than FM alone 
(Cazzola et al., 2004) . Furthermore, FM treatment resulted in a decline in partial 
pressure of oxygen in arterial blood (PaO2), which was reduced upon addition of Bud 
(Cazzola et al., 2006). Moreover, Bud/FM in a single inhaler (Symbicort ®) provided 
short-term improvements in FEV1, PEF and the HRQL, which were maintained for a 
year (Calverley et al., 2003b).  However, these effects were confirmed only for lung 
function and other clinical implications, whereas anti-inflammatory efficacy of the 
combinations has not been yet elucidated. 
The novel ultra long-acting combination, FF/VT, has recently entered phase III 
clinical trials, and several reports on the biological features of the two drugs have 
been published. Comparing inhaled FF with inhaled FP, Allen et al shown that FF had 
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prolonged absorption of the lung into the systemic circulation. This indicates a longer 
duration of lung retention as well as suggesting the potential of once-daily 
administration of FF (Allen et al., 2010).  There are several in vivo, in vitro and ex 
vivo studies evaluated the pharmacological profile of VT.  In electrically stimulated 
guinea pig trachea strips, VT was equipotent with FM; however it was more potent 
than SM or indacaterol. Removal of VT caused no recovery of the tissue after 1 hr, 
suggesting the longer duration of action of VT compared to FM and isoprenaline 
(Ford et al., 2010). Moreover, in Chinese hamster ovary (CHO) cells or membrane 
fractions, VT was shown to be highly selective for β2AR with greater efficacy to 
produce cAMP, compared to SM and indacaterol (Barrett et al., 2010). Finally, 
studies in healthy subjects, asthmatics and COPD patients suggested that VT was well 
tolerated and was not associated with any clinical systemic effects. The rapid 
bronchodilation was maintained over a period of 24 hrs and in combination with the 
long-acting CS, FF will be a potential combination for once-daily administration 
(Kempsford et al., 2010a; Kempsford et al., 2010b; Kempsford et al., 2010c).  
Finally, treatment method is as important as optimal CS/LABA combination. One 
study clearly showed that the combination of SM/FP, when administered via a single 
Diskus inhaler was more effective in achieving asthma control over a 28-week period, 
than when the two drugs were administered individually (Chapman et al., 1999). This 
is in agreement with several clinical studies, but this concept has never been tested in 
an in vitro system. In this study, using a monocytic cell line, U937 cells, I aimed to 
reproduce the study by Chapman and colleagues. As shown in Fig. 5.7, FP and SM 
pre-mixed for 60 min at RT, prior to treatment, significantly augmented the 
expression of MKP-1 mRNA compared to when the two drugs were added separately 
to the cells. This is the first study that shows the beneficial effect of pre-incubation of 
SM/FP as a “single” solution in vitro. Furthermore, the efficacy of the mixture is 
temperature-dependent, and the improved efficacy was seen at temperatures higher 
than RT. The molecular mechanism of superior effects of pre-mixed solution has not 
been elucidated in this thesis, however, according to GSK’s in house information; SM 
binds to FP in inhalers. This drug-drug physical interaction will be a key for the 
mechanism of superior effects of single inhalers. I am currently involved in a mass 
spectrometry analysis of pre-mixture in collaboration with GSK.   
Thus, in this chapter, combination of oxidative stress insensitive CS and LABA, that 
is FF and VT, showed superior effects compared to other combinations in cells from 
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COPD or U937 cells under simulative conditions of oxidative stress. Furthermore, I 
showed for the first time that pre-incubation of a CS and a LABA is essential for 
maximising the effect of the combination. These two findings will be a key for the 
development of COPD optimised combination inhalers. 
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Chapter 6,  
General Discussion 
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6.1 General Discussion 
 
Symptoms in patients with asthma are well controlled with ICSs in combination with 
LABAs. In COPD, LABAs are used as bronchodilators and are the mainstay therapy 
of the current management of COPD (Cazzola and Matera, 2009). However, current 
available bronchodilators and CSs have limited efficacy and duration of action. A 
logical approach would be to improve current CSs and LABA and/or their 
combination that can achieve longer duration of action and achieve higher anti-
inflammatory efficacy (Barnes, 2008a).  
The major risk factor of COPD is cigarette smoke, and air pollutants. The release of 
ROS from recruited macrophages and neutrophils is enhanced by cigarette smoke 
(MacNee, 2001). Osoata et al have shown increased oxidative stress in EBC from 
COPD patients and sputum macrophages (Osoata et al., 2009a). In addition, HDAC2 
activity has been reported to be reduced in the lungs of COPD patients. As HDAC2 is 
essential in the mechanism involved in switching off inflammatory gene transcription, 
this effect may account for the CS insensitivity seen in COPD (Ito et al., 2005). 
In this thesis, I have evaluated the pharmacological profile of a novel CS, FF with 
currently available CSs, such as FP Bud and MF and especially under oxidative stress 
conditions or in primary cells from healthy volunteers, asthma and COPD patients. 
Additionally, the impact of oxidative stress on β2AR-dependent signalling and several 
LABAs were investigated. To identify the best CS and LABA for COPD, their 
combination (i.e. CS/LABA) was also tested in several cell systems.  
FF has been developed as a once-daily CS for the treatment of allergic rhinitis. It is 
active beyond 24 hrs and has a higher affinity for the GR, compared to other currently 
available CSs (Kaiser et al., 2007). In this thesis, FF was tested in several cell lines 
and in PBMCs from healthy subjects and patients with asthma or COPD. The potency 
of FF and its duration of action were compared to that of FP, MF and Bud. The longer 
duration of action of FF was confirmed by my findings in an in vitro system, which is 
well supported by in vivo clinical data.  FF was the most potent CS and had a higher 
anti-inflammatory action. This novel enhanced-affinity CS was also found to be more 
resistant to oxidative stress, when compared to FP, as it was able to inhibit TNFα-
induced IL-8 production in H2O2-treated U937 cells and in PBMCs from COPD 
patients.  
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The longer duration of action and the resistance to oxidative stress of FF can be 
explained by the enhanced binding affinity conferred by the furoate ester within the 
17α pocket of the GR ligand binding site (Biggadike et al., 2008). In the presence of 
oxidative stress a conformational change might occur that allows greater binding and 
the improved sensitivity of FF. It would be interesting to test MF using the same cell 
systems and same readouts as FF and FP and compare its potency and duration of 
action, especially to that of FF. This will allow us to determine whether the furoate 
ester attached to the backbone of the CS plays any important role in their prolonged 
anti-inflammatory efficacy. Besides that, it might give insights for the development of 
novel CS to overcome CS insensitivity seen in COPD. 
LABAs are used as bronchodilators in respiratory diseases and in combination with 
ICSs are of great interest for research. Currently available LABAs are required to be 
administered twice-daily, although several once-daily LABAs with longer duration of 
action are now in clinical trials; indacaterol: Phase III, carmoterol: Phase III; 
milveterol: Phase IIb, GSK642444: Phase IIb, BI-1744-CL: Phase IIb and LAS-
100977: Phase IIa (Cazzola and Matera, 2009). In this thesis, SM (a partial agonist), 
and FM (a full agonist) were tested under oxidative stress. FM-dependent cAMP 
production was not affected by oxidative stress and FM improved CS sensitivity in 
both severe asthma and COPD patients. This beneficial effect of FM seems to be 
partially attributed to PI3K inhibition. On the other hand, SM-induced β2AR-
dependent signalling was altered under oxidative stress, as SM induced β2AR 
internalisation under H2O2 treatment. In addition, FM inhibited H2O2-induced 
phosphorylation of Akt, a downstream substrate of PI3K, through a PKA-driven 
mechanism, whereas SM did not. Interestingly, VT, a novel ultra LABA, was tested 
and it was stronger than the other two LABAs, in inhibiting H2O2-induced Akt 
phosphorylation. Preliminary experiments showed that FM did not directly inhibit 
PI3K enzymatic activity. Thus, FM inhibited PI3K signalling functionally rather than 
directly inhibiting enzymatic activity. In other words, combination of CS, LABA and 
PI3K inhibitor will be an oxidative stress insensitive treatment. In fact, PI3K 
inhibition is demonstrated to enhance CS effects in smoking mice or cultured cells 
under oxidative stress (To et al., 2010).   
In the first two results chapters, FF and FM (or VT) were identified as oxidative stress 
insensitive molecules and in the third results chapter, the pharmacological efficacy of 
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the combinations was tested. The most potent combination was FF/VT, especially 
under oxidative stress or in PBMCs from COPD patients.   
Furthermore, in this thesis, the superior effect of pre-incubating (mixing) FP with SM 
in solution in vitro compared to adding each component separately, was documented 
for the first time. This effect was previously shown in a clinical trial, as the 
combination of the two drugs was as effective and safe when administered to patients 
through the same Diskus inhaler (Chapman et al., 1999). Liquid-
chromatography/Mass spectrometry (LC/MS) analysis would reveal whether any 
binding occurs in solution in vitro between FP and SM prior to treatment to the cells. 
In addition, LC/MS analysis will also tell whether this beneficial effect of “pre-
incubated” mixture is a pure electrostatic interaction or maybe a conformational 
change occurs that might trigger a distinct molecular mechanism. 
The limitations of this study are the lack of information of in vivo efficacy and less 
information of the clinical samples (e.g. exact medication of patients). The 
comparison of efficacy of FF/VT combination with that of FP/SM in a smoking mice 
model would demonstrate the efficacy of the combinations in vivo. The in vitro 
efficacy should be tested in PBMCs from COPD patients at different stages of the 
disease. The efficacy could also be compared between current and ex-smokers, in 
order to understand the involvement of current smoking. Furthermore, a meta-analysis 
or new clinical trials might clarify the different efficacies between different 
combinations for the treatment of COPD. In addition, it would be remarkable to 
investigate further the molecular mechanisms involved and understand the different 
properties of the CSs or LABAs tested in this thesis under oxidative stress conditions. 
Thus, this thesis illustrates the different efficacies of CSs and LABAs under oxidative 
stress, and also FF/VT combination is more effective than FP/SM combination, under 
oxidative stress and in primary cells from COPD subjects. The pre-clinical 
optimisation of combination therapy under oxidative stress will give new insights for 
the development of combination inhalers for COPD. 
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